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Abstract: 
Oropharyngeal candidiasis is a localised infection in the oropharynx region caused 
by Candida species, predominately C. albicans. It is commonly spread among 
immunocompromised patients and aggravated by hyposalivation or xerostomia. 
Current treatment is by systemic antifungals, which might be accompanied by 
gastrointestinal tract disorders, headache, allergic reactions and drug interactions 
or Candida becoming resistant to them. In the present work, the anti-candida 
activity of chlorhexidine diacetate (CHD) was tested as the drug of choice, it has 
no systemic side effects and microorganisms do not develop resistance against it. 
Thymol and farnesol were also tested individually and in combination with CHD to 
investigate a synergistic effect against Candida planktonic cells. The effects of 
CHD and thymol were investigated against C. albicans biofilm after two hours 
exposure by testing the metabolic stress, vacuolar activity and protein content. The 
results of the anti-Candida activity of CHD and thymol based on the minimum 
inhibitory concentration (MIC) and the minimum biocidal concentration (MBC) were 
2.5 and 5 µg/ml for the former and 125 and 250 µg/ml for the later. Farnesol did 
not show an MIC and MBC at the investigated concentrations, however, it 
increased the MIC and MBC of CHD to 5 and 40 µg/ml and of thymol to 250 and 
>250 µg/ml, respectively. The antibiofilm activity of CHD and thymol was 
concentration dependent and CHD was more potent than thymol. A concentration 
of 20 µg/ml and 2 hours treatment of Candida biofilm grown for 24 hours showed 
an 85% decrease in oxidative stress, 78% and 60% loss of vacuolar activity and 
protein content, respectively. The combination of both drugs showed a limited 
increase in the activity. The cytotoxic effects of CHD and thymol were tested on 
human embryo kidney epithelial cell line (HEK 293); the metabolic stress, 
lysosomal activity and protein content were tested. The cytotoxic effects were also 
concentration dependent and the combination have increased the cytotoxicity. A 
concentration of 20 µg/ml and 2 hours treatment showed a 40% decrease in 
oxidative stress and neither the lysosomal activity nor protein content of HEK 293 
cells was affected by the treatment 
Finally, a mucoadhesive hydrogel buccal tablets for the controlled release of CHD 
were designed and prepared to increase the residence time of an effective 
concentration of CHD in the oral cavity for two hours. They were prepared using 
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Poloxamer 407 (P407), hydroxypropyl methylcellulose (HPMC) and either sorbitol, 
mannitol or xylitol at different ratios. The tablets were investigated for their physical 
properties, ex vivo mucoadhesion, the rate of hydration, gelling efficiency using 
image analysis, differential scanning calorimetry (DSC), Fourier transforms 
infrared spectroscopy (FTIR), X-ray diffractometry (XRD) and in vitro dissolution 
using Apparatus I and a novel method based on controlled flow rate to mimic 
salivary drug delivery in the oral cavity.  
Based on the antibiofilm activity and the cytotoxic effect of CHD a concentration of 
20 µg/mL was chosen to be released from the tablets to maintain both efficacy and 
safety. Accordingly, to maintain this concentration the final formulations were 
prepared with a 2.5 mg dose of CHD. Tablets analysis showed no chemical 
interaction with the excipient based on DSC, FTIR and XRD. Furthermore, a novel 
dissolution method was developed based on a constant flow rate of the dissolution 
media to mimic oral salivary flow. By comparing CHD release using App I and the 
flow rate method it was shown that hydrogel-forming tablets successfully controlled 
the release of CHD regardless of the volume of the dissolution media with 
approximately 90% release and an average release concentration of 19 µg/ml and 
1 ml/min flow rate. This making it a potential candidate for future application for 
treatment of candidiasis in all types of patients. 
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Chapter 1 : Introduction  
1.1 Oropharyngeal Candidiasis (OPC) 
Oropharyngeal Candidiasis (OPC) is a localised Candida spp. infection of the oral 
cavity and pharynx, characterised by inflammation and superficial, elevated white 
plaques resembling milk curds. Lesions may develop and spread to cover most 
of the mouth, accompanied by pain, burning or dryness, loss of taste and 
pharyngeal dysphagia (Hoepelman and Dupont, 1996). Although Candida 
albicans predominates, OPC is associated with a range of commensal Candida 
species (Kamikawa et al., 2013), including C. tropicalis, C. glabrata, C. 
dubliniensis, C. parapsilosis, C. krusei, C. utilis, C. guilliermondii, C. ciferrii and 
C. norve (Lin et al., 2013). In healthy individuals, protection against Candida spp. 
overgrowth and colonisation are achieved by the presence of bacterial flora which 
limits the opportunity for attachment and proliferation; the host’s epithelial cell 
barrier and defensive immune system activities are also implicated (Gow and 
Hube, 2012). 
The global annual incidence of oral and oesophageal candidiasis are 
approximately 2 and 1.3 million respectively, oral candidiasis might be 
proliferating to invasive candidiasis with an annual incident rate of 5142 in the 
UK. The estimated mortality rate from invasive candidiasis is >40% despite the 
introduction of new antifungals (Bongomin et al., 2017). This can be explained by 
the resistance of Candida to antifungal medications.  
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1.2 Host factors and OPC  
1.2.1 Normal flora 
Normal commensal oral flora, including Streptococcus sanguis, S. salivarius, E. 
coli and Porphyromonas gingivalis, effectively decrease Candida (C. albicans 
and C. krusei) colonisation on buccal epithelium in a species and concentration-
dependent manner (Nair and Samaranayake, 1996). Commensal microbial flora 
competes with pathogenic microorganisms for binding sites on the anionic 
biopolymer mucin a major component of the mucous membrane and secreted by 
epithelial cells (Derrien et al., 2010).  
1.2.2 From commensalism to pathogenesis 
Although C. albicans is commensal fungi on human mucosal surfaces, it invades 
the skin, oral cavity, oesophagus, gastrointestinal tract, vagina and vascular 
system (Calderone and Fonzi, 2001). It is a polymorphic fungus; it grows from 
oval unicellular budding yeast to a pseudohyphal form consisting of an elongated 
chain of budding cells that subsequently develop to hyphae, which are formed of 
parallel sided filaments. The transition of C. albicans from a commensal yeast to 
pathogenic pseudohyphal (intermediate stage) and hyphal forms is reversible 
(Bastidas and Heitman, 2009). This process is regulated by quorum sensing 
molecules (QSM) synthesized by C. albicans. They are involved in cell-to-cell 
communication and signaling, including 1) tyrosol (accelerates hyphal transition) 
(Brilhante et al., 2016), and 2) farnesol (suppresses transition to the hyphal form) 
(Han et al., 2011). Candida spp. transition from yeast to hyphal form can also be 
suppressed by 3-oxo-C12-homoserine lactone, a QSM secreted by P. 
aeruginosa (Lu et al., 2014). C. albicans pathogenicity can also be triggered by 
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the secretion of hydrolytic enzymes, including proteinase, phospholipase and 
lipase (Owotade and Patel, 2014). 
1.2.3 Epithelial cell activity 
The oropharynx is lined by mucosa or mucous membrane, which consists of 
epithelial cells and the underlying connective tissue that contains blood supply 
(Squier, 1991). Epithelial cells taken from healthy volunteers display anti-Candida 
activity in vitro, a feature which is also seen with epithelial cells taken from HIV 
positive (HIV+) patients without OPC infection. Epithelial cells appear to prevent 
the growth of Candida in the oral cavity by stimulating the release of cytokines in 
response to the presence of C. albicans.  (Lilly et al., 2006). Cytokines are 
proinflammatory agents activating cell phagocytic potential and generating a 
long-lasting immune response. Moreover, some cytokines promote a direct anti-
candida killing activity of epithelial cells, this requires a direct contact between 
epithelial cells and Candida (Dongari-Bagtzoglou and Fidel Jr, 2005). HIV+ 
patients with concurrent OPC infection display epithelial cells with lower anti-
Candida activity (Steele et al., 2000); interestingly this feature of a weakened 
epithelial cell response to the presence of C. albicans in HIV+ patients is 
observed regardless of their OPC infection status.  
1.2.4 Saliva 
Saliva is a clear, slightly acidic, dilute aqueous liquid composed of more than 99% 
water that is secreted from the major (parotid, sublingual and submandibular) and 
minor salivary glands located around the mouth, and from the gingival fluid. The 
normal salivary flow rate is ≥0.1mL/min for unstimulated and ≥0.7 mL/min for 
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stimulated saliva, respectively (Cho et al., 2010). A thin mobile layer of saliva 
covers the mucous membrane and forms an 8-40 μm thick pellicle over the teeth 
by selective adsorption by salivary protein molecules (Schipper et al., 2007). 
Saliva and its flow rate have a prominent role in controlling OPC (Akpan and 
Morgan, 2002).  
Saliva has different functions depending on its composition (Slomiany et al., 
1996):  
1. Lubrication and humidification  
2. Buffering and clearance  
3. Maintenance of tooth integrity  
4. Antibacterial activity  
5. Taste and digestion  
The organic and inorganic components of saliva are detailed in Table 1.1 
Table 1.1 Saliva composition. 
Component Function Reference 
Inorganic ions and 
salts (e.g. sodium, 
chloride, calcium, 
phosphate and 
bicarbonate) 
• Enhances taste sensation 
• Maintains dental structure 
• Buffering capacity 
Dodds et al., 
2005 
Mucin 
 
• Promote bacterial aggregation and 
clearance from the oral cavity 
• Protect the buccal epithelial from 
the pathogenic microorganisms 
• Lubricant 
Slomiany et 
al., 1996 
 
Derrien et 
al., 2010 
Salivary Agglutinin 
 
Promote bacterial aggregation and 
clearance from the oral cavity 
Reichhardt et 
al., 2014 
Cystatin-cysteine 
proteinase inhibitor 
Control the degradation of proteins 
by inhibiting proteinase enzyme 
produced by host and colonising 
microorganisms 
 
Baron et al., 
1999 
Von Ebner glands 
protein (VEGh) - 
cysteine proteinase 
inhibitor 
• Bitter taste perception 
• Proteinase inhibitor similar to 
cystatin 
Van't Hof et 
al., 1997 
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Secretory leucocyte 
proteinase inhibitor 
• Inhibit protease enzyme 
• Antibactericidal and antifungal 
activity which may be attributed to 
its positive charge 
Doumas et 
al., 2005 
Histatins 
• Anti-candida (kill candida or inhibit 
its germination) 
• Inhibit the protease enzymes of the 
host and the bacteria 
Xu et al., 
1991) 
Paul et al., 
2011 
Lactoferrin 
• Bacteriostatic, bactericidal activity 
and marker in periodontal disease 
• Inhibit the adhesion of 
microorganisms to host cells 
 
Valenti and 
Antonini, 
2005 
Defensins 
Antimicrobial, antifungal and 
cytotoxic activity. 
Abiko et al., 
2003 
Proline-rich Proteins 
• Lubricant and bind to bacteria 
• Maintain the homeostasis of 
calcium 
• Responsible for astringent 
sensation in food and beverage 
Pascal et al., 
2006 
Statherin 
• Inhibit calcium phosphate 
precipitation in the saliva 
• Maintain the mineralisation of the 
enamel surfaces 
• Anti-candida activity (inducing the 
conversion of C. albicans from 
hyphae to the yeast form) 
 
Sarode et al., 
2014 
 
Leito et al., 
2009 
Salivary IgA 
• Inhibit bacterial colonisation and 
adhesion to the mucosal epithelial 
cell 
• Neutralize toxins and enzymes 
produced by bacteria 
• Enhance the defence activity of 
lactoferrin and lysozymes 
Kilian et al., 
1988 
Calprotectin 
• Antimicrobial (competitive binding 
to zinc metal) 
• Anti-candida (by inhibiting yeast 
growth phase and transforming to 
hyphal phase) 
Kleinegger et 
al., 2001 
 
Peroxidase 
• Antibacterial, antifungal and 
antiviral activity (achieved by the 
oxidation of thiocyanate by 
hydrogen peroxide) 
• Protect the human cells from the 
carcinogenic and mutagenic 
activity of hydrogen peroxide 
Ihalin et al., 
2006 
Lysozyme 
Antibacterial, antifungal and antiviral 
activity (by enzymatic and non-
enzymatic activity) 
Yeh et al., 
1997 
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Chitinase 
Defence mechanism against chitin 
containing pathogen such as C. 
albicans 
Van Steijn et 
al., 1999 
α-Amylase 
Break down starch and glucose to 
maltose 
Mese and 
Matsuo, 
2007 
Lipase enzyme 
• Digest small fraction of triglyceride 
• Responsible for triglyceride taste in 
the human 
Mese and 
Matsuo, 
2007 
 
1.3 OPC Predisposing factors 
Whilst OPC is prevalent among immunocompromised patients, there are also 
several underlying conditions that can act as predisposing factors:  
1.3.1 Local factors  
Xerostomia and Sjögren's Syndrome: Xerostomia is a subjective sensation of 
oral dryness which might be attributed to salivary glands hypofunction (SGH), 
although it may occur with normal salivary glands function. SGH is characterised 
by a pronounced decrease in salivary flow rate (Plemons et al., 2014, Närhi et 
al., 1999). The prevalence of xerostomia and SGH is increased by the effect of 
systemic diseases and its related pharmacotherapy and/or radiotherapy (Holmes, 
1998). For instance, antihistamines, anticholinergics, antihypertensives, 
antidepressants and opioids (Bergdahl and Bergdahl, 2000) radiotherapy for 
head and neck cancer (Lovelace et al., 2014), anxiety, depression, stress 
(Bergdahl and Bergdahl, 2000), Sjogren's syndrome, diabetes (Moore et al., 
2001) and HIV infection (Islam et al, 2012) have been shown to be linked to 
xerostomia and or SGH a condition that increases with age (Närhi et al., 1999). 
It results in dry mouth, difficulty swallowing and increased susceptibility to 
infection. The oral carriage of Candida is directly related to the salivary flow rate, 
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although there is no linear relationship between candidiasis and salivary flow rate 
(Navazesh et al., 1995). Sjögren's syndrome is an autoimmune disease 
characterised by inflammation of lachrymal and salivary glands, results in 
xerostomia and viscous saliva with a concurrent rise in Candida colonisation 
(Plemons et al., 2014). The prevalence of this syndrome in Europe is 0.1-4.8% of 
the population (Both et al., 2017).   
The normal salivary flow rate is ≥ 0.1 mL/min for unstimulated and ≥ 0.7 mL/min 
for stimulated saliva, respectively (Cho et al., 2010). In fact, the number of 
Candida colony forming units is inversely proportional to the salivary flow rate. 
CFU of 400/ml was set as a cut of value, thus patients, with a history of 
xerostomia, who had a low  salivary flow rate of 0.71 ml/min had a high Candida 
CFU/ml (≥ 400), whilst those with a higher salivary flow rate of 0.96 ml/min gave 
counts of  < 400 ml/min (Torres et al., 2002, Holmes, 1998).  
For the relief of the dryness symptoms of the mouth many salivary substitute 
formulations have been used, for example, Biotène Oralbalance® gel Xerotin® 
spray, BioXtra® gel, Glandosane® spray, Saliva Orthana® spray or lozenges, 
Saliveze® spray and Salivix® pastilles (BNF, 2017). Muscarinic receptor 
agonists; pilocarpine (Leek and Albertsson, 2002) (BNF, 2017), and cevimeline 
(Petrone et al., 2002) are used to stimulate the release of saliva in patients with 
residual activity in their salivary glands.  
Radiotherapy of head and neck cancers: Radiotherapy results in damage to 
the mucosa, jaw muscles, alveolar bone and salivary glands, causing xerostomia 
(Bulacio et al., 2012).  
Dentures Immunosuppressed patients with dentures are more prone to Candida 
spp. infections. The acrylic resin found in dentures can control yeast adhesion by 
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increasing surface hydrophobic interaction between Candida and the surface of 
the denture (Yoshijima et al., 2010). Candida colonisation also increases by co-
aggregation with certain Streptococcus spp. that also adhere to dentures 
(Jenkinson et al., 1990). 
Carbohydrate intake: Candida spp. adherence to buccal epithelial cells is 
enhanced by higher carbohydrate intake (Samaranayake and Macfarlane, 1982). 
Abu-Elteen (2005) reported the effect of different carbohydrates (galactose, 
glucose, sucrose, fructose, maltose, sorbitol, lactose, trehalose and xylitol) on C. 
albicans, C. tropicalis, C. glabrata and C. parapsilosis adhesion to buccal 
epithelial cells. Galactose, glucose, sucrose, fructose and maltose were 
considered as a risk factor for candidiasis, by enhancing yeast adhesion when 
associated with poor oral hygiene, xylitol showed an inhibitory effect. As Candida 
spp. are unable to catabolise xylitol which leads to an increase in osmotic 
pressure, cell swelling and eventually death. 
1.3.2 Systemic factors 
HIV+ patients: The prevalence of HIV in the UK is estimated to be 0.16% in 2016 
(Public Health of England, 2016) and OPC is the first clinical sign of HIV+ patients 
with an incidence of 50-90% (Fidel., 2006). The prevalence is increased when 
the CD4+ T helper cell count is < 200/μl (Lin et al., 2013), these cells are 
considered as the predominant host defence mechanism against OPC (Fidel., 
2006). Although treatment with antiretroviral therapy (ART) increases CD4 cells, 
it was reported that there was no relationship between the extent of Candida 
infection for patients receiving ART (Katiraee et al., 2010). This might be 
attributed to HIV viral load, which has an equal importance of CD4 cells count. It 
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was found that OPC development increases with a viral load of >10000 copies/ml,  
which might have a role in host susceptibility to the infection (Thompson et al., 
2010).  
Moreover, in HIV patients there is also a significant reduction in saliva flow rate 
and the secretory proteins from the salivary glands, which possess antibacterial, 
anti-Candidal and antioxidant activity. (Leigh, 2004).   
Smoking: Smoking is a high-risk factor when combined with other predisposing 
factors for Candida infection (Shiboski and Shiboski, 2013). In tobacco smokers 
the population of oral leukocytes and immunoglobulins are decreased by the 
effect of nicotine, thus aggravating Candida infection (Soysa and Ellepola, 2005). 
The proportion of keratinised epithelial cells is also raised, which increases C. 
albicans tissue adherence and hence leads to greater yeast colonisation in 
smokers (Williams et al., 1999). Furthermore, secretion of histolytic enzymes and 
Candida spp. adherence increases in vitro following exposure to cigarette smoke 
condensate (Baboni et al., 2009).  
Malignancy: Patients with malignancy, specifically haematological ones, have a 
higher incidence of Candidiasis (resulting from neutropenia) even before starting 
treatment (Epstein and Polsky, 1998). In addition, cytotoxic drugs can cause 
atrophy of oromucosal epithelial cells which increases inflammation, ulceration 
and xerostomia and decreases the number of lymphocytes and neutrophils 
resulting in reducing the defence mechanism. All the above conditions are 
aggravated by the concurrent administration of antibiotics. (Soysa et al., 2004) 
Diabetes: Poor glycaemic control is the major reason behind diabetic related oral 
disorders, including gingivitis, periodontitis, dental caries salivary dysfunction, 
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oral mucosal disorders, oral candidiasis and other neurosensory disorders 
(Lamster et al., 2008). The incidence of candidiasis is five times higher in diabetic 
patients than in non-diabetics (Guggenheimer et al., 2000) and OPC incident in 
diabetic patients is increased with cigarette smoking, use of denture and salivary 
hypofunction (Ship, 2003). Moreover, Type II diabetics are more susceptible to 
Candida spp. infections resulting from neuropathic salivary gland impairment and 
consequently reduction in saliva flow rate (Mata et al., 2004). Another factor is 
the salivary glucose level which is higher in diabetic patients, the glucose 
resulting in glycosylated proteins which promote Candida adhesion (Soysa et al., 
2006) 
Elderly: Geriatric patients are more prone to Candida infections due to changes 
in normal flora and microenvironment, denture wearing, decreased salivary flow 
rate, decreased the immune response, the use of medications and systemic 
diseases (Zakaria et al., 2017, Ai et al., 2017). Wu et al., (2013) investigated the 
prevalence of C. albicans among ethnic eastern Chinese patients with 
leukoplakia and epithelial dysplasia. Finding that the incidence of candidiasis was 
higher amongst geriatric patients, this population group were also more prone to 
chronic conditions such as diabetes, bronchial asthma, xerostomia, the 
requirement for dentures and regular administration of polytherapeutics, all of 
which encourage Candida infections (Gonsalves et al., 2008).  
Low Body Mass Index (BMI): Low BMI is strongly related to malnutrition (Shahin 
et al., 2010) that can result in decreased salivary flow rate and reduced cytokines 
level, both of which are associated with candidiasis (Van Lancker et al., 2012). 
Patients with protein-energy malnutrition, have iron, folate Vitamin B12 and 
Vitamin C deficiencies may also result in a decrease in natural defence 
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mechanisms, loss of the mucosal integrity and thus aggravate Candida invasion 
(Farah et al., 2010). Amiri et al., (2012) also showed that patients with low BMI 
and malnutrition are more prone to Candida infection resulting from immune 
system suppression.  
1.3.3 Effect of medications 
Antimicrobials: Several mechanisms explain the effect of antimicrobials on 
Candida spp. virulence including reduced neutrophil activity, increased 
antibacterial activity against normal antagonistic flora (Soysa et al., 2008) and the 
subsequent reduction of these florae that increase nutrient availability (Seelig, 
1966). 
Inhaled Corticosteroids: The incidence of OPC in asthmatic patients treated 
with inhaled corticosteroids is 5% and positive mouth culture of Candida was 
found in 25% of patients treated with inhaled corticosteroids. This has been 
attributed to suppression of T lymphocytes, macrophages and neutrophils in the 
oral cavity and oesophagus, accompanied by increased salivary glucose levels. 
The extent of OPC is related to the type, dosage and form, as well as the dosing 
interval of the corticosteroid (Buhl, 2006).  
Chemotherapy: Direct mucosal epithelial loss and indirect suppression of bone 
marrow that leads to neutropenia, both increase the prevalence of OPC. The 
severity of OPC is directly related to the chemotherapeutic treatment regimen but 
also varies from patient to patient as a result of genetic factors (Brown and 
Wingard, 2004).  
Proton pump inhibitors (PPI): Amiri et al., (2012) reported an increased 
incidence of Candida spp. colonisation amongst critically ill ICU patients receiving 
proton pump inhibitor (PPIs) treatment. The authors suggested that OPC may be 
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facilitated by the anti-oxidant effects of PPIs that reduce the anti-inflammatory 
response by acting on neutrophils, monocytes, endothelial and epithelial cells. 
1.4 Treatment of OPC 
First-line treatment for OPC involves fluconazole tablets or intravenous injection, 
clotrimazole troches or nystatin suspensions (Thompson et al., 2010). 
Chlorhexidine and bicarbonate mouthwashes are also prescribed as adjuvant 
treatments (Ferreirós et al., 2012). 
Based on the British National Formulary (BNF), (Joint Formulary Committee, 
2017) OPC is treated with nystatin suspension, miconazole (gel or buccal tablet), 
fluconazole (tablets or suspension), posaconazole (tablet or suspension), 
itraconazole (oral liquid or capsules), voriconazole (tablet or suspension) and 
ketoconazole (tablet or suspension). The mechanism of action of currently used 
antifungals is illustrated in Table 1.2. 
Table 1.2: The mechanism of action of currently used antifungals. 
Group Drugs Mechanism of 
action 
Reference 
Polyenes Nystatin  
 
Bind to ergosterol on 
candida cell wall 
leading to leakage of 
cell constituent. 
(Odds et al., 2003) 
Azoles Fluconazole 
Voriconazole 
Posaconazole 
Ketoconazole 
Itraconazole 
Block ergosterol 
synthesis the major 
component of the 
cytoplasmic 
membrane.  
(Kathiravan et al., 
2014) 
Echinocandins Caspofungin 
 
Glucan synthesis 
Inhibitors leads to 
damage the cell wall 
of the fungi.  
(Denning, 2003) 
 
Degregorio et al., (1982) found that nystatin was ineffective in the treatment of 
OPC in immunocompromised patients, the latter will be under a significant risk of 
the development of systemic candidiasis. In OPC patients, C. albicans is the most 
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common species resistant to fluconazole (Revankar et al., 1998). Cross-
resistance between fluconazole and itraconazole can lead to refractory infection 
by non-albicans spp. such as C. glabrata and C. tropicalis. Posaconazole (a 
triazole) however, have a potent in vitro activity against these strains (Skiest et 
al., 2007). The development of the resistance to azoles is considered as the major 
drawback in the treatment of OPC which is most likely attributed to the incomplete 
eradication of Candida due to its fungistatic activity rather than fungicidal 
(Morschhäuser, 2002, Campoy and Adrio, 2017).  Capsofungin is a second line 
treatment for patients show refractory to azoles and polyenes, its effectiveness 
resulting from the different drug mechanisms of action (Kartsonis et al., 2004). 
Caspofungin is available as Intravenous infusion only due to its poor intestinal 
absorption and short half-life, this led to its limited usage to hospitalised patients 
only (Campoy and Adrio, 2017). Based on these findings, CHD was chosen to be 
investigated for the treatment of OPC because it has no drug resistance, systemic 
side effects and drug interactions. 
1.4.1 Local Treatment of OPC 
Local oral drug delivery for the treatment of OPC is a targeted drug delivery for 
the treatment of Candida infection in the oral cavity. The advantages of this mode 
of drug delivery are that it: reduces the systemic side effects of the drug; 
minimizes the dose of the drug required; and provides a targeted drug delivery 
(Sankar et al., 2011). Moreover, it is regarded as cost-effective as treatment is 
achieved by the lower amounts of the drug used. For these reasons, this mode 
of drug delivery was adopted in this work to prepare the local delivery of CHD in 
the oral cavity. 
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Clinical investigation has been conducted by researchers for the local treatment 
of candidiasis by different antifungals. Fluconazole mouth rinses (2 mg/mL) were 
used by patients with oral candidiasis three times daily for one week. Seventeen 
patients out of 19 showed complete recovery after the end of the treatment 
(Epstein et al., 2002). Cardot et al., (2004) compared salivary concentration and 
the residence time of miconazole mucoadhesive tablets (50 and 100 mg) and 
miconazole 125 mg gel in healthy volunteers. The tablets were administered once 
daily whilst the gel was applied three times daily, they found that both tablets (50 
and 100 mg) gave a prolonged detectable concentration even after the six-hour 
application. However, a similar comparison was conducted on cancer patients 
with OPC. Lauriad® (50 mg miconazole) applied once daily and Daktarin® (125 
mg miconazole) applied four times daily and were used for fourteen days. The 
responses to the treatment were nearly similar, taking in account that the tablet 
taken once daily in one-tenth of the concentration of the gel made it superior to 
the gel (Bensadoun et al., 2008). 
Another study compared the effect of the local mouthwash of Itraconazole (200 
mg) oral solution and systemic tablets of fluconazole (100 mg) in OPC patients, 
both treatments were given once daily. The solution had the same effectiveness 
of the tablet, but it is preferable due to ease of use and avoidance of systemic 
side effects (Graybill et al., 1998). Although azole formulations showed a 
promising effect for the treatment of OPC, the resistance of C. albicans to azoles 
cannot be overcome (Revankar et al., 1998). Whereas, resistance to miconazole 
is very limited (Fothergill, 2006), GIT disturbances obtained from the 
administration of miconazole mucoadhesive buccal tablet is common. Moreover, 
It shows unfavourable drug interaction with a drug metabolised by CYP2C9 and 
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CYP3A4, such as oral hypoglycaemics, phenytoin and ergot alkaloids, due to the 
enzyme inhibitory activity of miconazole (Lalla and Bensadoun, 2011).     
Moreover, Lamfon et al., (2004) investigated the effect of fluconazole, miconazole 
and CHD on C. albicans biofilm, they found that the MIC for planktonic cells and 
72 hours biofilm increased from 0.25 to >256 µg/ml for fluconazole and 
miconazole, while for CHD from 400 to 3000 µg/ml. 
1.4.2 Biguanide Disinfectants 
Biguanides are synthetic cationic compounds, widely used as antiseptics, 
disinfectants and preservatives. Polyhexamethylene biguanide (PHMB) and 
chlorhexidine are the most common salts used as disinfectants.  
1.4.2.1 Polyhexamethylene biguanide (PHMB) 
PHMB or polyhexanide is a linear polymeric biguanide, available as a 20% 
concentrated solution (Carrijo-Carvalho et al., 2017). Although it has a higher 
anticandidal activity than CHD (Koburger et al, 2010) the powdered form of PHMB 
produces acute toxicity if inhaled (Bernauer, 2015), which limits its preparation 
into tablet dosage forms. 
1.4.2.2 Chlorhexidine (CHD) 
CHD is 1:6-di-4'-Chlorophenyldiguanidohexane (Figure 1.1), it was first 
investigated by the Imperial Chemical Industries, Limited (Manchester, UK). The 
company proved its high antimicrobial potency against a wide range of 
microorganisms (Davies et al., 1954), with the MIC ranging from 2.67 to 4 µg/ml 
for bacteria (Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, C. 
albicans, Prevotella intermedia, Porphyromonas gingivalis, Porphyromonas 
endodontalis, Prevotella denticola and Prevotella melaninogenica) (Amorim et 
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al., 2004) and MIC values for thirty-two C. albicans species were found to be from 
0.78 µg/ml – 6.25 µg/ml (average 3.125 µg/ml) (Salim et al., 2013). It is an 
odourless, hygroscopic, white crystalline powder with a bitter taste (Rowe et al., 
2006, Lim and Kam, 2008) with established topical disinfectant properties and no 
systemic effects (Davies et al., 1954). CHD’s optimal antimicrobial activity occurs 
between pH 5-7; above pH 8 precipitation and hence inactivation is observed 
(Rowe et al., 2006). CHD is available as a gluconate salt (liquid), making it 
unsuitable for tablet preparation, or as acetate and hydrochloride salts. Acetate 
is ten times more soluble than the hydrochloride salt (Zeng et al., 2010), hence 
its suitability for inclusion in buccal tablet formulations (used in this study). 
 
Figure 1.1 Chemical structure of CHD. 
 
CHD is used topically for localised antiseptic and disinfection activity in the oral 
and nasal cavities, skin, wounds and burns. For treatment of oral infections, CHD 
is available as a 0.2 % w/v mouthwash, 0.2 % w/v oral spray and 1 % w/v dental 
gel (Joint Formulary Committee, 2015). The main advantage of these oral 
formulations is the unspecific cellular target for microbiocidal activity that retards 
the development of resistance against CHD (Ankola et al., 2008). 
Mechanism of action: The antifungal activity is achieved by the binding of the 
CHD cation to the anionic surface charge of the fungal cell wall surface, leading 
to a decrease in the adhering capacity, losing the structural integrity, and finally 
disrupting the cell wall (Williams et al., 2011). CHD activity is concentration and 
time-dependent. It produces cell coagulation at high concentration, it also 
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irreversibly precipitates adenosine triphosphate (ATP) and nucleic acids resulting 
in cell death. However, at low concentration, it distorts the plasma membrane 
followed by cytoplasmic leakage and coagulation of nucleoprotein (Bobichon and 
Bouchet, 1987). 
At low concentration, it has a direct effect on yeast hydrolases activity, inactivates 
proteases (Grenier, 1993) and decreases the activity of phospholipase produced 
by C. albicans (Kadir et al., 2007).  
Effect on Normal Flora: Sreenivasan and Gittins (2004) investigated the effect 
of chlorhexidine on oral flora; they found that it has a significant effect against 
Gram-positive, Gram-negative and anaerobic bacteria after treatment with CHD 
mouth rinse. Jones (1997) found that a single rinse with CHD can decrease oral 
flora by up to 90% for several hours. However, oral biofilms show a greater 
resistance toward antifungals, for instance, the MIC of chlorhexidine against C. 
albicans strain GDH-2346 was increased from 8 to 128 µg/ml for planktonic and 
biofilm cells respectively (Mukherjee and Chandra, 2004). Furthermore, the 
sensitivity of planktonic cells towards antifungals is higher than of biofilm cells, 
because there is a more uniform distribution of the drug in planktonic cell culture 
media whereas a concentration gradient of extrinsic and intrinsic material results 
from the uneven thickness and cell density in the biofilm, hence their different 
responses (Suci and Tylor, 2002). The growing biofilms produce extracellular 
polysaccharide materials composed of mannose and glucose, and this might 
cause a physical interaction between the drugs and the extracellular materials 
and decrease their effectiveness. Moreover, it has been suggested that in the 
biofilm there is a differential regulation of the gene encoding for the enzymes 
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involved in carbohydrate biosynthesis for the formation of extracellular material 
which resulted in decreasing drug activity (Chandra et al., 2001). 
CHD shows superior activity in vitro compared to fluconazole against different 
Candida spp. with a geometric mean MIC (minimum inhibitory concentration) of 
3.03 µg/ml and 19.12 µg/ml, respectively with no cross-resistance between them 
(Salim et al., 2013). 
Oral hygiene: It is used for the treatment of periodontics, caries prevention, oral 
and maxillofacial surgery, prosthodontics and endodontics (Ankola et al., 2008). 
It binds to the oral mucosa via electrostatic forces inhibiting plaque formation and 
promoting prolonged bacteriostatic activity (Lim and Kam, 2008).  
Stability of chlorhexidine in the oral cavity: Because it has a high binding 
capacity to compounds, it binds to both soft and hard oromucosal tissues 
resulting in prolonging its activity (Ankola et al., 2008). Musteata and Pawliszyn 
(2005) reported that the oral cavity acts as a reservoir for CHD because of its 
high protein binding capacity; CHD continues to release in the oral cavity up to 8 
hours with a final concentration equal to 2 μg/mL after a single mouthwash rinse 
of 1 mg/mL. Furthermore, the stability of chlorhexidine in the oral cavity is at least 
9 hours. A single mouth rinse with chlorhexidine maintains its activity for 5 hours 
in saliva and 12 hours at the oral surfaces (Jones, 1997). However, the 
concertation of chlorhexidine cannot be considered as an effective concentration 
against Candida biofilm. This can be overcome by preparing a controlled release 
dosage form to maintain the release of a higher effective concentration of CHD. 
Side effects:  CHD has a reversible effect on taste perception, it decreases the 
intensity of salty and bitter perceptions, but it has no effect on sweat and sour 
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tastes (Helms et al., 1995). Another common side effect is tooth staining, which 
is enhanced by chromogenic drinks such as tea and coffee (Leardand and Addy, 
1997) as well as rare transient dulling of taste (Lim and Kam, 2008). 
Cytotoxicity: The cytotoxicity of CHD is concentration and time-dependent 
(Hidalgo and Dominguez, 2001). The mechanism of cell death, changes from 
apoptosis to necrosis with increasing concentration of CHD (Li et al., 2014), 
although the precise mechanism of cytotoxicity is not well defined. A study on 
human blood lymphocyte found that CHD produces toxic effects through 
oxidative stress and damage to the mitochondria and lysosomes has been 
observed. Finally, depletion of Glutathione (GSH) precedes apoptosis or necrosis 
(Salimi et al., 2017). Osteoblast has been found to be more vulnerable to CHD 
toxicity than endothelial or fibroblast cells although once initiated all showed the 
same mechanism of cytotoxicity (Giannelli et al., 2008). 
Based on the above finding, the cytotoxic effect of CHD has been investigated in 
this work to find safe concentration on human cells for the treatment of OPC. 
1.5 Hydrogels and OPC 
Currently, the greatest disadvantage of CHD formulations (mouthwashes, gels) 
is their short retention and activity time in the oral cavity. Consequently, there is 
a genuine need for a new approach to the localised, prolonged delivery of 
antifungal agents for enhanced OPC therapy. Hydrogel polymers were used to 
formulate the mucoadhesive buccal tablet to prolong and control the release of 
CHD in the oral cavity. 
Localised drug delivery can be used to treat a range of oral conditions including 
xerostomia, oral cancer, fungal and bacterial infection, periodontal disease, 
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toothache, aphthous stomatitis etc. (Smart, 2005). The advantages of local 
delivery are fewer systemic side effects and more targeted drug activity (Sankar 
et al., 2011); disadvantages include drug loss by swallowing and unpleasant taste 
that can lead to issues with patient compliance.  
To control localised drug delivery in the oral cavity mucoadhesive controlled 
release hydrogel dosage forms were recently investigated. Hydrogels are a three-
dimensional crosslinked structure of hydrophilic homopolymer, copolymer, 
multipolymer or interpenetrating hydrogels, they can retain water and form porous 
structures (Roy et al., 2009), They are either ionic or nonionic depending on the 
pendant group, the network structure of the hydrogel are either amorphous or 
crystalline. They are used as drug delivery systems due to their resemblance to 
natural tissue because they retain large quantities of water and they have smooth 
and soft texture (Peppas et al., 2000) this make hydrogels a good candidate for 
drug delivery. 
1.3.1 Hydrogel in drug delivery: advantages and limitations 
Advantages of using hydrogel in buccal drug delivery (Hoare and Kohane, 2008): 
1. Biocompatibility due to its high-water content  
2. Drug loading, the highly porous structure enables drug loading followed by 
subsequent disintegration and dissolution  
3. Biodegradability or dissolution by the effect of enzyme, temperature and 
pH.  
4. Deformability (takes the shape of the surface applied to).  
 
Limitations of using hydrogel in buccal drug delivery (Hoare and Kohane, 2008):  
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1. Low tensile strength leads to premature dissolution or detachment from 
the site of application.  
2. Drug loading and homogeneity of hydrophobic drug is limited.  
3. High porous structure and high-water content may result in the rapid 
dissolution of the drug.  
1.6 Mucoadhesion  
Mucoadhesive dosage forms can be applied to various parts of the oral cavity 
(e.g. palate, gingiva, buccal mucosa or periodontal pocket) to localise and retain 
the drug (Bruschi and De Freitas, 2005).  
Bioadhesion is defined as the adherence of polymeric material to the biological 
surfaces, while mucoadhesion is the adherence of the polymeric material to the 
mucosal surfaces (Salamat-Miller et al., 2005; Smart, 2005). In the oral cavity 
mucin at the physiological pH 5.8-7.4 is negatively charged due to the ionization 
of sialic acid and ester sulphate residues, which may have a considerable role in 
the process of mucoadhesion. At this pH, it forms a strongly cohesive viscoelastic 
hydrogel (mucus), which binds to the epithelial cells with a 10-100 μm thickness 
and due to the abundance of positive and negative charge it acts as a protective 
layer by forming electrostatic attractions with the charged molecules. The 
turnover of the mucus in the human oral cavity is 12-24 hours (Campisi et al., 
2010). 
Mucoadhesive polymers are widely used in the preparation of salivary substitute 
due to its lubrication activity, they decrease the friction in the oral cavity 
(Partenhauser and Bernkop-Schnürch, 2016), (Dost and Farah, 2013). For 
example, carbomer, hydroxypropyl cellulose, poloxamer, 
44 
 
carboxymethylcellulose, sodium carboxymethylcellulose and acacia (BNF, 2017). 
Mucoadhesive hydrogel formulations have been used for the treatment of 
hyposalivation due to their hydration capacity and long residence time in the 
mouth (Tsibouklis et al., 2013). 
The use of mucoadhesive tablets as a prolonged dosage form has been 
successfully utilised. In the BNF miconazole buccal tablet (Loramyc®) is used for 
the treatment of OPC, each 50 mg miconazole tablet applies for 7 hours daily.  
1.6.1 Factors affecting mucoadhesion 
Factors affect mucoadhesion are: 
Molecular weight (MW) of the polymer: the optimum MW ranging from around 
104 Da to 4 x 106 Da. Low MW polymer will dissolve rapidly or make a loose gel, 
while high molecular weight polymer needs time to hydrate and make the 
functional groups ready for interaction (Kharenko et al., 2009).  
Flexibility: is an important factor for interpenetration and entanglement, makes 
more binding group available for interaction. (Andrews et al., 2009).  
Cross-linking density: this property of the polymer is inversely related to the 
degree of swelling, resulting in a decrease in the interpretation of the polymer 
with the mucous membrane (Salamat-Miller et al., 2005, Blanco-Fuente et al., 
1996).  
pH: affect the mucoadhesion of ionisable polymers, changing the pH change the 
degree of ionization. (Rahamatullah et al., 2011).  
Hydrophilicity: polymers containing carboxyl, hydroxyl, amino and sulfate 
groups have the ability to form hydrogen bonds with the mucous membrane 
(Andrews et al., 2009). They can retain water, swelling, increase the flexibility and 
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improve drug release (Rahamatullah et al., 2011). However, polymer with low 
wettability may show weaker mucoadhesive properties such as chitosan and 
Eudragit® (Wong et al., 1999). 
Concentration: there is a critical concentration of each polymer to achieve 
optimum adhesion, at low concentration the interaction between the polymer and 
the mucous membrane will be unstable. While at high concentration the degree 
of wetting of the polymer will decrease and this will either greatly decrease or not 
produce adhesion (Salamat-Miller et al., 2005).  
Contact time and contact force: the force and the time provided by the patient 
to make the tablet adhere to the oral mucosa, furthermore the contact time is 
more influential than contact force and the latter when increased it may damage 
the mucosa (Wong et al., 1999).  
Spatial conformation: linear conformation of Poly Ethylene Glycol with a 
molecular weight 200000 show the same adhesive properties as Dextran with a 
molecular weight 19500000. In the latter due to its helical conformation, not all of 
the functional group are exposed to attach to the mucosa (Rahamatullah et al., 
2011).  
1.6.2 Oral mucoadhesive dosage forms 
The desired characteristics of bioadhesive dosage forms intended for application 
in the oral cavity are flexibility, smooth texture, ease of application and low 
irritancy (Salamat-Miller et al., 2005). Drug release from such systems can be 
affected by:  
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1. Drug-polymer interaction: depending on drug properties, it is sometimes 
occupying the functional group of the polymer leading to decrease its 
mucoadhesion (Blanco-Fuente et al., 1996)  
2. Site of application: salivary flow rate varies in the oral cavity, resulting in 
variable drug release (Codd and Deasy, 1998). 
In the oral cavity the mucus is thin and discontinuous, so the preferred dosage 
form should be dry or partially hydrated such as tablet or films and to a lesser 
extent semisolids (Smart, 2005). 
1.6.2.1 Mucoadhesive tablets 
By far the most commonly used mucoadhesive dosage form in the buccal cavity, 
mucoadhesive tablets can be applied to different sites within the mouth 
(Rahamatullah et al., 2011). After wetting of the solid matrix, mucoadhesive 
tablets soften and adhere to the mucosa until dissolved or removed (Salamat-
Miller et al., 2005), their residence time depends on the site of application: 7-12 
hrs for gingiva, and 4-6 hrs for palate (Bruschi and De Freitas, 2005). The major 
disadvantage is the lack of flexibility which leads to poor patient compliance upon 
repeated or prolonged use (Salamat-Miller et al., 2005), in addition to tablet 
detachment, swallowing and subsequent adherence to the œsophagus in 
geriatric and paediatric patient groups (Bruschi and De Freitas, 2005). There are 
several factors affecting the mucoadhesion of mucoadhesive buccal tablets, 
including: 
1. Force of compression: Increasing the force of tablet compression can 
decrease in vivo and in vitro tablet mucoadhesion (Perioli et al., 2008), this 
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might be explained by the production of smoother surfaces with a higher 
compression force, resulting in decreasing the surface area and consequently 
the contact point. 
2. Polymer ratio: increasing polymer concentration in the tablet improves the 
mucoadhesion by increasing the sites of adhesion to the mucosa 
(Mohammadi-Samani et al., 2005).  
3. Type of excipients: may affect the adhesion properties of the polymer, e.g. 
oils degrade the adhesion of polyacrylic acid (Peppas and Sahlin, 1996). 
1.6.2.2 Mucoadhesive films 
Soft, elastic and strong enough to withstand stress due to mouth movements, the 
swelling capacity of mucoadhesive films must be limited to avoid patient 
discomfort (Salamat-Miller et al., 2005). They have the advantage of adopting the 
shape of underlying structures (Kharenko et al., 2009). Its limitations are due to 
their methods of preparation, which is either by solvent casting method which 
results in poor content uniformity or by hotmelt extrusion which requires specific 
equipment (Morales and McConville, 2011).  
1.6.2.3 Mucoadhesive semisolids or gels 
Semisolid drug delivery systems have a major advantage in the treatment of oral 
infections resulting from their close contact with the oral mucosa and concurrently 
rapid drug release. However, it is difficult to control the dose of gel preparation, 
making them unsuitable for API’s with a narrow therapeutic index (Kharenko et 
al., 2009). 
Table 1.3 shows the conducted research investigating the mucoadhesive 
formulations for OPC treatment. 
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Table 1.3 OPC treatment using different antifungals incorporated in different 
mucoadhesive dosage forms. 
Drug Dosage 
form 
Polymer Reference 
Chlorhexidine 
diacetate  
Tablet  Sodium alginate  
Chitosan  
(Giunchedi et 
al., 2002) 
Chlorhexidine 
diacetate  
Tablet  
 
Polyacrylic acid (PAA), 
Hydroxyethyl cellulose (HEC) 
(Irwin et al., 
2003) 
Chlorhexidine 
diacetate 
Tablet HPMC, Carbomer  (Ceschel et 
al., 2006) 
Chlorhexidine 
diacetate  
Film 
 
Sodium alginate, chitosan  (Juliano et 
al., 2008) 
Chlorhexidine 
digluconate  
Gel HPMC, 
Carboxymethylcellulose(CMC), 
Hydroxypropyl cellulose (HPC) 
(Fini et al., 
2011) 
Lactoferrin  Tablet  Sodium alginate  (Kuipers et 
al., 2002) 
Miconazole 
nitrate with or 
without 
Chlorhexidine 
diacetate  
Lozenges  Acacia, Carbopol  (Codd and 
Deasy, 1998) 
Miconazole  Patches  Sodium carboxymethyl 
cellulose(SCMC), chitosan, 
Hydroxyethyl cellulose (HEC), 
Polyvinyl alcohol (PVA), 
HPMC 
(Nafee et al.  
2011) 
Metronidazole  Tablet  Hydroxypropyl cellulose 
(HPC), Hydroxyethyl cellulose 
(HEC), HPMC SCMC  
(Perioli et al., 
2004) 
 
1.7 CHD mucoadhesive buccal tablet  
Recently, investigations were conducted to examine the use of sustained release 
CHD to treat OPC. This is feasible because CHD has no systemic side effects 
like other antifungals and so an effective concentration of the drug equal to or 
above the minimum fatal Candida concentration can be maintained. For instance, 
Ceschel et al. (2006) prepared CHD buccal tablet using carbopol and/or HPMC 
with lactose. They found that 2.5 mg of CHD in a 60 mg tablet sustained the 
action of CHD more than a Corsodyl gel containing 1% chlorhexidine gluconate 
over an 8 hours period. In another study, Chitosan was used to formulate CHD in 
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a gel and a film format, in which the concentration of CHD in the gel was 1% or 
2% while in the film 0.1% or 0.2%. In these formulations, the CHD release was 
maintained for 3 hours for the gel and 4 hours for the film (Şenel et al., 2000). 
Moreover, Juliano et al. (2008) used chitosan and sodium alginate to prepare a 
CHD mucoadhesive film using a solvent casting method, which when tested in 
vivo successfully maintained the concentration of CHD up to 3 hours. None of the 
investigated formulation showed a constant release over time, tested against 
Candida biofilm, or studied their cytotoxic effect over the intended time of 
application. 
In this current work, CHD mucoadhesive buccal tablets were prepared using 
hydroxypropyl methylcellulose (HPMC) and Poloxamer 407 polymers and sugar 
alcohols (sorbitol, mannitol and xylitol).  
1.7.1 Hydroxypropyl methylcellulose (HPMC) 
HPMC is a non-ionic hydrophilic polymer with mucoadhesive and hydrogel-
forming properties. It has widely been investigated in buccal drug delivery and is 
included in marketed products (Sudhakar et al., 2006). 
HPMC or Hypromellose is a partly O-methylated and O-(2-hydroxypropylated) 
cellulose ether derivative (Figure 1.2). Based on the substitution, it is available in 
three groups which are commercially defined by codes (2208, 2906 and 2910) 
The first two digits refer to the approximate percentage content of the methoxy 
group, while the second two digits refer to the approximate percentage content 
of the hydroxypropoxyl group (Li et al., 2005). Moreover, each group is available 
in different molecular weights, the variation in the molecular weight and the 
degree of substitution affect the solubility, thermal gelation temperature in 
aqueous solution, swelling, diffusion, and drug-release rate (Brady et al., 2017). 
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In oral tablet dosage forms it is used as a binder, film-coating and as a matrix for 
controlled-release tablet formulations (Rowe et al., 2006). 
 
 
Figure 1.2 Chemical structure of HPMC. 
 
Hypromellose 2906: In this current work, a high purity medium substituted 
HPMC, Hypromellose 2906, was used with an average viscosity of 4000 cp (2% 
aqueous solution). It has been used for its medium molecular weight and 
consequently its viscosity. The formulations prepared in this work were aimed to 
release CHD over two hours, rather than using the higher viscosity HPMC which 
is usually used for a minimum 8 hours sustained release formulations.  
1.7.2 Poloxamer polymers: 
Poloxamers are non-ionic block copolymers of polyethylene oxide (EO) and 
polypropylene oxide (PO) arranged in a basic structure EOx -POy - EOx (Figure 
1.3). The hydrophilic nature of EO and the hydrophobic nature of PO results in 
an amphiphilic molecule with consequent surfactant properties. Poloxamers with 
different x and y values result in variation in the hydrophilic-lipophilic balance 
(HLB) (Kabanov et al., 2002). Poloxamers are followed by three-digit number, the 
first two digits when multiplied by 100 represents the average molecular weight 
of EO and the third digit when multiplied by 10 corresponds to the PO percentage 
by weight. Their physical properties change from liquid to solid upon increasing 
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the molecular weight and are used as a solubilizing agent, emulsifying agent, 
wetting agent, binder and coating agent in formulations (Rowe et al., 2006). 
 
Figure 1.3 Chemical structure of P407. 
 
Poloxamer P407 (P407) 
P407 is a non-ionic copolymer of polyethylene oxide and polypropylene oxide, in 
solution, it forms a thermosensitive hydrogel at a concentration of ≥ 25 %. It has 
a wide application in drug delivery, for example, parenteral, ophthalmic, inhaler, 
oral solution, suspension, and topical formulation. Its mucoadhesive property was 
exploited in rectal and ophthalmic preparation (Dumortier et al., 2006). Poloxamer 
407 (P407) has an average molecular weight of 12,600 (9,840-14,600) and HLB 
value of 22 at 22°C. It is used as an excipient in different formulations, for 
instance, Intravenous, inhalation, oral solution, suspension, ophthalmic and 
topical formulations (Dumortier et al., 2006). Alike other poloxamers, P407 has a 
thermoreversible hydrogel-forming ability with a mucoadhesive property, it gels 
at a concentration > 20% at 25°C (Ruel-Gariepy and Leroux, 2004). In the current 
work, P407 was chosen due to its pronounced gelling properties and high 
viscosity of 3100 cp which is attributed to its high molecular weight compared to 
other poloxamers and its availability as microprills (Matanović et al., 2014). 
Although, it is not commonly used in controlling the release of the drug from solid 
dosage forms, in the current work it was formulated in tablet dosage form to 
52 
 
control the release of CHD alongside with HPMC by exploiting its 
thermoreversible hydrogel-forming properties. 
1.7.3 Sugar alcohols (Polyols) 
Polyols or sugar alcohols are naturally available in fruits and vegetables. They 
have a sweet taste, stimulate salivation, widely used as noncarcinogenic 
sweetening agents, make them the best candidates as a sweetener (Carocho et 
al., 2017). Sorbitol, mannitol and xylitol are sugar alcohols, they either minimise 
or do not promote tooth decay and have a low glycaemic index (Gliemmo et al., 
2004). Sorbitol and Xylitol have humectant activity, which is attributed to the 
availability of the hydroxyl group in their chemical structure, which forms 
hydrogen bonding with water. As a consequence, this humectant property 
reduces water activity, a feature exploited in the food industry to improve the 
stability of food products (Ergun et al., 2010).  
Mannitol and sorbitol are isomers (Figure 1.4 a and b ) with a molecular formula 
of C6H14O6, however, xylitol (Figure 1.4 c) has one carbon atom less with a 
molecular formula of C5H12O5. They have different physical properties (Table 1.4) 
 
 
Figure 1.4 Chemical structure of a- sorbitol, b-mannitol and c-xylitol. 
 
 
a b c 
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Table 1.4 Physical properties of sorbitol, mannitol and xylitol 
Sugar 
alcohol 
M. wt * 
g/mol 
Solubility 
20° C* 
mg/mL 
Heat of 
Solution* 
Sweetness 
** 
Sucrose=100 
 
Glycemic 
Index*** 
Glucose=100 
 
Sorbitol 182.172 2000 -106.3 50-60 9 
Mannitol 182.172 181 -120.9 50-60 0 
Xylitol 152.15 625 -157.1 90-100 13 
*(Rowe et al, 2006) 
**(Ghosh & Sudha, 2012) 
***(Livesey, 2003) 
Due to their sweet taste, cooling sensation resultant from their negative heat of 
dissolution, low glycaemic index, non-cariogenic (Deshpande & Jadad, 2008), 
polyols are frequently used in oral dosage forms, such as orally disintegrating 
tablets, lozenges, chewable tablets, chewing gum toothpaste (Bolhuis et al, 2009) 
and as moisturizers in artificial saliva (Femiano et al, 2011). 
Moreover, both xylitol and sorbitol due to their humectant property are used to 
relieve oral dehydration, for example; XyleMelts® is a marketed mucoadhesive 
buccal tablet which proofs its activity for the relief of oral dryness, especially 
during sleeping. The main ingredients are xylitol and cellulose gum and relief of 
the dryness might be attributed to the slow release of xylitol which stimulates 
saliva and to the activity of the mucoadhesive polymer which acts as a lubricant 
and a humectant (Burgess and Lee, 2012). 
Biotine® oral balance gel, another marketed product, contains 2% HPMC, xylitol 
and sorbitol. Epstein et al., (1999) investigate the effect of the gel on xerostomia 
patients treated with head and neck radiation, the outcome of their study showed 
improvement in the dryness of the mouth, but it had no effect on the colonisation 
by Candida.  
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1.8 Thymol  
The combined effect of Chlorhexidine with natural products has been previously 
investigated, for instance, eucalyptus oil and Chlorhexidine gluconate showed a 
synergistic effect against both the planktonic cells and the biofilm of C. albicans, 
Staphylococcus aureus, and methicillin-resistant S. aureus (Hendry et al., 2009). 
Thymol (2-isopropyl-5-methylphenol) is a phenolic essential oil produced by 
plants belonging to Lamiaceae family, such as thyme. Its antifungal activity is 
associated with disruption of the lipid packing of the cell membrane, increasing 
its fluidity and changing its permeability. The damaging effect on the cell 
membrane interferes with hyphae production, which is considered one of the 
most important pathogenicity traits of Candida (Braga et al., 2007a). Both thymol 
and CHD affect the cell wall of Candida, their combined effect was tested in this 
work to check synergistic or additive anticandidal effect.   
It has an antioxidant activity and is also used as a mouthwash (Dušan et al., 
2006). It is toxic to human gastric carcinoma cells (AGS) inducing chromatin 
condensation and cleavage of DNA followed by apoptosis via depolarisation of 
mitochondrial membrane potentials (Kang et al., 2016). Moreover, in Caco-2 cells, 
it has been shown to cause lipid degeneration, mitochondrial damage, nucleolar 
segregation and apoptosis (Llana-Ruiz-Cabello et al., 2014). The antioxidant 
activity of thymol has been associated with protection from oxidative stress and 
mitochondrial damage produced by HgCl2 in HepG2 cells (Shettigar et al., 2015). 
As mentioned earlier, CHD produces metabolic stress which might be overcome 
by the antioxidant activity of thymol, the combination of CHD and thymol were 
tested as an attempt to minimise the cytotoxic effect of CHD.  
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1.9 Farnesol 
Quorum sensing is a process of microbial communication for intra and 
interspecies. It regulates growth, biofilm formation, virulence and competence (Lu 
et al., 2014). C. albicans releases different QSMs including tyrosol, farnesol, 
farnesoic acid, phenyl ethyl alcohol and tryptophol. It is believed that all these 
QSMs play a role in Candida morphogenesis (Kruppa, 2009). The release of 
these QSM is regulated by cell density (Han et al., 2011).  
Farnesol is a quorum sensing molecule produced by C. albicans to control 
filamentation, it is released when the yeast cells concentration is below 106 
CFU/mL (Albuquerque and Casadevall, 2012). It inhibits hyphal formation at a 
concentration of 10-250 µM but has no effect on cell elongation (Lu et al., 2014). 
It enhances the resistance of Candida to oxidative stress, and it plays an 
important role in the competence of Candida with other fungi by promoting 
apoptosis in Saccharomyces cerevisiae, Aspergillus nidulans, and Penicillium 
expansum), and suppresses the growth of Paracoccidioides brasiliensis (Han et 
al., 2011). In the current work, farnesol was investigated to be incorporated with 
CHD and thymol as an attempt to stop the filamentation of Candida, preventing 
the biofilm formation and consequently preventing the invasion of candida to new 
sites in the oral cavity. 
To avoid the burden of medication systemic side effects of antifungals 
formulations, CHD was investigated for its applicability for local delivery as it has 
no systemic side effect and has a broad-spectrum biocidal activity.  The dosage 
form was designed in the form of a mucoadhesive buccal tablet to provide a 
controlled release for two hours, the time being selected to minimise distress that 
might be obtained from tablet application. Moreover, thymol and farnesol were 
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preliminarily tested for their antifungal activity and cytotoxicity for evaluating 
potential incorporation into future formulations. Hydrogel polymers were used to 
formulate the mucoadhesive buccal tablet to prolong and control the release of 
CHD in the oral cavity. 
1.10 Research aim and Objectives 
OPC is an opportunistic infection commonly spread among immunocompromised 
patients which are normally under the treatment with potent drugs with a 
considerable side effect.  For this reason, there is an immense need for an 
efficient treatment with a minimum side effect. Local targeted drug delivery will 
help in avoiding the systemic side effects that are normally accompanied by 
systemic drug delivery. To achieve this goal Hydrogel mucoadhesive buccal 
tablets were used to deliver and control the release of chlorhexidine locally to the 
oral cavity at a safe and effective concentration for the treatment of OPC.    
This project was conducted to meet the following objectives: 
1. To investigate the anticandidal activity of CHD on C.albicans planktonic cells 
and biofilms of different ages. 
2. To study the effect of thymol and farnesol on the anticandidal activity of CHD. 
3. Study the cytotoxicity of CHD on human epithelial cells (the model used in this 
study is HEK293) 
4. To prepare CHD mucoadhesive buccal tablets using HPMC and P407 
polymers 
5. Study the effect of different flow rates of the dissolution media on the release 
of CHD to mimic the release in the oral cavity. 
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6. The prepared tablets will be optimised to comply with the British 
Pharmacopoeia standards. 
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Chapter Two 
Anti-candida activity of 
CHD, Thymol and 
Farnesol
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Chapter 2 : Anti-candida activity of CHD, thymol and farnesol 
This chapter investigated the anti-Candida effects of CHD on planktonic cells and 
on biofilm cells with different maturity stages. Moreover, the effects of thymol and 
farnesol on the activity of CHD were investigated to check the feasibility of their 
incorporation into future formulations. CHD damages the cell wall of C. albicans 
(Williams et al., 2011) and changes its lipid composition (Abu-Elteen and 
Whittaker, 1997), thymol disrupts the lipid packing of the cell wall resulting in 
increasing its fluidity (Braga et al., 2007b). Based on these findings the combined 
effect of CHD and thymol were investigated for a probable synergistic effect. 
Farnesol blocks the conversion of the yeast to a hyphal form, thus the combined 
effects with CHD or thymol were initially investigated to evaluate the potential of 
stopping Candida invasion via hyphae formation and the anticandidal effect of 
CHD and thymol. Furthermore, the effects of HPMC and P407 as the main 
polymers in future formulations were also investigated.  
2.1 Materials and Methods 
2.1.1 Preparation of growth medium and C. albicans culture 
Preparation of growth medium 
Malt extract broth (MEB), Muller Hinton broth (MHB) and Sabauroud dextrose 
agar (SDA) (Sigma-Aldrich, UK) were prepared according to manufacturer’s 
instructions and sterilised by autoclaving at 121°C for 15 minutes. SDA was 
cooled to approximately 50°C then aseptically poured into sterile Petri dishes. 
Preparation of C. albicans stock culture 
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C. albicans strains were obtained from the University of Wolverhampton. MEB 
(10 mL) was seeded with one colony of C. albicans and incubated in an orbital 
shaking incubator (Innova, New Brunswick Scientific, USA.) at 150 rpm and 30°C 
for 18-24 hours. The overnight culture was centrifuged at 1650 g for 5 minutes, 
the broth was decanted, and the cells were resuspended in 30:70 glycerol/MEB. 
Aliquots of 1 mL were transferred to sterile Eppendorf tubes and stored at -80°C. 
Subcultures were prepared from this stock by spreading onto SDA then 
incubating at 30°C for 48 to72 hours. The plate was stored in the fridge for 7-10 
days as a stock for overnight culture. 
Preparation of 0.5 McFarland standard solution 
The standard solution was prepared by adding 0.5 mL of 0.48 M barium chloride 
to 99.5 mL of 0.18 M sulfuric acid. The turbidity of this suspension is equal to the 
absorbance of 0.12-0.15 at 530nm which is equivalent to the turbidity of C. 
albicans overnight culture at a concentration of 1-5x106 CFU/mL.  
Preparation of C. albicans overnight culture  
From an SDA plate incubated at 30°C for 18-24 hours, colonies of C. albicans 
were transferred to MHB and the absorbance was adjusted to 0.12-0.15 at 530nm. 
2.1.2 Minimum Inhibitory concentration (MIC) and minimum biocidal 
Concentration (MBC) 
MIC and MBC were performed for the two drugs under investigation, polymers 
and sugar alcohols which will be used for mucoadhesive buccal tablets 
preparation. Chlorhexidine diacetate salt hydrate (CHD) (Sigma Aldrich, Uk) and 
thymol (Alfa Aesar, UK). Three polymers were investigated namely MethocelTM 
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F4M premium hydroxypropyl methylcellulose (HPMC, viscosity of 2663-4970 cps 
for 2% solution at  20°C, 27-30% methoxyl and 4-7.5% hydroxypropyl 
substitution) was kindly gifted by Colorcon, Uk. Hydroxypropyl methylcellulose 
(HPMC-S, Mn ~86,000, viscosity of 4000 cps for 2% solution at  20°C, 29% 
methoxyl and 7% hydroxypropyl substitution) (Sigma Aldrich, UK). Poloxamer 
407 (P407) (Sigma Aldrich, Uk). Moreover, three sugar alcohols were 
investigated, Sorbitol (Sigma Aldrich, Uk), xylitol (Xylisorb XTAB 240) and 
mannitol (Pearlitol 200 SD), (kindly gifted by Roquette, UK) and farnesol, a 
quorum sensing molecule (Alfa Aesar, Uk). 
The MIC test was performed using the broth tube dilution method, the tested 
compounds were serially double diluted in MHB to a final volume of 5 mL, and 
uninoculated MHB was used as a negative control. 200 µL of an overnight culture 
was transferred to each test tube and to the positive control (giving a final cell 
density of 104-105 CFU/mL, and the tubes were incubated at 30C for 24-48 
hours. The MIC is defined as the lowest concentration giving no visible growth. 
The MBC was determined by inoculating SDA plates with 10 µL from MIC tubes 
showing no visible growth and incubating at 30C for 24-48 hours. The MBC is 
the lowest concentration of the tested compound with no visible growth after 
subculture. 
2.1.3 Time-kill assay 
Time-kill studies were performed by the broth macro-dilution method, each drug 
was serially double diluted using MHB and seeded with 200 µL of a C. albicans 
overnight culture. All tubes (including positive and negative controls) were 
incubated in a shaking water bath (Mickle Laboratory Engineering Company, 
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Gomshall, Surrey, UK) at 30ºC and 80 rpm. Samples of 50 µL were withdrawn at 
time zero and 20 minutes intervals for four hours and at 24 hours, subcultured on 
SDA plates and incubated at 30ºC for 24-48 hours. The results were assessed 
qualitatively for the presence of the growth.  
Quantitative time kill studies were performed at MIC and MBC concentrations for 
up to 2.5 hours. Samples of 100 µL were withdrawn every 30 minutes, serially 
tenfold diluted and a 50 µL were aliquoted from each dilution and spread onto 
SDA plates, the plates were incubated at 30 ºC for 24-48 hours. Colony counts 
were performed for plates with a growth of 30-300 colonies, and the viable count 
was calculated. This test was performed to check the degree of killing for two 
hours which is the proposed time of the tablet to be placed in the oral cavity. 
2.1.4 Microdilution checkerboard assay 
Using a 96 well microtiter plate, CHD stock solution of 10 µg/mL was serially 
double diluted horizontally and thymol 250 µg/mL was serially double diluted 
vertically in MHB. The wells (with the serial dilutions and positive controls) were 
inoculated with 8 µL of C. albicans overnight culture. Sterile MHB was used as 
a negative control. The plate was incubated at 30°C for 24 hours. The turbidity 
was measured using a microtiter plate reader (BioTec, EL800, UK) at 595 nm. 
The fractional inhibitory concentration (FIC) was calculated as follows. 
𝐹𝐼𝐶 =  
MIC of drug A tested in combination
MIC of drug A tested alone
+
MIC of drug B tested in combination
𝑀𝐼𝐶 𝑜𝑓 𝑑𝑟𝑢𝑔 𝐵 𝑡𝑒𝑠𝑡𝑒𝑑 𝑎𝑙𝑜𝑛𝑒
 
The interaction between the tested drugs was predicted from the FIC value: FIC 
≤ 0.5 indicates synergy; FIC > 0.5–4.0 indicates no interaction; and FIC > 4.0 
indicates antagonism (Odds, 2003). 
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2.1.5 Farnesol effect on Candida 
Farnesol stock solution was prepared by adding 70 µL of the stock oily farnesol 
(3.79 M) to 10 mL of a 10% (w/v) solution of P407, the molarity of the prepared 
stock solution is 26.6 mM. Aliquots of 200 µL of C. albicans ATCC 10231 
overnight culture (prepared as described above) was added to 5 mL MHB and to 
5 mL of 2.66 mM of farnesol in MHB. The tubes were incubated at 30°C for 24 
hours. After incubation, the cells were centrifuged (Centrifuge 5804R, Eppendorf, 
Germany) washed twice with Ringer’s solution, stained with 1% crystal violet and 
examined at 1000x magnification using an optical microscope under oil 
immersion lens (Nikon Eclipse ME600, Japan). 
2.1.6 C. albicans biofilm formation 
Preparation of RPMI-1640 
RPMI-1640 medium (dry powder, Sigma-Aldric, UK) was prepared as instructed 
by the manufacturer. The pH of the liquid medium was adjusted to 7.2 with 0.165 
M MOPS (3-(N-Morpholino) propane sulfonic acid, Sigma-Aldrich, UK). 
Growth of C. albicans biofilms 
C. albicans ATCC 10321 was grown on SDA plates for 24 hours at 30°C; then 
colonies were harvested using sterile inoculating loops and seeded into RPMI-
1640 medium. The turbidity of the fungal suspension was adjusted to give an 
absorbance of 1.7±0.3 at 530nm. C. albicans biofilms were formed in 96 well 
microtiter plates by placing 200 µL of the prepared suspension into the wells, 200 
µL of medium (without cells) were used as a negative control. The plates were 
incubated at 37ºC for 4 hours (initial biofilm formation), 24 hours (biofilm) and 72 
hours (mature biofilm) (Pierce et al., 2008).  
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2.1.7 Assessment of antibiofilm activity 
The effect of the drugs used upon existing biofilm was evaluated for their effect 
upon biofilm removal and viability indicators of the remaining cells. To measure 
the antibiofilm activity of the tested drugs, the medium was removed from the 
wells and biofilms washed twice with 200 µL phosphate buffer saline (10 mM, 
pH=7.4), to remove planktonic and non-adherent cells. Pre-prepared serial 
double dilutions of the tested drug in RPMI-1640 medium were added to the 
washed biofilms and incubated for two hours at 37°C. The drug(s) were 
subsequently removed and the biofilm washed with 200 µL phosphate buffered 
saline and the antibiofilm activity was evaluated using the XTT, NR, CV assays 
or by viable counts. Different methods were used to evaluate the effect of the test 
compounds on the metabolic stress and lysosomal activity as indicators of the 
viability condition of the cells. However, the CV assay was used to measure the 
loss from the biofilm. Viable count was performed to check whether the treated 
biofilm cells were dead or alive. 
2.1.7.1 XTT assay 
XTT reduction assay measures the mitochondrial metabolic activity of the cells in 
the biofilm by the reduction of tetrazolium (XTT) to a water-soluble formazan with 
an orange colour. There is a good correlation between the metabolic activity using 
XTT and cell density, the assay adopted from Pierce et al., (2008). XTT is a water-
soluble compound with a negative charge; this prevents its cell penetration. To 
promote its activity, intermediate electron coupling reagent was added to transfer 
electrons from the cytoplasm and plasma membrane to the medium and facilitate 
the reduction of the tetrazolium to formazan (Riss et al., 2004).  
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XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, 
(Alfa Easer, UK)) was prepared by dissolving XTT-sodium salt in PBS (pH 7.4) at 
0.5 mg/mL, followed by filter sterilisation through a 0.22 µm pore size filter. XTT 
stock solution was stored at -80°C in the dark. Menadione (2-Methyl-1,4-
Naphthoquinone or vitamin K3, Alfa Easer, UK) solution was prepared in acetone 
(Sigma-Aldrich, UK) at three concentrations 1, 10 and 100 µM, then the minimum 
concentration with the better detection was used. 
For the XTT assay, the selected menadione concentration was added to 10 mL 
of the XTT solution immediately before the assay, then a 100 µL of this 
XTT/menadione solution was added to each well of a microtiter plate containing 
Candida biofilms, then incubated for two hours at 37°C. Subsequently, 80 µL 
aliquots were pipetted from the supernatant of each well into a new microtiter 
plate and the absorbance was recorded at 450nm using a spectrophotometric 
plate reader (BioTec, EL800, UK). Biofilm viability was calculated based on the 
ratio of the treated cells to untreated cells (positive control) as shown below. 
𝐵𝑖𝑜𝑓𝑖𝑙𝑚 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦% =
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑒𝑙𝑙 − 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑚𝑒𝑎𝑛 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑒𝑙𝑙𝑠 − 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
× 100 
2.1.7.2 Neutral red uptake (NR) assay 
Neutral red is a weekly basic dye, it penetrates cells by diffusion and accumulates 
in the lysosomes and staining them red, due to their low pH compared to the 
cytoplasm. In live healthy cells, the pH gradient was maintained, however when 
the cell dies lysosomes are not able to retain the dye due to the loss of the pH 
gradient (Repetto et al., 2008).  
NR (3-amino-7-dimethylamino-2-methyl-phenazine hydrochloride, Sigma-
Aldrich, UK) stock solution was prepared using ultrapure water at a concentration 
of 4 mg/mL and stored at room temperature in the dark for 1-2 months. A working 
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solution was prepared at a concentration of 80 µg/mL in PBS (pH 7.4), incubated 
at 37°C for 24 hours and then filtered through a 0.45 µm filter to remove 
precipitated dye crystals. Aliquot of 100 µL of this solution was added to each 
Candida biofilm well and the plate was incubated for two hours at 37°C. NR was 
removed, biofilms were washed with 150 µL PBS, followed by fixation with 100 
µL 5% glutaraldehyde (Alfa Easer, UK) for 2 minutes in a fume hood. After the 
fixative solution was removed, 150 µL de-stain solution (50% absolute ethanol, 
48% ultrapure water and 2% glacial acetic acid) was added to each well and the 
plate left for 30 minutes on an orbital shaker to extract NR from the biofilm. Finally, 
from each well, a 100 µL was transferred into a new microtiter plate and the 
optical density was measured at 540nm (Multiskan Ascent, Thermo Labsystems, 
Finland). The anti-biofilm activity was calculated as a percentage of untreated 
cells. 
2.1.7.3 Crystal violet (CV) assay 
Crystal violet is a basic compound which binds to the negative charge of both 
dead and live cells, it is used to measure the biomass of biofilms. It does not 
reflect the killing of the biofilm, but the mass left after treatment (Peeters et al., 
2008).  
Biofilms were fixed with 100 µL/well of absolute ethanol for 15 min, then ethanol 
was removed, and the microtiter plate left to air dry. A volume of 100 µL of 0.1% 
(w/v) CV (Chadwell Heath, UK) was added to each Candida biofilm well, after 20 
minutes the stain was removed, and the plate was washed under a gentle stream 
of running tap water. CV was then extracted from the biofilm by adding 150 µL of 
33% acetic acid (Sigma-Aldrich, UK). Then a 100 µL of the supernatant was 
transferred to a new plate, diluted as required and the absorbance was read at 
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595nm using a plate reader (BioTec, EL800, UK). Antibiofilm activity was 
calculated as a percentage of untreated cells. 
2.1.7.4 Viable count 
Viable counting was used to determine the number of living (capable of 
reproduction) cells after treatment on SDA plates. To the washed biofilm 100 µL 
of MHB was added to each well, the biofilm was resuspended (by repeatedly 
pipetting up and down). The resultant suspension was serially tenfold diluted up 
to seven dilutions in sterile Eppendorf tubes and 50 µL was transferred from each 
dilution and spread onto SDA plate and incubated for 24-48 hours at 30°C. Plates 
with a count of 30-300 colonies were selected the viability was calculated as a 
percentage count of untreated biofilm. 
2.1.7.5 Statistical Analysis  
Tow-way ANOVA (analysis of variance) was obtained using Microsoft Excel to 
test the significant difference between the tested compounds. 
2.2 Results 
2.2.1 Minimum Inhibitory concentration (MIC) and minimum biocidal 
concentration (MBC) 
MIC and MBC were conducted to test the anti-Candidal activity of CHD, thymol, 
and the additives of future formulations against planktonic cells.  
CHD was studied over the range from 10 to 0.087 µg/mL and thymol from 250 -
1.95 µg/mL. The results are presented in Table 2.1.  C. albicans ATCC 10231 
strain showed more resistance toward CHD than the NCYC 854 strain. Therefore 
the former was chosen for testing other compounds. 
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Table 2.1 MIC and MBC of the tested compound at 30°C, n = 3. 
Testing compounds 
(µg/mL) 
C. albicans ATCC 
10231 
C. albicans NCYC 
854 
MIC MBC MIC MBC 
CHD 2.5 5 1.25 2.5 
Thymol 125 250 - - 
HPMC, HPMC-S or P407 >500 >500 - - 
Sorbitol, Xylitol or 
Mannitol 
>10000 >10000 - - 
 
The antifungal activity of the polymers (HPMC, HPMC-S and P407) and Sugar 
Alcohols (sorbitol, xylitol and mannitol) was investigated to check any future 
impact on the activity of the drug in the formulations. Each polymer was serially 
diluted from 500 to 0.005 µg/mL, and sugar alcohols from 10 to 0.0001 mg/mL. 
Neither the polymers nor the sugar alcohols showed any anti-Candidal activity 
against C. albicans ATCC 10231 at the investigated concentrations. 
Due to the mucoadhesive nature of the polymers, polymer-CHD combinations 
were investigated, each polymer was co-dissolved with each drug at a ratio of 
5:1. None of the polymers had an effect on the anti-Candidal activity of CHD 
against planktonic cells. Similarly, thymol-HPMC or HPMC-S showed no effect 
on the activity of thymol Table 2.2. However, P407 at 5:1 ratio increased the MBC 
of thymol above 250 µg/mL with no effect on the MIC. Due to the limited solubility 
of thymol, no further concentrations were investigated. 
Table 2.2  MIC and MBC of drug-polymer combinations at 30°C, n = 3. 
Testing compounds (µg/mL) C. albicans ATCC 10231 
MIC MBC 
CHD + HPMC, HPMC-S or P407 (5:1) 2.5 5 
Thymol + HPMC or HPMC-S (5:1) 125 250 
Thymol + P407 (5:1) 125 >250 
Thymol + P407 (4:1) 125 >250 
Thymol + P407 (2:1) 125 >250 
Thymol + P407 (1:1) 125 ≥250* 
* 2 with no growth and 1 with growth. 
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The effect of P407 on the activity of thymol was further investigated at 4:1, 2:1 
and 1:1 ratio. At 4:1 and 2:1 ratio, the MBC of thymol was >250 µg/mL, while at 
1:1 ratio two out of three replicates showed no growth (Table 2.2). This means 
the effect of P407 on the antifungal activity of thymol is concentration dependent.   
2.2.2 Time-kill assay 
2.2.2.1 CHD 
Qualitative time kill study was performed against ATCC 10231 and NCYC 854 
strains, CHD was serially double diluted from 10 to 0.156 µg/mL.  
The results (Table 2.3) show a complete inhibition of growth after one hour at 10 
µg/mL CHD, however, the MBC (5 µg/mL) had no apparent kill until after 4 hours 
and before 24 hours for ATCC 10231. However, NCYC 854 strain was more 
susceptible with a loss of viability seen after 40 minutes at 10 µg/mL, after 3 hours 
at 5 µg/mL and for the MBC (2.5 µg/mL) the loss of viability was after 4 hours, up 
to 24 hours (Table 2.4). All other dilution showed no apparent loss of viability over 
the 24 hours period. 
Table 2.3 Time-kill results for CHD against C. albicans ATCC 10231 for 24 hours 
and 30°C in MHB, n = 4. (*results are 50%.) 
 
Time (min) 
Concentration (µg/mL) 
10 5 2.5 1.25 0.625 0.3125 0.15625 
Negative 
control 
20 + + + + + + + - 
40 + + + + + + + - 
60 + + + + + + + - 
80 - + + + + + + - 
100 - + + + + + + - 
120 - + + + + + + - 
150 - + + + + + + - 
180 - + + + + + + - 
210 - + + + + + + - 
240 - -* +* + + + + + - 
24 hours - - + + + + + - 
  
Table 2.4 Time-kill results for CHD against C. albicans NCYC 854 for 24 hours 
and 30°C in MHB, n = 4. 
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Time (min)  
Concentration (µg/mL) 
10 5 2.5 1.25 0.625 0.3125 0.15625 
Negative 
control 
20 + + + + + + + - 
40 + + + + + + + - 
60 - + + + + + + - 
80 - + + + + + + - 
100 - + + + + + + - 
120 - + + + + + + - 
150 - + + + + + + - 
180 - + + + + + + - 
210 - - + + + + + - 
240 - - + + + + + - 
24 hours - - - + + + + - 
 
The effect of CHD upon the viable cell count with time was studied (Figure 2.1). 
The results show that at the MBC (5 µg/mL), cell viability was decreased within 
the first 60 minutes and eventually by 1 log, while both the MIC and the positive 
control showed no change in cell viability over the tested period.  The time 
performed was chosen based on the proposed time for the tablet in the oral 
cavity.  
 
Figure 2.1 Time-kill curves for CHD against C. albicans ATCC 10231 strain, at 
the MBC (5 µg/mL), MIC (2.5 µg/mL) and positive control (0 µg/mL CHD) at 30°C 
and shaking at 80rpm in MHB. Data are expressed as mean percentage ± SD, n 
= 3. 
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2.2.2.2 Thymol 
A thymol time kill study was performed against C. albicans ATCC 10231, at a 
concentration range from 250 µg/mL to 15.6 µg/mL. The results (Table 2.5) show 
that the only fungicidal activity was found at 24 hours for 250 µg/mL; which is the 
MBC concentration. 
Table 2.5 Time-kill results for thymol against C. albicans ATCC 10231 for 24 
hours and 30°C in MHB, n = 3. 
Time (min) 
Concentration (µg/mL) 
250  125  62.5  31.25  15.625  Negative control 
20 + + + + + - 
40 + + + + + - 
60 + + + + + - 
80 + + + + + - 
100 + + + + + - 
120 + + + + + - 
150 + + + + + - 
180 + + + + + - 
210 + + + + + - 
240 + +  + + + - 
24 hours - + + + + - 
 
A more detailed time kill study was undertaken which monitored the number of 
viable cells with respect to time of exposure to thymol (Figure 2.2). 
 
Figure 2.2 Time-kill curves for thymol against C. albicans ATCC 10231 strain, at 
the MBC (250 µg/mL), MIC (125 µg/mL) ad positive control (0 µg/mL thymol) at 
30°C and shaking at 80rpm in MHB. Data are expressed as mean percentage ± 
SD, n = 3. 
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Quantitatively, thymol at the MBC (250 µg/mL) showed continuous loss of cell 
viability from 30 minutes leading to a 1 log reduction in viable cells, by 2.5 hours. 
There was no change in the cell viability at the MIC concentration (125 µg/mL) or 
the absence of thymol (control). 
2.2.3 Microdilution checkerboard assay 
C. albicans ATCC 10321 susceptibility to the combination of CHD and thymol 
was examined using a checkerboard assay, the results are presented in Table 
2.6. Although there is a reduction in the MIC of both drugs, the MIC for the 
combination was 1.25 µg/mL CHD and 31.25 µg/mL thymol, the FIC value was 
equal to 0.75 which means there was no interaction (FIC =0.5-4) (Odds, 2003). 
However, the MBC of CHD did not change after the addition of thymol and was 
equal to 5 µg/mL. 
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Table 2.6 Checkerboard assay for the combination of CHD and thymol against C. albicans ATCC 1023 for 24 hours at 30°C in MHB, 
Data are expressed as mean percentage ± SD, n = 5.  
Thymol 
concentration 
µg/mL 
CHD concentration µg/mL 
5 2.5 1.25 0.625 0.312 0.156 0.078 0.039 0.019 
125 - - - - - - - - - 
62.5 - - - - - - - - - 
31.25 - - - 75.54±16.93 60.47±5.52 66.21±13.51 62.57±0.81 62.84±14.10 66.10±11.02 
15.625 - - 57.26±34.44 77.80±2.34 66.03±6.27 71.33±4.48 72.04±6.72 70.84±5.96 79.95±8.36 
7.8125 - - 75.56±15.97 77.75±8.46 74.29±10.47 76.66±17.51 76.23±3.10 68.61±9.31 75.06±8.59 
3.906 - - 90.94±24.29 88.28±14.81 75.41±13.56 80.33±14.08 82.11±0.94 78.41±8.19 79.37±8.58 
1.953 - - 77.19±9.22 85.07±7.78 86.19±14.92 88.87±20.30 83.67±9.60 91.53±11.09 88.15±5.87 
0.977 - - 90.34±16.47 84.12±9.09 82.71±13.04 86.61±18.30 88.16±5.69 89.32±6.68 90.60±5.75 
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2.2.4 Effect of farnesol on C. albicans 
Farnesol is a quorum sensing molecule produced by C. albicans to stop hyphae 
formation. The MIC and MBC were tested by serially ten-fold dilution from 1.06 x 
10-4 to1.06 mM. After incubation, all tubes showed turbidity which indicates no 
growth inhibition. The turbidity in the first three tubes was less than the control 
without farnesol, due to inhibition of hyphae formation, because cells showed less 
density. No MBC was attained at a concentration ≤1.06 mM against C.albicans 
ATCC 10231.  
The morphological investigation was performed by taking the highest 
concentration of 1.06 mM farnesol in MHB and examined microscopically under 
oil immersion (1000x). Untreated cells showed long hyphae, however, treated 
cells had an oval shape (Figure 2.3), indicating that farnesol successfully inhibited 
the filamentation of Candida.  
  
Figure 2.3 C. albicans stained with crystal violet, left grown in MHB, right grown 
in 1.06 mM of farnesol in MHB and incubated at 30°C for 24 hours (1000x). 
2.2.4.1 Effect of farnesol on the activity of CHD and Thymol 
The MIC and MBC for CHD were investigated in the presence of farnesol (1.06 
mM). It was found that the MIC increased from 2.5 to 10 µg/mL and the MBC 
increased from 5 to 40 µg/mL. The MIC and MBC for thymol in the presence of 
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farnesol at 1.06 mM was similarly investigated. It was found that the MIC was 
increased from 125 to 250 µg/mL and MBC was >250 µg/mL. Due to the limited 
aqueous solubility of thymol, no further analysis was performed to estimate the 
MBC in the presence of Farnesol.  
2.2.5 Effect of CHD and thymol on C. albicans biofilm  
The major pathogenicity of C. albicans is attributed to its ability to form a biofilm, 
which is more resistant to antifungals. This explained by the upregulation of efflux 
pumps, the presence of extracellular matrix and persister cells (Gulati and Nobile, 
2016). So, it is very important to study the effect of CHD and thymol on C. albicans 
biofilm. The antibiofilm effect of CHD and thymol and their combination were 
investigated for two hours which is the intended time of mucoadhesive buccal 
tablet application, for the treatment of OPC which is commonly available in the 
form of biofilms.  
There are several methods to measure the viability of the biofilm, in this work XTT 
assay, CV assay and NR uptake assay were used. 
2.2.5.1 XTT reduction assay 
XTT reduction assay was selected to measure the metabolic activity of the cells 
in the biofilm (Pierce et al., 2008). Menadione was added to facilitate the 
reduction of the tetrazolium (XTT) to orange colour, water soluble formazan (Riss 
et al., 2004). In this experiment, the optimisation of menadione concentration (1, 
10 and 100µM (n=24)) was performed on Candida biofilms which were grown in 
96 well plates for 24 hours. Each concentration was added to XTT solution 
instantly before adding to the biofilm as a 100 µL of XTT/menadione solution, the 
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plate was incubated for 2 hours at 37°C and the colour change was measured. 
The absorbance values were 0.063±0.040, 0.470±0.041 and 0.685±0.193 for 1, 
10 and 100 µM, respectively. 10 µM was chosen due to its reasonable detection 
with low standard deviation for subsequent experiments. 
Anti-biofilm activity of CHD, CHD-HPMC and CHD-P407 were investigated at a 
5:1 ratio of polymer to CHD. The concentrations of CHD were 160 to 0.63 µg/mL 
(serially double diluted). The percentages of the absorbance of the treated 
biofilms to the average of untreated cells represented the metabolic activity of the 
biofilms (4, 24 or 72 hours) after two hours exposure of the drug. 
Candida in the 4-h biofilm, had started adhering to the plate and producing 
hyphae. After two hours treatment with CHD at a concentration of ≥10 µg/mL, 
XTT results show nearly 100% loss of the mitochondrial activity. Moreover, there 
was a considerable loss in the activity at 5 µg/mL and this loss is decreased with 
the decrease in CHD concentration (Figure 2.4-a).  
 
Figure 2.4 Effect of CHD on initial C. albicans biofilm, (a) 4 hours and (b) 24 
hours, for 2 hours at 37°C using XTT assay. Data are expressed as mean 
percentage ± SE, n = 12. 
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With the increase in the maturity of the biofilm at 24 hours (Figure 2.4-b), the 
resistance to CHD was increased. As evidenced by CHD concentration of ≥40 
µg/mL showing nearly 100% suppression of metabolic activity, with a significant 
reduction to 15% and 26% at 20 and 10 µg/mL CHD, respectively. The reduction 
was decreased gradually with the decrease of CHD concentration. Furthermore, 
there is no apparent difference between the activity of CHD alone or in 
combination with the polymers for both biofilms. 
 
Figure 2.5 Effect of Chlorhexidine on C. albicans biofilm (72 hours), for 2 hours 
at 37°C using XTT assay. Data are expressed as mean percentage ± SE, n = 4. 
Biofilms grown for 72 hours showed nearly 100% loss in activity at concentrations 
of ≥40 µg/mL. The loss was started from a concentration of 2.5 µg/mL and it was 
higher than 24-h biofilm. This explained by the fragile nature of the 72-h biofilm, 
a visual loss was noticed during the several washing steps, this might result in 
false negative results showing more sensitivity toward CHD than 24-h biofilm 
(Figure 2.5).  
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Similarly, thymol was investigated for its antibiofilm activity alone and in 
combination with HPMC or P407 of 5:1 polymer to drug ratio. Concentrations of 
250 µg/mL to 0.98 µg/mL (serially double diluted) were examined on (4, 24 and 
72 hours) C. albicans biofilms. Although there was a reduction in the metabolic 
activity at a thymol concentration of ≥62.5 against 4-h biofilm (Figure 2.6-a), the 
effect was fluctuating with no certain pattern for all tested compounds. Similar 
results were found for the 24-h biofilm (Figure 2.6-b) and at 250 µg/mL an 
increase in the absorbance to 120% for thymol, followed by a loss in its value to 
75% at 62.5 and 125 µg/mL. 
 
 
Figure 2.6 Effect of thymol on initial C. albicans biofilm (a)4-h and (b) 24-h for 2 
hours at 37°C using XTT assay. Data are expressed as mean percentage ± SE, 
n = 12. 
 
There was a concentration-dependent loss in the metabolic activity of the biofilm 
which grown for 72 hours (Figure 2.7). Due to the visual loss of the 72-h biofilm 
mass as mentioned earlier with CHD results, 72-h biofilm investigations will be 
omitted from future experiments. 
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Figure 2.7 Effect of thymol on C. albicans biofilm 72-h, for 2 hours at 37°C using 
XTT assay. Data are expressed as mean percentage ± SE, n = 4. 
 
2.2.5.2 Crystal violet (CV) assay 
CV is used to measure the biomass of the biofilms (Peeters et al., 2008). Biofilms 
grown for 4 and 24 hours were treated with CHD, CHD-P407 and CHD-HPMC at 
concentrations from 160 to 1.25 µg/mL for two hours at 37°C. The percentage of 
the absorbance of treated to untreated cells represents the biomass per cent 
remained after treatment. The biomass for 4-h biofilms treated with 
concentrations of ≥10 µg/mL had approximately an absorbance percentage 
ranging from 30±5 % for CHD and CHD-polymer combinations (Figure 2.8-a). At 
5 µg/mL, the loss was approximately 50% which was decreased with decreasing 
CHD concentration and no 100% biomass was noticed even at the lowest 
concentration of 1.25 µg/mL. 
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Figure 2.8  Effect of CHD on initial C. albicans biofilm (a) 4-h, (n = 6), (b)24-h, (n 
= 8), for 2 hours at 37°C using CV assay. Data are expressed as mean 
percentage ± SE. 
 
In contrast, the biomass of 24-h biofilm showed slightly less reduction (45±5%) 
at the concentrations of ≥20 µg/mL and at 10 µg/mL was 55%. The loss was less 
with the lower concentrations and at 1.25 µg/mL no loss was detected (Figure 
2.8-b). Moreover, HPMC and P-407 had no pronounced effect on CHD activity at 
≥10 µg/mL for both biofilms, at lower CHD concentrations the effects of the 
polymers were unpredictable. 
Light microscopy images for 24-h biofilm (Figure 2.9), showed that the intensity 
of the colour and the thickness of the mycelium stained with CV decreases with 
the increase in the concentration of CHD, compared to the control and indicates 
a loss in the biomass.  
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The effect of thymol on the biomass of C. albicans was investigated using CV at 
the concentrations from 250 to 1.95 µg/mL. Biomass loss was increased with the 
increase in thymol concentration, the effect of both MBC and MIC on the biomass 
of the 4-h biofilm, is presented in (Figure 2.10-a). The absorbance percentages 
were 29% and 48% respectively and increased to 65% at 62.5 µg/mL, this 
followed by a gradual increase in biomass with the decrease in thymol 
concentration and no loss was recorded at 3.91 µg/mL. However, the 24-h biofilm 
was less affected; the percentages increased to 63% and 68% at MBC and MIC, 
respectively (Figure 2.10-b). Moreover, at concentrations of ≥7.81, there was 
100% retaining of the biomass. This indicates that the sensitivity to the drug is 
affected by the maturity of the biofilm. 
 
 
10 µg/mL 
 
20 µg/mL 
 
40 µg/mL 
 
80 µg/mL 160 µg/mL Control 
Figure 2.9 Images of C. albicans biofilm 24-h treated with CHD and stained with 
CV (x400). 
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Figure 2.10 Effect of thymol on the biomass of initial C. albicans biofilm (a) 4-h, 
(n = 8), (b) 24-h, (n = 8) for 2 hours at 37°C. Data are expressed as mean 
percentage ± SE. 
 
Light microscopy studies showed that the effect of thymol on 24-h biofilm was not 
distinct compared to the control (Figure 2.11) indicating the low effect of thymol 
on the biomass of Candida biofilm.  
 
 
 
  
 
 
Figure 2.11 Images of C. albicans biofilm 24-h treated with thymol and stained 
with CV (x400). 
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2.2.5.3 Neutral red (NR) uptake assay 
NR is a basic dye retained by the lysosomes of viable cells (Repetto et al., 2008). 
This assay is widely applied to measure the cytotoxicity for human cell lines, and 
depending on the same principle, since the pH of the vacuoles is around 5.5 
(Patenaude et al., 2013), the assay was applied to C. albicans cells. Washed 
biofilms were incubated for two hours with CHD at concentrations of 160-1.25 
µg/mL. The biofilms were then washed, incubated with the NR, and after washing 
and fixation the stain was extracted and measured. The percentage absorbance 
of CHD treated biofilm to untreated is an indicator of cell viability. The results 
(Figure 2.12-a) show the observed viability based on the vacuolar staining of the 
biofilm cells. NR uptake was decreased with increasing CHD concentration and 
that at ≥10 µg/mL was around 10% with a considerable effect of 40% retaining in 
activity at 5 µg/mL and around 100% at ≤2.5 µg/mL. 
 
Figure 2.12 Effect of CHD on initial C. albicans biofilm using NR assay (a) 4 hours, 
(n = 9), (b) 24-h, (n = 5), for 2 hours at 37°C. Data are expressed as mean 
percentage ± SE. 
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A similar effect was seen on 24-h biofilm (Figure 2.12-b) at ≥20 µg/mL, with 
apparent viability only reduced to 21-27% and 36% at 10 µg/mL and no effect 
recorded at 2.5 µg/mL. CHD-HPMC showed slightly higher absorbance for almost 
all concentrations, whereas CHD-P407 was similar to that of CHD alone.  The 
effect of HPMC may be attributed to the mucoadhesive nature of the polymer 
which might form a barrier against the change in the pH and the release of the 
NR from Candida or interfere with the mechanism of the assay. 
Microscopical analysis of stained cells showed that the colour intensity of NR in 
the vacuoles. Colour intensity is decreased with increasing CHD concentration. 
This is due to the loss of the vacuolar activity and pH gradient (Figure 2.13), which 
in agreement with the colourimetric assay. The hazy appearance of the image 
may be due to the presence of the extracellular material in the growing biofilm 
(Chandra et al., 2001)  
 
 
 
 
 
 
 
 
 
Figure 2.13  Images of C. albicans biofilm 24-h treated with CHD and stained 
with NR (x400). 
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Figure 2.14  Effect of thymol on initial C. albicans biofilm using NR assay (a) 4-
h, (n = 6) (b) 24-h, ( n = 5) for 2 hours at 37°C. Data are expressed as mean 
percentage ± SE. 
 
The effect of thymol upon vacuolar activity (viability) of C. albicans 4-h biofilm are 
presented in Figure 2.14-a. It can be seen, that thymol at concentrations > 15.63 
µg/mL have decreased the apparent viability, for instance at 125 and 250 µg/mL 
the viability was 28% and 10%, respectively. There was a clear antagonistic effect 
of P407 on thymol activity at 125 and 250 µg/mL, which was similar to the finding 
on planktonic cells as it affected the MIC and the MBC. On the contrary, P407 
showed an increase in thymol activity at a concentration of ≥62.5 µg/mL. HPMC 
has a similar antagonistic effect at 250 µg/mL.  
Thymol activity against C. albicans 24-h biofilm was substantially reduced (Figure 
2.14-b) compared to 4-h biofilm in which loss of cell viability occurred only at 
concentrations ≥125 µg/mL. Both polymers exerted an antagonistic effect on 
thymol antimicrobial activity at 250 µg/mL. Microscopical images for the effect of 
thymol on 24-h biofilm (Figure 2.15) agreed with the CV images reflecting the low 
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potency of thymol against C. albicans biofilm even at high concentration (250 
µg/mL).  
 
 
 
 
 
 
 
 
Figure 2.15 Images of C. albicans biofilm 24-h treated with thymol and stained 
with NR (x400). 
2.2.6 Recovery of biofilm after treatment 
Biofilm cells’ recovery was performed to check if the cells have lost their viability 
after treatment with the drugs and if the damage is reversible or permanent. 
Based on the previous analyses using XTT, NR uptake and CV assays, although 
the behaviour of the drug was the same, but the values were different for instance 
treating 24-h biofilm with CHD at concentration of ≥40 µg/mL showed ~100% 
inhibition of mitochondrial activity, ~60% loss of biomass and ~80% loss of 
vacuolar activity. Accordingly, the recovery experiment is to check if the biofilm 
maintained its viability.  
2.2.6.1 CV and NR assays 
Biofilm cell viability recovery was performed for 24-h biofilm treated with CHD or 
thymol for 2 hours, followed by washing and re-incubating in a fresh medium for 
Control 
31.25 µg/mL 
 
62.5 µg/mL 
 
125 µg/mL 
 
250 µg/mL 
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another 24 hours. The viability was assessed using CV and NR assays (Figure 
2.16). 
The test was not reproducible due to the damage of the biofilms, uneven growth 
with floating of non-adherent pieces of the biofilms was noticed visually after 24 
hours of recovery, in most of the wells. Moreover, for both drugs, unlike the 
previous results, the biomass results were lower than the vacuolar activity. It can 
be concluded that the cells were viable, but the accuracy of these results is 
questionable. 
 
Figure 2.16 Recovery of C. albicans biofilm for 24hours after treatment with 
different concentrations of (a) Chlorhexidine (b) thymol using NR uptake and CV 
assays at 37°C, Data are expressed as mean percentage ± SE, n = 6. 
 
2.2.6.2 Viable count 
Based on the previous analysis, the quantitative value of biofilm recovery was 
inconclusive. Therefore, the need for another experiment with a minimum 
washing and treating steps were necessary. By using viable count, these steps 
were kept to a minimum. 
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Viable count for 24-h biofilms treated with CHD was performed and Candida was 
grown on SDA plates (Figure 2.17). It was noticed that the viability is decreased 
with increasing CHD concentration. The viability was 0.02%, 1.06% and 4.3% at 
160, 80 and 40 µg/mL, respectively and 100% recovery with 2.5 µg/mL. 
 
Figure 2.17 viable count of C. albicans biofilm after treatment with CHD at 30°C, 
Data are expressed as mean percentage ± SE, n = 3. 
 
2.2.7 Effect of CHD and Thymol combination on C. albicans biofilms  
Thymol and CHD affect the cell wall of C. albicans in different ways. Therefore, 
the combined effect of CHD and Thymol was investigated to check the possibility 
of synergistic or additive effect against Candida biofilm. The investigated 
concentrations were chosen based on the previous analysis and the results were 
evaluated using CV and NR uptake assays. The XTT assay excluded due to the 
reducing activity of thymol. 
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Crystal violet assay 
CV assay was used to detect the combined effect of the drugs on the biomass of 
the biofilm grown at 4-h and 24-h. CHD concentrations were 5, 10 and 20 µg/mL, 
whereas thymol concentrations were 31 and 62 µg/mL. 
It was found that the addition of thymol to CHD had a limited additive effect 
(Figure 2.18). Statistical analysis was performed individually between CHD and 
CHD combinations at the same concentration. There was a significant difference 
for both treatment groups. At 5 µg/mL CHD and 62.5 µg/mL thymol, there was a 
10 and 15% decrease in the biomass compared to CHD alone for 4-h and 24-h 
biofilms, respectively. Although other statistical analysis showed significant 
differences, the effect was ≤10%. 
 
Figure 2.18 Effect of the combinations of CHD and thymol on C. albicans biofilm 
(a) 4-h and (b) 24-h for two hours treatment at 37°C using CV assay. Data are 
expressed as mean percentage ± SE, n = 12, p>0.05.  
*Asterisks represent values significantly different from CHD alone of the same concentration. 
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Neutral red uptake assay 
Using the NR uptake assay to examine the effect of antifungal combinations on 
vacuolar activity in 4 and 24 hrs biofilms, revealed significant differences at 5 
µg/mL CHD. The greatest effect was seen for 62.5% thymol on the 4 hrs biofilm 
with a 20% reduction in vacuolar activity, followed by the 5 µg/mL CHD and 31.25 
% thymol combination which was 15% higher than CHD alone (Figure 2.15). 
 
Figure 2.19 Effect of the combinations of Chlorhexidine and thymol on C. albicans 
biofilm (a) 4-h and (b) 24-h for two hours treatment at 37°C using NR uptake 
assay. Data are expressed as mean percentage ± SE, n = 12, p>0.05. 
*Asterisks represent values significantly different from thymol alone of the same concentration 
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final stage of a developed biofilm is the dispersal stage where yeast cells are 
liberated from the biofilm to invade new sites (Gulati and Nobile, 2016).  
The MIC of CHD were 1.25 and 2.5 µg/mL and MBC 2.5 and 5 µg/mL for NCYC 
854and ATCC 10231 strains, respectively. This finding is comparable with a 
previous work, in which MIC and MBC values for thirty-two C. albicans species 
were found to be 3.125 and 6.25 µg/mL, respectively (Salim et al., 2013). Time-
kill studies were performed to check the antimicrobial activity with respect to time, 
due to its importance for future formulations which are intended to be applied in 
the oral cavity for two hours. The antimicrobial effect of CHD was time and 
concentration dependent (Table 2.3 and Table 2.4), and at a concentration of 10 
µg/mL, the fungicidal effect was achieved within 40-60 minutes for both strains. 
The fungicidal effect of the MBC was recorded at the 4th hour, and there was 1 
log reduction in the growth of Candida after 2.5 hours (Figure 2.1). Moreover, 
there was no change in cells viability for the first 30 minutes, i.e. the onset of 
action of CHD appeared after 30 minutes, which was attributed to its 
concentration and time-dependent activity (Bobichon and Bouchet, 1987). 
The effect of CHD on Candida biofilm was concentration-dependent when using 
XTT, CV and NR assays. A 100% loss of the mitochondrial activity (XTT assay) 
was found at a concentration of ≥10 and ≥40 µg/mL for 4-hr and 24-h biofilms, 
respectively (Figure 2.4). The result of the 4-h biofilm was comparative to the time 
kill assay for planktonic cells (Table 2.3), all cells were killed after one hour at a 
concentration of 10 µg/mL. Surpriµy, the 24-h biofilm finding is equivalent to the 
MBC of CHD in the presence of farnesol against planktonic cells, and there is no 
evidence that farnesol release by the biofilm had a direct effect on CHD activity. 
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Bobichon and Bouchet (1987) reported that C. albicans exposure to 1 µg/mL of 
CHD gluconate (MIC for the chosen strain) resulted in mitochondrial swelling after 
only 2 hours. In the current work, there was a complete loss of the mitochondrial 
activity at a concentration of ≥10 and ≥ 40 µg/mL, and the residual biomass for 
the same concentrations was around 30% and 45% for 4-h and 24-h biofilms, 
respectively. It therefore appears that because CHD damaged the cells or even 
made them detached from the biofilm, there were cells residues or stressed cells 
that can interact with CV staining. This is accompanied by a substantial loss in 
the vacuolar activity leaving 4-h biofilm with 10% and 24-h with around 24% 
activity. Accordingly, the C. albicans cells suffer a complete loss of metabolic 
activity, a significant loss of pH gradient and to a lesser extent, a reduction in 
biomass.  The microscopical images are shown in Figure 2.9 and Figure 2.13 are 
in agreement with the colourimetric assays, that visually it shows the intensity of 
colour decreasing with increasing the concentration.  
Moreover, based on these analyses, there is no evidence whether the loss is 
permanent or temporary, so NR, CV assay and viable count were used to assess 
the damage by leaving the treated cells to grow for another 24 hours. Using viable 
count, almost 100% fungicidal activity was recorded at 160 µg/mL, the viability 
increased with decreasing the concentration (Figure 2.17) and all concentration 
above the MIC (2.5 µg/mL) of planktonic cells showed a reduction in the viability.  
Furthermore, by comparing XTT, CV and NR, XTT has a better comparison to 
viable count than CV and NR assays. Although XTT results were lower than the 
viable count, this might be attributed to the sensitivity of colourimetric absorbance 
assay.  
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Previous investigations (Chandra et al., 2001) were performed using CHD 
against planktonic cells and biofilm of C. albicans. It was found that the resistance 
of C. albicans biofilm of pathogenic strains increased towards different 
antifungals compared to planktonic cells including CHD, the MIC increased from 
16 to 256 µg/mL for ~4-h and 72-h biofilms, respectively. The increase in 
resistance might be due to the extracellular material, genetic or biochemical 
changes in the cells (Chandra et al., 2001). Furthermore, Chlorhexidine might be 
more effective against planktonic cells than biofilm due to the uniform 
concentration of the drug in the medium in the former. In the latter, there would 
be a concentration gradient for both extrinsic and intrinsic material, attributable to 
the uneven thickness and cell density in the biofilm (Suci and Tylor, 2002).  
The MIC of thymol was identical to a previous study (Braga et al., 2007a) and it 
is equal to 125 µg/mL against C. albicans ATCC 10231, and the MBC was 250 
µg/mL. Although both polymers are mucoadhesive, HPMC did not affect the MBC 
of thymol, while P407 increased it to ≥250 µg/mL and the effect was 
concentration-dependent and that might be explained by its surfactant activity. 
Rhee et al. (2006) found there is an interaction between P407 and thymol by 
changing the gelling temperature and thermal behaviour of P407 by thymol. 
Moreover, it was found that the effect of thymol against Salmonella typhimurium 
was counteracted by the non-ionic surfactant Tween 80, and this effect increased 
with the increase in Tween concentration. The authors assumed that by the 
addition of the surfactant, thymol became more soluble in the aqueous medium 
leading to decrease its solubility in the cell membrane of the microorganism 
(Juven et al., 1994). Thymol fungicidal activity at the MBC was only found at 24 
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hours (Table 2.5). Moreover, time-kill studies showed continuous loss of cell 
viability from 30 minutes leading to a 1 log reduction in viable cells, by 2.5 hours 
(Figure 2.2) indicating a slow rate of kill. 
Similar to CHD, the effect of thymol on Candida biofilm was investigated using 
XTT, CV and NR assay. The XTT results were inconsistent, at 24-h biofilm and 
250 µg/mL, the mitochondrial activity was 120% (Figure 2.6). This can be 
explained by the reducing activity of thymol (Ozen et al., 2011) which gave false 
positive results by increasing the reduction of XTT by thymol itself and masks the 
real mitochondrial activity of live cells. The effects of thymol on the biomass and 
vacuolar activity were concentration dependent, and the effectiveness of the 
thymol decreased with the increase in maturity of the biofilm. The maximum effect 
on the biomass was with 250 µg/mL leaving the biofilm with a biomass of 29% 
and 63% for 4-h and 24-h, respectively (Figure 2.10). Lower thymol 
concentrations led to a lower reduction of biomass. Furthermore, the effect upon 
the vacuolar activity at 250 µg/mL left the remaining biofilm with 10% and 47% 
vacuolar activity for 4-h and 24-h biofilm, respectively (Figure 2.14). Braga et al., 
(2007b) found that thymol interacted with C. albicans and changed the 
morphology of the cell envelop and the permeability and fluidity of the cell wall. 
Thymol was previously investigated by Braga et al., (2008) against C.albicans. 
ATCC 3153A and ATCC MYA 2876 biofilm grown for 24 hours and treated with 
different concentrations of thymol for 6,12 and 24 hours at concentrations of 250 
to15 µg/mL. The effect was measured using XTT assay and the results were 
concentration and time-dependent, and at 250 µg/mL, there was ~40% reduction 
in the mitochondrial activity. Another investigation showed 80% inhibition of C. 
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albicans biofilm after 24 hours treatment with 0.06% of thymol (Dalleau et al., 
2008). 
The reducing activity of thymol was measured by Deng et al., (2016) using Ferric 
reducing antioxidant potential, its effect on the XTT assay cannot be exempted, 
especially after the viability of 24-h biofilm treated with 250 µg/mL showed 129% 
of metabolic activity and based on the CV and NR assay the activity was 68% 
and 47%, respectively.  
From the results, it can be confirmed that CHD has more potent anti-Candida 
activity than thymol. Other research work compared the activity of chlorhexidine 
gluconate and thymol mouthwashes, also found that CHD was more potent than 
thymol mouthwash against planktonic cells and biofilms of C. albicans clinical 
isolates (Shrestha et al., 2011 and Ramage et al., 2011). 
The effect of the polymers on the activity of CHD and thymol was variable 
between XTT, CV and NR assays. No distinctive effect of both HPMC and P407 
on CHD activity was observed with the XTT assay. Using CV assay, HPMC 
increased the effect of CHD on the 4-h biofilm at concentrations <10 µg/mL 
(Figure 2.8-a). Generally, using NR assay, HPMC decreased the activity of CHD 
(Figure 2.12). However, P407 did not show a clear effect on CHD activity. By 
comparing the three methods the effect was not consistent and it can be assumed 
that none of the polymers has a direct effect on the activity of CHD. 
On the other hand, HPMC decreased the activity of thymol at 250 µg/mL and 
neutral red assay this effect diminished at lower concentrations (Figure 2.14). 
This effect was dictated neither on planktonic cells nor using CV analysis and it 
was noticed with CHD-HPMC and NR assay, the mucoadhesive nature of HPMC 
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might have resulted in the inconsistency of the results. P407 had no effect on 
thymol assessed by CV assay which might be attributed to the measurement of 
both dead and live cells. However, it decreased thymol activity, assessed by NR 
assay at 250 µg/mL thymol for 4-h and 24-h biofilm, similar to planktonic cells. 
Accordingly, there is no effect of HPMC on thymol activity while P407 at high 
concentration decreased the activity of thymol. 
Farnesol inhibited the filamentation of C. albicans (Figure 2.3). The effect of 
farnesol was previously investigated by other researchers who found complete 
inhibition of filamentation at 300 µM (Ramage et al., 2002). The anti-Candidal 
activity of CHD and thymol was decreased in the presence of farnesol. Shirtliff et 
al., (2009) studied the effect of farnesol on C. albicans and they found that 
farnesol at a concentration of 200 µM causes upregulation of proteins involved in 
oxidative stress, protein folding and protection against the environment. This 
might explain the decreased activity of CHD and thymol, which have their direct 
effect on the cell wall. The effect of farnesol on the MIC of amphotericin B, 
fluconazole, itraconazole and caspofungin was studied, and it was found that 
there is a synergistic effect between the tested antifungals and farnesol with FIC 
< 0.5 (Cordeiro et al., 2013). The authors also found that the potentiation was 
more with azoles, which was attributed to the involvement of both compounds in 
sterol pathway of Candida and they assumed the activity increased due to the 
accumulation of intermediate toxic metabolites. A similar investigation was 
performed by Katragkou et al., (2015), by studying the combined effect of farnesol 
with micafungin, fluconazole or amphotericin B on C. albicans biofilm. 
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Amphotericin B showed no interaction while both micafungin and fluconazole 
showed a synergistic effect with an FIC value of 0.49 and 0.5, respectively. 
CHD-thymol combination showed a decrease in the MIC of the planktonic cells, 
although no MBC reduction was registered, the MIC for the combination was 1.25 
µg/mL CHD and 31.25 µg/mL thymol. The combined effect was more influential 
at lower concentrations of CHD and thymol (Figure 2.18 and Figure 2.19). 
Previous researchers investigated chlorhexidine–thymol combinations against 
different microorganisms. They found that it was more effective against biofilms 
of Streptococcus mutans and Lactobacillus plantarum than their planktonic cells, 
and S. mutans biofilm was more sensitive toward the combination (Filoche et al, 
2005). 
2.4 Conclusion  
Chlorhexidine showed a promising effect at a low concentration compared to 
thymol, with MIC and MBC against planktonic cells of 2.5 and 5 µg/mL for CHD 
and 125 and 250 µg/mL for thymol, both drugs showed concentration dependant 
antifungal effect. Farnesol is not a suitable candidate to be added to the 
formulation due to its negative effect on the activity of the drugs, it increased the 
MBC of CHD and Thymol. The effect of CHD on the 24-h mature biofilm was 
more than 50% reduction at concentrations of ≥20 µg/mL, however, thymol at the 
highest concentration of 250 µg/mL was around 50%. P407 and HPMC did not 
have a negative impact on the activity of CHD while on thymol the antagonistic 
effect of p407 was only at high concentration. Combination of CHD and thymol 
did not show any synergistic effect. To select the proper formulation further 
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investigations on human cells, need to be conducted for CHD, thymol and the 
combination. 
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Chapter Three 
Cytotoxic effect of CHD 
and Thymol on HEK293 
cell line
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Chapter 3 :  Cytotoxic effect of CHD and Thymol on HEK293 cell 
line 
In this chapter, the cytotoxicity of CHD and thymol will be examined both 
individually and in combination together with any potentiating effects of HPMC 
and P407. Accordingly, the effective concentration will be considered in the 
buccal tablet. In the previous chapter, an additive effect of the drugs against C. 
albicans biofilm was not observed, however, the addition of thymol was as an 
attempt to overcome the oxidative stress produced by CHD. To our knowledge, 
the cytotoxic effect of CHD-thymol in combination has not been investigated to 
date. 
3.1 Materials and Methods 
3.1.1 Preparations of HEK293 cells cultures 
HEK293 cells (Human embryonic kidney cells) were used to test in vitro 
cytotoxicity of CHD, thymol, HPMC and P407.  
3.1.1.1 Reagents and medium preparation 
Preparation of DMEM (Dulbecco's modiﬁed Eagle's medium): 
Dulbecco’s Modified Eagle’s Medium - high glucose powder (DMEM), Foetal 
Bovine Serum (FBS), L-Glutamine solution (200 mM), Antibiotic-Antimycotic 
Solution (10,000 U penicillin, 10 mg streptomycin and 25 μg amphotericin B per 
mL), Sodium bicarbonate (Sigma Aldrich, UK) 
DMEM was prepared as instructed by the manufacturer, the powdered medium 
was dissolved in 900 mL of RNase, DNase free sterile ultrapure water, then 3.7 
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g of sodium bicarbonate was added and the pH was adjusted to 7.4 with 1 M HCl, 
followed by completing the volume to one litre. To prepare DMEM complete, 50 
mL of FBS, 5mL of L-Glutamine solution and 5 mL of Antibiotic antimycotic 
solution were added to 500mL of DMEM then it was filter sterilised and stored at 
4°C. 
Gelatine solution: Gelatine (Sigma Aldrich, UK) was prepared at a concentration 
of 0.1% in ultrapure water, autoclaved and stored at 4°C. 
Sorensen's glycine buffer:  Glycine and sodium chloride (Sigma Aldrich, UK) 
were prepared at a concentration of 0.1 M and the pH was adjusted to 10.5 using 
5 M NaOH. 
Phosphate buffered saline (PBS) pH 7.2-7.6: was prepared by diluting PBS 
10x (Sigma Aldrich, UK) to 1x with ultrapure water (RNase and DNase free) 
3.1.1.2 HEK293 cells culture 
Tissue culture flask (T75) was coated with 5 mL of 0.1% gelatine solution and 
incubated for 10-15 minutes, then gelatine was aspirated followed by the addition 
of 10 mL of DMEM complete. HEK293 cells were recovered from liquid nitrogen 
storage (-180 °C), defrosted in a water bath. Cells were added to the flask and 
incubated to subconfluency at 37°C in a humidified 5% CO2 incubator. Cells 
subculture was performed by aspirating the medium, washing the cells with 10 
mL of PBS, followed by cells detachment with the aid of 2 mL of 0.25% trypsin-
EDTA (Sigma-Aldrich, UK) which left for 3-4 minutes. Cells detachment can be 
seen visually, then 6 mL of DMEM complete was added to deactivate trypsin-
EDTA. Then cells were ready for subculturing, cytotoxicity study and freezing.  
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HEK293 cells for cryopreservation 
Trypsinized cells were centrifuged at 1650 g for 3 minutes, the medium was 
discarded, and the pellets were resuspended in 0.95 mL FBS and 0.05 mL DMSO 
and transferred to cryovials. The vials were stored for 5-6 hours at -80°C and then 
transferred to -180°C. 
3.1.2 Cytotoxicity studies 
Cytotoxicity studies were performed to test the effect of the drugs on human cells. 
The effect of the polymers on HEK293 cells were tested individually and with 
CHD or thymol. The treatment was performed for two hours which is the time that 
intended to apply the tablet in the oral cavity. Cells were treated first with the 
tested solutions followed by measuring the cytotoxicity using MTT, NR uptake 
and SRB assays. 
Determination of cell seeding density (calibration curve) 
Seeding density was investigated to choose the proper number of the cells to be 
seeded in each well for the cytotoxicity assay. Trypsinized Hek293 cells were 
counted using haemocytometer, then serially diluted in DMEM complete and 
transferred to 96 well plate at a cell number range from 2.0 x 105 to 781 cells/well 
and incubated for 24 hours. MTT assay was performed to find the optimum 
number of cells. 
Cell treatment for cytotoxicity studies 
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Based on the result of the calibration curve, 4.0 x 104 cells were placed in each 
well of the 96 well microtiter plate, the latter was incubated for 24 hours at 37°C 
and humidified 5% CO2. The cytotoxic effect of CHD, CHD-HPMC and CHD-P407 
was studied at 5:1 polymer to CHD ratio. Concentrations of 160 µg/mL of CHD in 
DMEM alone or with the polymer were serially double diluted in the same 
medium. For thymol, thymol-P407 and thymol-HPMC, a concentration of 250 
µg/mL of thymol in DMEM were serially double diluted. The ratio of polymers to 
thymol was 5:1 similar to CHD. The medium of overnight cells culture was 
replaced with the serial dilution of the investigated drug solutions and incubated 
for two hours. The latter were aspirated, and cell viability was dictated using MTT, 
NR uptake and SRB assays. 
3.1.2.1 MTT assay 
MTT reduction assay was used to measure the metabolic activity of human cells. 
It is a water-soluble salt and converted to insoluble formazan by the cleavage of 
the tetrazolium ring by succinate dehydrogenase within the mitochondria. 
Formazan is impermeable through the cell membrane. Consequently, it 
accumulates inside the metabolically active cells (Fotakis and Timbrell, 2006). 
MTT stock solution: MTT 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (Sigma Aldrich, UK) was dissolved in PBS at a concentration 
of 5 mg/mL and stored at 4°C in the dark. 
MTT working solution was prepared freshly prior the addition to the cells, by 
diluting the stock solution in DMEM complete to a concentration of 0.5 mg/mL, 
then 100 µL was added to each well and incubated for two hours. The medium 
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was aspirated, and formazan salt was dissolved using 80 µL of dimethyl sulfoxide 
(Alfa Aesar, UK) and 20 µL of glycine buffer, and the absorbance was measured 
at 540nm. The viability was calculated as a percentage of the absorbance of 
treated cells to untreated cells. DMSO was added to dissolve formazan and 
glycine buffer to shift the pH to 10.5, at this pH formazan gives one peak, however 
at pH 7, it gives two peaks at 500 and 570 which underestimates the amount of 
formazan (Plumb, 2004). 
3.1.2.2 Neutral red uptake (NR) assay 
As mentioned in chapter three, Neutral red is a weekly basic dye, it penetrates 
cells by diffusion and accumulates in the lysosomes due to its low pH compared 
to the cytoplasm. In healthy or live cells, pH gradient was maintained, upon cells 
death, lysosomes will not be able to retain the dye (Repetto et al., 2008). NR 
stock solution was prepared using RNase, DNase free sterile ultrapure water at 
a concentration of 4 mg/mL and stored in the dark for 1-2 months at room 
temperature. A working solution was prepared freshly in DMEM complete at a 
concentration of 80 µg/mL, incubated at 37°C for 24 hours, then filtered through 
a 0.45 µm filter to remove precipitated dye crystals. Aliquots of 100 µL were 
added to each well, and the plate was incubated for two hours. NR was removed, 
washed with 150 µL PBS, followed by fixation with 100 µL of 5% glutaraldehyde 
for 2 minutes. After removing the fixative solution, 150 µL of de-stain solution 
(50% absolute ethanol, 48% ultrapure water and 2% glacial acetic acid) was 
added to each well, and the plate left for 30 minutes on an orbital shaker to extract 
NR from cells. The optical density was measured at 540nm, and the cytotoxicity 
was measured as a percentage of untreated cells. 
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Imaging of HEK293 cells 
Microscopical images were used to study the morphological changes in the 
treated cells. Each well of the 6 well plate was seeded with 2.0X105 / 2mL and 
incubated for 24 hours. For CHD 2mL of 160, 80, 40, 20, 10 µg/mL were tested. 
For thymol 250 and 125 µg/mL with and without P407 and a negative control.  
Cell imaging was performed after staining with NR and SRB using a phase 
contrast microscope (Nikon Eclipse TS100, UK). The Images of SRB stained cells 
were further investigated using fluorescence microscopy (EVOS FL, UK). 
3.1.2.3 Sulforhodamine B (SRB) assay 
SRB is a water-soluble dye, used to measure the cellular density based on 
cellular protein content. Under acidic condition it binds to the basic amino acid 
residue in proteins (Skehan et al., 1990), it is used to measure both dead and live 
cells, the method was adopted from Vichai and Kirtikara (2006). SRB (Alfa-easer, 
UK) stock solution was prepared at a concentration of 0.057% in 1% acetic acid. 
Treated cells with CHD and thymol solutions were fixed with 100 µL of cold 10% 
TCA (Trichloroacetic acid, Sigma Aldrich, UK) and stored for 1 hour at 4°C. TCA 
was removed under a low stream of running tap water and the plate was left to 
dry at room temperature. SRB (100 µL) solution was added to each well and left 
at room temperature for 30 minutes, then the dye was removed, and the microtiter 
was washed quickly with 1% acetic acid to remove the excess dye. SRB was 
extracted with 200 µL of 10 mM Tris base solution (Sigma-Aldrich, UK), pH of 
10.5, the absorbance was measured at 540nm. The viability was calculated as the 
percentage of the absorbance of treated to untreated cells. 
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3.1.2.4 Statistical Analysis  
Tow-way ANOVA (analysis of variance) was obtained using Microsoft Excel to 
test the significant difference between the tested compounds. 
3.2 Results 
3.2.1 Determination of cell seeding density 
The calibration curve was performed to choose the proper number of cells for 
cytotoxicity studies. As presented in Figure 3.1 there is a linear relationship 
between the number of cells and the absorbance using MTT assay up to cell 
density of 105. Therefore, to perform the cytotoxicity assay, 4.0x104 was chosen 
as a seeding density with a relative absorbance of ~0.7. 
 
Figure 3.1 Absorbance of different numbers of HEK293 cells grown for 24 hours 
using MTT assay. Data are expressed as mean absorbances ± SD, n = 18. 
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3.2.2 Cytotoxicity assay 
3.2.2.1 MTT assay 
MTT reduction assay was used to measure the oxidative stress of human cells 
and consequently the cytotoxic effect of the drugs on HEK293 cells. The cytotoxic 
effect of CHD, HPMC, P407, CHD-HPMC and CHD-P407 were tested at a 
concentration range from 160 to 1.25 µg/mL of CHD. The absorbance of the 
dissolved formazan was recorded, and the mitochondrial activity was calculated 
as a percentage of the average absorbances of treated to untreated cells, the 
results were displayed in Figure 3.2. 
 
The effect of HPMC and P407 were tested individually, at a concentration range 
from 1.25 to 0.02 mg/mL. Both polymers had no effects on cell viability. 
The inhibitory effect of CHD on the mitochondrial activity of HEK293 cells (Figure 
3.2) was increased progressively with the increase in CHD concentration and 
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Figure 3.2 The effect of two hours exposure to different concentrations of 
CHD, on the viability of HEK293 cells measured using an MTT assay. Data 
are expressed as mean percentage ± SE, n = 34. 
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becoming more pronounced at CHD concentrations of P407 at ≥ 20 µg/mL. Here, 
cytotoxic effect was greater than an equivalent concentration of CHD and CHD 
HPMC.  
Similarly, MTT assay was tested for thymol, thymol-P407 and thymol-HPMC at a 
concentration range from 250 to 0.49 µg/mL of thymol. Figure 3.3, shows a 
considerable inhibitory effect of thymol on HEK293 cells at a concentration of ≥ 
125 µg/mL. At 250 µg/mL, both thymol and thymol-HPMC had an almost 
complete inhibitory effect. However, P407 showed an intensive protective effect 
against thymol, resulted in maintaining the viability to around 46% and 83% at 
concentrations of 250 and 125 µg/mL, respectively.  
 
 
Figure 3.3 The effect of two hours exposure to different concentrations of thymol, 
on the viability of HEK293 cells measured using an MTT assay. Data are 
expressed as mean percentage ± SE, n = 34. 
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3.2.2.2 Neutral red uptake (NR) assay 
NR assay was used to measure the lysosomal activity of human cells and 
consequently, it estimates the cytotoxic effect of the drugs.  
The cytotoxic effect of CHD, HPMC, P407, CHD-HPMC and CHD-P407 were 
tested at a concentration range from 1.25 to 160 µg/mL of CHD. After staining 
with NR and de-staining, the absorbance of the de-stain solution was measured, 
and the results were displayed in Figure 3.4. The retained lysosomal activity was 
~20% at 80 and 160 µg/mL and 85% at 40 µg/mL. 
 
 
 
 
 
 
 
Figure 3.4 The effect of two hours exposure to different concentrations of CHD, 
on the viability of HEK293 cells measured using an NR uptake assay. Data are 
expressed as mean percentage ± SE, n = 9. 
 
For further investigation, images were obtained for cells treated with a 
concentration range from 10 to 160 µg/mL and the positive control. Visually, at 
160 µg/m no NR stain detected in the cells and at 80 µg/mL, few cells were 
stained compared to the lower concentrations (Figure 2.13).  
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Figure 3.5  Images of HEK293 cells treated with CHD and stained and with NR, 
x200. 
 
Images of living untreated and treated HEK293 cells with 160 µg/mL of CHD were 
examined under the microscope to investigate the morphological changes. 
Treated cells show chromatin condensation and cell shrinkage (Figure 3.6). 
 
Figure 3.6 microscopical images of live HEK293 a) non-treated and b) treated 
with 160 µg/mL CHD (x200), (arrows showing chromatin condensation). 
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NR assay results for thymol, thymol-P407 and thymol-HPMC are presented in 
Figure 3.7, at a concentration range from 1.95 to 250 µg/mL of thymol. Thymol 
and thymol-HPMC showed nearly 100% loss of lysosomal activity, however, 
thymol-P407 preserved 25% of the activity. Furthermore, both polymers thymol 
combinations have nearly double the activity compared to thymol alone at a 
concentration of 125 µg/mL.  
 
Figure 3.7 The effect of two hours exposure to different concentrations of Thymol, 
on the viability of HEK293 cells measured using an NR uptake assay. Data are 
expressed as mean percentage ± SE, n = 6.  
 
 
Microscopical images were obtained for cells treated with 125 and 250 µg/mL of 
thymol and thymol-P407. At 125 µg/mL images do not show a significant 
difference between thymol and thymol-P407. However, at 250 µg/mL, no cells 
are shown in the image due to their detachment after the treatment with thymol 
and staining with NR (Figure 3.8). On the other hand, cells treated with thymol-
P407 are visualised in the well. Although by comparing it to the positive control 
image, it shows vacuolizations of the cytoplasm (Figure 3.9). 
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Figure 3.8 Images of HEK293 cells treated with thymol and thymol-P407 and 
stained and with NR, (x200). 
Control 125 µg/ml+P407 250 µg/mL+P407 
Control (NR) 125 µg/mL 250 µg/mL 
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Figure 3.9 Images of HEK293 (A)cells treated with thymol-P407 250 µg/mL (B) 
HEK293 control and stained with NR (x200), (arrows showing vacuolization) 
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3.2.2.3 Sulforhodamine B (SRB) assay 
SRB assay was used to measure cells density based on the protein content of 
dead and live cells, this method is used to measure the degree of cytotoxicity.  
Solutions of CHD, CHD-HPMC and CHD-P407 were tested at a concentration 
range from 1.25 to 160 µg/mL of CHD. After staining the cells with SRB, the 
absorbance of the extracted stain was measured, and the results are displayed 
in Figure 3.10. There was a 40% loss in cellular density at a concentration of 80 
and 160 µg/mL, the polymers showed no clear effect on the activity of CHD. The 
microscopical images show an agreement with the absorbance% of the extracted 
stain, visually the density of the colour for cells treated at 80 and 160 µg/mL was 
less intense than the control and cells treated at lower concentrations (Figure 
3.11).  
 
Figure 3.10 The effect of two hours exposure to different concentrations of CHD 
on the viability of HEK293 cells measured using an SRB assay. Data are 
expressed as mean percentage ± SE, (n = 9). 
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Figure 3.11 microscopical images of HEK293 cells treated with different 
concentrations of CHD for two hours at 37°C and stained with SRB. (x200), 
(arrows showing the difference between chromatin condensation in a treated cell 
and normal cell).  
 
The same cells were examined using fluorescence microscopy, the results 
confirmed the previous finding shown in Figure 3.6. HEK293 cells attaining were 
homogenous due to the interaction of SRB to the cellular proteins, while cells 
treated with 160 µg/mL showed chromatin condensation, cell shrinkage, and 
vacuolization resulted in the loss of proteins and consequently cell membrane 
damage (Figure 3.12). This effect was seen to a lesser extent at 80 µg/mL, no 
morphological changes were noticed for lower concentrations (results not 
shown). 
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Figure 3.12 Fluorescence microscopy images for HEK293 a) non-treated and b) 
Treated with CHD 160 µg/mL and stained with SRB stain, (x400), (arrows 
showing chromatin condensation). 
 
SRB assay was performed to detect the effect of thymol, thymol-P407 and 
thymol-HPMC at a concentration range from 1.95 to 250 µg/mL of thymol. The 
effect of thymol on the cells was obvious at 250 µg/mL, however, P407 protected 
the cells from the effect of thymol, this result agreed with the NR assay (Figure 
3.13). 
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Figure 3.13 The effect of two hours exposure to different concentrations of 
Thymol, on the viability of HEK293 cells measured using an SRB assay. Data are 
expressed as mean percentage ± SE, n = 9. 
 
Figure 3.14 shows the microscopical images of the cells treated with Thymol and 
thymol-P407 at 125 and 250 µg/mL, no morphological changes were detected 
between different treatments accept the loss of the cells treated with 250 µg/mL 
of thymol.  
 
Figure 3.14 microscopical images of HEK293 cells treated with Thymol and 
Thymol-P407 at a concentration of 125 and 250 µg/mL for two hours at 37°C and 
stained with SRB (200x).  
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3.2.3 Cytotoxic effect of CHD and Thymol on HEK293 
The combined effect of CHD and thymol were investigated at concentrations of 
5, 10 and 20 µg/mL for CHD with 31.25 and 62.5 µg/mL of thymol. The tested 
concentrations were chosen based on the cytotoxicity studies and the feasibility 
of incorporation into the buccal tablet. The effect was investigated using NR 
uptake and SRB assays. 
NR uptake assay 
The lysosomal activity of the cells was affected more by the combined drugs and 
the effect was concentration-dependent. For instance, CHD 20 µg/mL with thymol 
31.25 µg/mL has decreased the activity to 67% compared to 94% for CHD alone 
(Figure 3.15). One-way ANOVA results show that CHD has a significant 
difference when combined with thymol at 62.5 µg/mL, and at CHD 10 µg/mL with 
thymol at 31.25 µg/mL, this effect resulted in an increase in the cytotoxic effect of 
CHD in the presence of thymol. 
 
Figure 3.15 The effect of two hours exposure to selected concentrations of CHD 
and Thymol, on the viability of HEK293 cells measured using an NR uptake 
assay. Data are expressed as mean percentage ± SE, n = 12. 
*Asterisks represent values significantly different (p<0.05) from CHD alone of the same 
concentration. 
0
20
40
60
80
100
%
 A
b
so
rb
an
ce
 (
ly
so
so
m
al
 a
ct
iv
it
y)
Concentration (µg/mL)
 
        
        
        
  119 
 
SRB assay  
The same combinations of thymol and CHD were tested using SRB assay.  A 
similar effect was noticed with a less decrease in cellular density compared to the 
lysosomal activity (Figure 3.16) statistically, the results are identical with the NR 
assay results.  
 
Figure 3.16 The effect of two hours exposure to selected concentrations of CHD 
and Thymol, on the viability of HEK293 cells measured using an SRB assay. Data 
are expressed as mean percentage ± SE, n = 12. 
*Asterisks represent values significantly different (p<0.05) from thymol alone of the same 
concentration. 
 
3.3 Discussion 
Different methods were used to inspect the cytotoxic effect of CHD and thymol. 
Based on the MTT assay, the exposure of HEK293 cells to different 
concentrations of CHD resulted in dose-dependent mitochondrial inhibitory effect. 
Treating the cells at a concentration of 160 µg/mL left the cells with 2.6% 
mitochondrial activity this was increased to 92.8% at 0.315 µg/mL. The effect 
aggravated by the addition of P407 at a concentration of ≥20 µg/mL, which might 
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be attributed to the surfactant activity of P407, led to increased cellular 
penetration of CHD and consequently, its toxicity (Figure 3.2). 
In a previous work on human fibroblast cells, which were exposed to different 
concentrations of CHD for three hours and analysed using XTT assay, 100% 
suppression was found for concentrations of ≥ 0.005% which is equivalent to 50 
µg/mL (Hidalgo and Dominguez, 2001). Another investigation was performed on 
odontoblast cell line MDPC-23 and treated with 0.02%, 0.004% and 0.0024 CHD, 
the effect was analysed using MTT assay, the results showed a concentration-
dependent inhibitory effect. The loss of viability for 0.04% (= 40µg/mL) was 
29.9%. Moreover, the morphology of the cells for 0.004% and 0.0024 was similar 
to the control. However, cells treated with 0.02% CHD showed a change in the 
morphology to a round shape (Souza et al., 2007). In this work at a concentration 
of 40 µg/mL showed around 60% loss in the viability of cells.  
By comparing the current results to C. albicans antibiofilm results in chapter 2, 
using XTT assay, C. albicans showed more sensitivity toward CHD than HEK293. 
CHD showed nearly 100% suppression of the metabolic activity on the biofilm at 
a concentration of ≥ 40µg/mL. 
Whereas, the cytotoxicity of thymol was pronounced at 125 and 250 µg/mL, and 
it was greatly antagonised by P407 (Figure 3.3). Although, there was no effect 
against neuronal cells as reported by García et al., (2006). They investigated the 
effect of thymol at a concentration of 150 µg/mL on neuronal cells for 30 minutes 
and 24 hours and MTT assay, no effect on the mitochondrial activity was 
recorded. However, Türkez and Aydın (2013) studied the effect on human blood 
cells at a concentration range from 0 to 200 µg/mL for 24 hours and using MTT 
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assay, the finding was a reduction in the viability to around 60% at concentrations 
of 150 and 200 µg/mL. 
To further investigate the effect of CHD and thymol on HEK 293 cells, NR assay 
was used to test its effect on the lysosomal activity. Although the effect of CHD 
at a concentration of ≥80µg/mL was comparable to the result obtained by the 
MTT assay, the cytotoxicity was much less at lower concentrations. For instance, 
at 40µg/mL the viability was 40% using MTT and 85% using NR assay (Figure 
3.2 and Figure 3.4). Images obtained for cells stained with NR confirm the 
colourimetric results and the morphological changes were represented by cell 
shrinkage and chromatin condensation (Figure 3.6).  
Cells treated with 125 and 250 µg/mL of thymol and tested using NR showed a 
high agreement with MTT result with nearly 100% suppression of activity at 250 
µg/mL and around 40% remaining of activity at 125 µg/mL and P407 showed a 
similar protective behaviour with less viability (Figure 3.7). This observation 
confirms a previous finding, in which P407 decreased the toxicity of tramadol by 
approximately 2-fold when tested using MTT and NR uptake assays (dos Santos, 
et al., 2015). In the current work, the micrographs (Figure 3.8) of cells treated with 
250 µg/mL of thymol show the disappearance of the cells resulted from their 
detachment by thymol, which might be explained by anoikis (Kroemer et al., 
2009). Using the same concentration of thymol combined with P407 led to 
protecting the cells from detaching and this might be attributed to the 
mucoadhesive properties of P407, preventing the cells from detachment. It 
seems that P407 protect the cells from detaching, but not from vacuolization 
(Figure 3.9). The latter agreed with a previous work performed by Llana-Ruiz-
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Cabello et al. (2014), Caco-2 cells were treated with 37.5 µg/mL of thymol for 48 
hours, cells showed vacuolization, which is one of the features related to 
apoptosis. In the same work cell detachment was shown with carvacrol but not 
thymol and this attributed to the lower concentration of thymol investigated in the 
work. Both carvacrol and thymol have the same chemical formula C10H14O and 
they found in the oil of thyme. 
Another research group found that the effect of thymol was antagonised by the 
non-ionic surfactant Tween 80, and this effect increased with the increase in 
Tween concentration. The assumption was, by the addition of the surfactant, both 
proteins and thymol became more hydrophilic, this resulted in decrease the 
degree of binding between them. Moreover, the addition of bovine serum albumin 
showed a similar effect (Juven et al., 1994).  Dušan et al., (2006) tested the 
cytotoxicity of thymol against Caco-2 cells and based on the morphology, cells 
treated with 120 µg/mL led to cell necrosis at ~10 and 15% after 1 and 24 hours 
treatment respectively, with less than 1% of apoptosis. 
However, based on the morphology, no sign of necrosis was seen, and apoptosis 
is the mechanism of cell death based on anoikis and vacuolization, and this effect 
is concentration dependent and it was found at 250 µg/mL and for two hours 
exposure. 
Protein mass was investigated using SRB assay, cells exposed to CHD at 80 and 
160 µg/mL preserved a 60% of total protein after treatment, lower concentrations 
have no effect on the protein mass based on SRB assay (Figure 3.10). 
Microscopical images (Figure 3.11 and Figure 3.12) show chromatin 
condensation and confirm the previous images (Figure 3.6). Regarding thymol 
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treated cells the major loss in proteins was found with cells treated with thymol 
and thymol-HPMC at a concentration of 250 µg/mL and this attributed to their 
detachment. CHD produces metabolic stress which might be overcome by the 
antioxidant activity of thymol, the combination of CHD and thymol were tested as 
an attempt to minimise the cytotoxic effect of CHD. However, CHD and thymol 
combination showed an increase in the cytotoxicity of CHD and that effect was 
higher with increasing concentrations of thymol. 
3.4 Conclusion 
CHD is toxic toward HEK293 cells within a concentration range 80 and 160 
µg/mL, while thymol at 250 µg/mL for two hours exposure with a decrease in 
cellular density reflecting irreversible cellular damage. However, at lower 
concentrations there were effects on the mitochondrial and lysosomal activity with 
no changes in the microscopical morphology. The cytotoxicity of CHD and thymol 
at the highest concentrations might lead to apoptosis through the mitochondrial 
pathway, further investigations need to be performed to investigate the 
mechanism of cell death.  
Furthermore, there is no advantage to design a tablet with CHD and thymol, due 
to the increase in the toxicity of the drug combination. Moreover, the anti-candidal 
activity of these combinations has neither a synergistic nor an additive effect. 
Generally, polymers showed no negative impact on the cytotoxicity of CHD and 
thymol, although, there was a clear protection activity of P407 against thymol 
cytotoxicity. Based on the results achieved in this chapter and on C. albicans 
planktonic and biofilms, it is recommended to prepare the tablets with CHD only. 
Dosage adjustment will be performed to control the release of the drug at a 
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concentration of 20 µg/mL for two hours. This concentration has an effective (and 
therefore possibly therapeutic) anti-candidal activity and low cytotoxicity.  
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Chapter Four 
Tablet Design, 
Formulation and 
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Chapter 4 : Tablet Design, Formulation and Analysis    
The aim of this investigation was to develop and evaluate mucoadhesive buccal 
tablets based on hydroxypropyl methylcellulose (HPMC) and Poloxamer 407 
(P407) for the controlled release of CHD over two hours. HPMC is widely 
investigated for the preparation of controlled release hydrophilic matrices, due to 
its water solubility, ease of manufacturing, low cost, not affected by the pH and 
nontoxic (Ghori and Conway, 2015). In the current chapter is an attempt to control 
the release for two hours which might not achieve by HPMC, accordingly, P407 
was added to increase the hydrophilicity and maintaining the hydrogel network 
structure. P407 forms a three-dimensional network structure at a concentration 
>20% at 25°C (Ruel-Gariepy and Leroux, 2004).  
Two different sources of HPMC were investigated to assess whether there were 
any physicochemical differences between the polymers that could affect drug 
release individually and also in the presence of P407.  
4.1  Materials and method 
Tablet formulations were prepared using CHD, P407, HPMC and HPMC-S, as 
previously investigated in chapters 2 and 3.  
4.1.1 Characterization of raw materials 
4.1.1.1 Solubility of CHD  
CHD solubility was investigated to find a suitable solubilising and dissolution 
medium. The solubility of CHD was determined by adding excess CHD to 3 mL 
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of water or phosphate buffer saline (PBS) solution at pH 6.8. The samples were 
shaken at 37 ± 0.1 C for 24 hours. The suspensions were filtered through a 
0.45µm Millipore membrane filter (Merck Millipore Ltd, Ireland), the filtrates 
diluted, and CHD concentration determined at 254 nm (Biochrom WPA Biowave 
II UV- Spectrophotometry, UK) in triplicate. The concentration of CHD was 
obtained from the calibration curve of pre-prepared standard solutions of CHD. 
4.1.1.2 Particle size analysis 
Particle size distribution of CHD, HPMC, HPMC-S, P407 and Magnesium 
stearate (MgSt) was assessed by laser diffraction using a Malvern Mastersizer 
3000 with Aero S dry dispersion unit system (Malvern Instruments, Malvern, 
U.K.). Cumulative particle sizes at 10, 50 and 90 % were displayed as D0.1, D0.5 
and D0.9, respectively. The particle size distribution (span) was calculated using 
Equation 1. 
𝑆𝑝𝑎𝑛 =
𝐷0.9  − 𝐷0.1
𝐷0.5
 
Equation 1 
4.1.1.3 Morphology of the ingredients of the tablets 
Scanning electron microscopy (SEM) images were obtained for a small amount 
of the samples, which were mounted onto standard pin stubs using a double-
sided adhesive tape and then loaded on a universal specimen holder, followed 
by gold sputter coating of each sample under low vacuum (Zeiss Evo® 50EP 
SEM, Germany). 
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4.1.2 Formulations and characterisation of the tablets  
Three different groups of formulations with CHD were prepared based upon 
different drug to polymer (CHD to HPMC-S) ratios; different HPMC-S to P407 and 
HPMC to P407 ratios. 
4.1.2.1 Tablet formulations  
Formulations of CHD mucoadhesive tablets were formulated as shown in Table 
4.1. The powders were blended for 5 minutes in a V-shaped powder blender 
(CapsulCN®).  
Table 4.1 Formulations of CHD mucoadhesive buccal tablets. 
Formulations Weight (mg)/tablet 
CHD  
 
HPMC-S  HPMC  P407  Tablet 
Weight  
F1 
5 
25 mg - - 30 
F2 45 mg - - 50 
F3 65 mg - - 65 
F4 85 mg - - 90 
F5 23.5 - 1.5 30 
F6 20.5 - 4.5 30 
F7 17.5 - 7.5 30 
F8 14.5 - 10.5 30 
F9 11.5 - 13.5 30 
F10 6.25 - 18.75 30 
F11 - 25 - 30 
F12 - 20.5 4.5 30 
F13 - 17.5 7.5 30 
F14 - 11.5 13.5 30 
F15 - 6.25 18.75 30 
 
4.1.2.2 Dry granulation  
Dry granules were prepared using the slugging method (Tuğcu-Demiröz et al., 
2004) which involved formulations being manually pressed to form slugs 
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(diameter = 4 cm, weight = 5.5 ± 0.5 g) using a manual hydraulic hand press. 
Slugs prepared using HPMC-S and HPMC were formed with 1 and 4 tons 
compression force, respectively. The slugs were granulated using a Sinopham, 
YK60 Mini Lab Rotary Granulator (China) in which granules were passed through 
1 mm screen (mesh no. 18). The granules were collected and characterised 
similar to powder blends. MgSt was added prior to compression of the granules 
into tablets. 
4.1.2.3 Powder Flow properties and compressibility 
Powder and granule bulk and tapped volumes were assessed using a Tapped 
Density tester (Varian, U.K.). Tapped volumes were obtained by subjecting the 
powders to 200 taps each time until a constant volume was achieved. Carr’s 
(compressibility) index (CI) and Hausner ratio (HR) were calculated using 
Equation 2 Equation 3: 
𝐶𝑎𝑟𝑟′𝑠 𝐼𝑛𝑑𝑒𝑥 = (1 −
𝑉𝑡
𝑉0
) Equation 2 
 
𝐻𝑎𝑢𝑠𝑛𝑒𝑟 𝑟𝑎𝑡𝑖𝑜 =
𝑉0
𝑉𝑡
 Equation 3 
Where V0 is bulk volume and Vt is the tapped volume. 
4.1.2.4 Preparation of CHD buccal tablets 
Dry granules (10 ± 2 g) and 0.5% (w/w) of MgSt were blended for 3 minutes using 
a mini V-shaped powder Mixer (CapsulCN, China). Tablets were pressed using 
a ZPS heavy duty mini rotary tablet machine (Shanghai, China) at 8.6 RPM speed 
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of compression and tablets with a biconvex 6 mm diameter round shape punch, 
the setting of the tablet press was thickness of 0.3 mm and weight of 
approximately 30 mg (F1, F5-15), which resulted in compression force of 1-2 KN. 
F2, F3 and F4 were pressed using the same punch, tablet weight 50, 70 and 90 
mg respectively, with the same compression force of 1-2 KN. 
4.1.2.5 Friability  
A sample of approximately 1 g of each formulation was placed in the drum of the 
friability tester (Charles Ischi AG, AE-1, U.K.), and rotated 100 times at 25 rpm. 
The tablets were dedusted, reweighed and percentage weight lost calculated 
according to Equation 4. 
𝐹𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑊𝑖 − 𝑊𝑓
𝑊𝑖
× 100 
Equation 4 
Where 𝑊𝑖 is the initial weight and 𝑊𝑓 is the final weight. 
4.1.2.6 Tensile strength 
The mechanical strength of the biconvex tablet is calculated based on Equation 
5 (Pitt et al., 1988).  
 
𝜎𝑥 =
10 𝐹
𝜋𝐷2
[
2.84𝐻
𝐷
−
0.126𝐻
𝑊
+
3.15𝑊
𝐷
+ 0.01]
−1
 Equation 5 
 
Where 𝜎𝑥 is the tensile strength, F is tablet hardness (Newtons), D is tablet diameter, H is tablet 
thickness, and W is central cylinder thickness (tablet wall height), with all tablet dimensions in 
mm.  
 
        
        
        
  131 
 
Tablet hardness was measured using a Varian VK 200 (U.K.) hardness tester (n 
= 10). 
4.1.2.7 Content Uniformity and mass variation 
To maintain the consistency of the formulations within the acceptable level, the 
content uniformity and mass variation were investigated. 
Mass Variation 
Mass variation was measured to evaluate the consistency of the weight of the 
prepared tablets. For the investigated tablets, the weight of 20 tablets of each 
formulation was measured; acceptance criteria of  10% of average tablet weight 
were determined. Not more than two tablets should deviate with more than 10% 
and one tablet with more than 20%. Although, for the investigated formulations 
this test is not a mandatory requirement according to the BP due to a drug content 
of <25% (BP, 2018 a).  
Content uniformity 
According to the BP, content uniformity is mandatory for tablet dosage forms with 
active ingredients <25% (BP, 2018 a). The content was analysed by taking 10 
tablets, each was dissolved individually in 100 mL of distilled water, the 
concentration was calculated from the absorbance at 245. The formulation is 
considered a fail if more than one tablet deviates from the range of 85-115% or if 
one tablet deviates from the range of 75-125% of the average content. 
 
        
        
        
  132 
 
4.1.2.8 Ex Vivo Mucoadhesion  
Mucoadhesion was measured to estimate the adherence of the tablets in the oral 
cavity and was it measured by two means; duration and force of adhesion. 
Duration of mucoadhesion 
The mucoadhesion was determined as a function of dosage form residence time 
using a modified protocol adopted from Nafee et al. (2003). Freshly harvested 
chicken pouches were carefully washed to remove food residue and were 
subsequently stored at -80 C. The pouches were defrosted before use, cut into 
small pieces (1 cm x 2 cm) and fixed to a glass slide using cyanoacrylate glue. 
The tissue was hydrated using one drop of ultrapure water before a CHD tablet 
was placed on top and weighed down with a 4 g weight for 20 seconds to aid the 
adhesion process. The glass slide was then placed into the disintegration 
apparatus tubes (Varian VK 100, U.K.), prefilled with 37 ± 0.2C ultrapure water. 
The test was performed for 120 minutes at 50 rpm and samples examined every 
15 minutes. Each tablet formulation was assessed in triplicate.  
Force of detachment  
The force of detachment was measured using the modified two-arm balance 
method adopted from Parodi, et al. (1996) with a slight modification of putting the 
sample inside a jacketed beaker to maintain the temperature at 37°C.  
The tablet was fixed with cyanoacrylate glue to a disc and fixed on an inverted 
container hung on one side of the balance (Figure 4.1). It was then left to adhere 
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to the chicken pouch for 5 minutes, with the aid of a 4 g weight. The chicken 
pouch was previously fixed on a top of a container and placed in a jacketed 
beaker which was maintained at 37°C. On the other side of the balance, a small 
beaker was placed to collect the water received from a peristaltic pump at a rate 
of 1mL/min. Once the tablet had adhered to the chicken pouch the pump was 
switched on, the amount of the water in the beaker was increased until the tablet 
detached from the chicken tissue. The weight of the collected water was then 
measured.     
 
 
4.1.2.9 Swelling Index 
Swelling index was determined by weighing an individual CHD tablet (W0) and 
sticking it to a previously weighed glass coverslip using a single water droplet and 
allowing it to equilibrate for 30 s. The coverslip was then placed vertically in a 
beaker in a 37 ± 0.2 C water bath (Clifton, Nickel-Electro Ltd, UK). The weight 
of the swollen tablet (Ws) was recorded at 30, 60, 90 and 120 minutes. Swelling 
index (SI) was calculated using Equation 6 (Kassem et al., 2014). 
PBS 
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with PBS 6.8 
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Figure 4.1 Diagram illustrating the measurement of the force of mucoadhesion. 
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𝑆𝐼 =
𝑊𝑠 − 𝑊0
𝑊0
 
Equation 6 
4.1.2.10 Tablet morphology (SEM) 
Tablet morphology was investigated for aqueous media swollen tablets. They 
were prepared by adding 0.5 mL distilled water to each tablet unit in a 5 mL test 
tube and left until it swollen, and then freeze-dried using Beta 1-8 LSC Freeze 
Dryer, (Christ, UK). Tablets were cut in half and analysed by SEM as previously 
described (4.1.1.3). 
4.1.2.11 In Vitro Dissolution of CHD (Apparatus I) 
The dissolution was performed in a BP Dissolution Apparatus type I basket 
method (BP, 2018 b) using Varian 705 DS (Varian, U.K.). One tablet of each 
formulation was placed in 500 mL Ultrapure distilled water at 37 ± 0.1 C, with 
the basket rotating at 50 ± 1 rpm. At predetermined time intervals, 4 mL was 
withdrawn from the dissolution medium and replaced with the same volume of 
fresh media. CHD concentration was determined spectrophotometrically by 
measuring the UV- Absorbance at 254 (Biochrom WPA Biowave II UV- 
Spectrophotometry, UK). 
4.1.2.12 Similarity (f2) and Difference (f1) factors 
Both factors Were investigated to check the similarity and the difference for drug 
release from the formulations of the same polymer ratios. 
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i. Similarity factor(f2) 
This analysis is applied to the dissolution profile of more than three-time points 
(except zero point) and not more than one value above 85% of the drug released. 
The difference at each time point should be less than 10%, and 12 individual 
value for each time point. The results of this analysis lie between 0-100%, and f2 
≥ 50 suggests a similarity between the standard and the test (CPMP, 2000). 
Similarity factor is calculated by applying Equation 7. 
𝑓2 = 50 × 𝑙𝑜𝑔 {[1 + (1 𝑛⁄ ) ∑ (𝑅𝑡 − 𝑇𝑡)
2
𝑛
𝑡=1
]
−0.5
× 100} 
Equation 7 
Where n is the number of time points, Rt is the per cent release of the standard and Tt is the 
per cent release of the test. 
In the current work, we will apply f2 on each 2 replicates of the triplicate. 
 
ii. Difference factor (f1) 
Difference factor is defined as the cumulative difference between the two tested 
replicates (equation 3). Values between 0-15 indicate the difference between 
the samples is acceptable. When f1 = 0, this means the two samples (n = 12) 
are identical. 
𝑓1 = {[∑ |𝑅𝑡 − 𝑇𝑡
𝑛
𝑡=1
] / [∑ 𝑅𝑡
𝑛
𝑡=1
]} × 100 
                     
Equation 8 
 
When applying Equation 8, and interchange the standard with the test, the values 
of f1 will be changed (O'hara et al., 1998). To overcome this limitation, Equation 
9 was used to test the difference between a pair of pharmaceutical products 
(Costa and Lobo, 2001). 
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𝑓1 = {[∑ |𝑅𝑡 − 𝑇𝑡
𝑛
𝑡=1
] / [∑ (𝑅𝑡 + 𝑇𝑡) 2⁄
𝑛
𝑡=1
]} × 100 Equation 9               
 
4.1.2.13 Kinetics of drug release  
The kinetics of CHD release was investigated to further understand the 
mechanism of CHD release and the effect of the different ratios of the polymers. 
Five models (Costa and Lobo, 2000) were used to analyse the release of CHD 
from the tablet matrices, namely zero order (Equation 10), first order (Equation 
11), Higuchi equation (Equation 12), Hixon-Crowell model (Equation 13) and 
Korsmeyer-Peppas equation (Equation 14) as follows: 
𝑄 = 𝑄0−𝐾0𝑡 Equation 10 
log 𝑄 = 𝐿𝑜𝑔𝑄0−
𝐾1𝑡
2.303
 Equation 11 
𝑄𝑡 = 𝐾𝐻𝑡
1/2 
Equation 12 
𝑄1 3⁄ = 𝑄0
1 3⁄ − 𝐾𝑐𝑡 Equation 13 
𝑄𝑡 𝑄∞⁄ = 𝐾𝑡
𝑛 Equation 14 
 
Where Q is the amount of drug released or dissolved at time t; Q0 is the amount of drug release 
or dissolved at time t (usually t = 0); Qt/Q is the fraction of drug released at time t; K is constant, 
and n indicates the release mechanism. 
4.1.2.14 Drug polymer interaction (FTIR and DSC) 
Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR was used to investigate the possibility of interaction between the polymers 
and CHD. Spectra were obtained using a Bruker Alpha spectrometer (Germany) 
scanning from 4000-400 cm-1. 
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Differential Scanning Calorimetry (DSC) 
DSC analysis was performed to investigate the interaction between CHD and the 
polymers during the processing steps.  Samples of 5.0 ± 0.2 mg of each CHD, 
HPMC, P407, F15 Physical mix, F15 granules and F15 tablet were investigated. 
Each was heated in an aluminium pan under a nitrogen flow of 40 mL/min from 
25°C to 300°C at a scan rate of 10°C/min. The analysis was performed using 
DSC (Mettler Toledo DSC823e, Switzerland). 
4.2   Results 
4.2.1 Charectarisation of raw materials 
The physical properties of the CHD, HPMC, HPMC-S and P407 were investigated 
to evaluate their impact on tablet preparation and characterisation. 
4.2.1.1 Solubility of Chlorhexidine diacetate salt  
CHD solubility was investigated to determine the dissolution medium to achieve 
sink condition. Its solubility in water and phosphate buffer saline (PBS) at pH 6.8 
was 23.069 ± 1.928 and 0.047 ± 0.0124 mg/mL, respectively. The solubility in 
water agreed with the British Pharmacopoeia (BP, 2018 c), which classifies CHD 
solubility as “sparingly soluble” in water. However, it can be described as 
“practically insoluble” in PBS and based on the British Pharmacopeia the volume 
of the dissolution media should be 3-10 times of the saturated volume. 
Accordingly, PBS will not attain the sink condition.  
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4.2.1.2 Particle size analysis 
All powders are classified as fine powders according to the British 
Pharmacopoeia with a different degree of fines (BP, 2018 d). Particle size and 
particle size distribution of CHD and the excipients are shown in Figure 4.2 and 
Table 4.2, CHD and MgSt show a bimodal particle size distribution with a span 
value of 3.04 and 3.15. Both HPMC and HPMC S showed bigger particle size. 
 
Table 4.2 Particle size distribution of CHD, HPMC, HPMC-S, P407 and MgSt. 
 Raw material D 0.1 (µm) D 0.5 (µm) D 0.9 (µm) Span (µm) 
CHD 5.14 21.00 69.00 3.04 
HPMC S 33.00 84.60 172.00 1.64 
HPMC  26.50 70.80 202.00 2.48 
P 407 11.50 34.50 74.30 1.82 
MgSt 1.17 6.27 20.90 3.15 
  
 
Figure 4.2 Particle size distribution of CHD, HPMC, HPMC-S, P407 and 
MgSt. 
SEM analysis (Figure 4.3) confirmed the previous results, both CHD and P407 
have smaller particle sizes and the latter tend to be more spherical, however, 
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HPMC and HPMC-S possess larger particle size with irregular and rod shape, 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.1 Characterisation of the tablets and tablet blends  
The flowability of the various powder formulation blends was found ‘very poor’ 
and ‘very, very poor’ (Table 4.3). Dry granulation improved the flow properties of 
all formulation. Increasing the ratio of polymer to drug from 5:1 to 17:1 had no 
effect on the flow properties of the various granules, and P407 content of 25% or 
more improved the flowability to poor flowability with CI and HR, especially in 
HPMC formulations.  
a b 
c d 
Figure 4.3 SEM images of (a) CHD (b) P407, (c) HPMC-S and (d) HPMC, x500 
 
P407 0% 5% 15% 25% 35% 45% 62.5% 
HPMC-S F1 F6 F6 F7 F8 F9 F15 
HPMC F11 - F12 F13 - F14 F15 
  140 
 
Table 4.3 Compressibility index (CI%) and Hausner ratio for tablet bend before and after granulation (descriptive terms are 
those used by BP). 
 
 
 
 
 
Formulations 
Powder Blends Granules 
CI% Flow Character HR CI% Flow Character HR 
F1 36.59 ± 4.00  Very poor 1.58 ± 0.10 29.41 ± 1.03 poor 1.42 ± 0.02 
F2 35.00 ± 1.25 Very poor 1.54 ± 0.03 28.57 ± 0.25 poor 1.40 ± 0.01 
F3 35.00 ± 0.81 Very poor 1.54 ± 0.02 21.43 ± 0.35 Passable 1.27 ± 0.01 
F4 36.84 ± 1.50 Very poor 1.58 ± 0.04 25.00± 0.00 poor 1.33 ± 0.00 
F5 35.71 ± 2.71 Very poor 1.56 ± 0.07 33.95 ± 1.67 Very poor (CI) Poor (HR) 1.38 ± 0.07 
F6 42.31 ± 1.61 Very, very poor 1.73 ± 0.05 32.38 ± 1.58 Very poor 1.50 ± 0.06 
F7 42.86 ± 1.55 Very, very poor 1.75 ± 0.02 32.29 ± 1.47 Very poor 1.50 ± 0.03 
F8 41.38 ± 1.50 Very, very poor 1.71 ± 0.02 25.93 ± 0.00 poor 1.36 ± 0.00 
F9 31.43 ± 2.91 Very poor 1.46 ± 0.03 26.38 ± 0.00  poor 1.35 ± 0.00 
F10 34.21 ± 3.62 Very poor 1.52 ± 0.05 27.92 ± 0.92 poor 1.43 ± 0.02 
F11 43.74 ± 1.32 Very, very poor 1.78 ± 0.19 34.92 ± 1.37 Very poor 1.54 ± 0.03 
F12 39.28 ± 2.24 Very, very poor 1.65 ± 0.11 34.85 ± 0.00 Very poor 1.53 ± 0.00 
F13 41.36 ± 2.12 Very, very poor 1.69 ± 0.06 30.33 ± 3.21 poor 1.43 ± 0.07 
F14 38.45± 4.43 Very, very poor 1.63 ± 0.06 27.50 ± 0.87 poor 1.38 ± 0.02 
F15 42.36 ± 5.81 Very, very poor 1.75 ± 0.04 26.83 ± 0.76 poor 1.37 ± 0.01 
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 Figure 4.4 shows the morphology of the granules for selected HPMC and HPMC-
S formulations with the same ratio of P407 (0%, 25%, 45% and 62.5% P407). Dry 
granulation showed a limited improvement of the flowability, this may be 
attributed to the generation of fine particles fraction (Herting and Kleinebudde, 
2007). 
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 Figure 4.4 SEM images of selected tablet formulations of HPMC-S and HPMC, 
x200.
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4.3.1.1 Physical properties of the tablets 
The physical properties of the prepared tablet formulations are presented in Table 
4.4. All the tablets showed tensile strength less than 1 MP, and HPMC 
formulations showed higher tensile strengths than HPMC-S formulations which 
might be due to the higher force used in the granulation for the former.  All had 
acceptable levels of friability of less than 1%. Moreover, the resultant tablets 
showed acceptable weight variation 90-110%. Although F11 showed one tablet 
out of this range, it is still acceptable based on the BP (BP, 2108 a) the content 
uniformity was within the acceptable range 85-115% (Table 4.4). 
In conclusion, all the tablet formulations exhibited acceptable physical 
characteristics for further study. 
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Table 4.4 Physical characteristics of the tablets (n = 10), * n=20, ** Friability was performed with 1g of tablets. 
Formulations 
Weight 
(mg)* 
Min% and 
Max% 
tablet 
weight 
Diameter 
(mm) 
Height 
(Edge) 
(mm) 
Thickness 
(Centre) 
(mm) 
Hardness 
(N) 
Tensile 
strength 
(MPa) 
Friability 
(%)** 
Min% 
and 
Max% 
tablet 
content 
F1 30.3 ± 0.7 98-105 6.03 ± 0.02 1.54 ± 0.03 0.91 ± 0.03 7.64 ± 1.95 0.67 ± 0.18 0.48 94-105 
F2 50.2 ± 0.9 94-102 6.01 ± 0.16 2.21 ± 0.14 1.45 ± 0.48 10.29 ± 1.06 0.56 ± 0.13 0.44 97-103 
F3 67.6 ± 1.3 97-102 6.02 ± 0.02 2.79 ± 0.07 2.21 ± 0.07 18.91 ± 2.74 0.76 ± 0.11 0.30 96-104 
F4 87.7 ± 1.7 98-102 6.01 ± 0.01 3.44 ± 0.08 2.88 ± 0.10 22.74 ± 3.09 0.67 ± 0.09 0.59 97-102 
F5 29.1 ± 1.0 95-106 5.99 ± 0.04 1.49 ± 0.04 0.98 ± 0.04 5.68 ± 1.01 0.49 ± 0.09 0.68 92-104 
F6 30.2 ± 1.0 93-104 6.01 ± 0.01 1.50 ± 0.02 0.99 ± 0.07 6.57 ± 1.91 0.56 ± 0.18 0.28 94-109 
F7 29.7 ± 1.2 95-108 5.99 ± 0.01 1.46 ± 0.05 0.99 ± 0.07 6.66 ± 1.72 0.58 ± 0.17 0.12 93-109 
F8 29.5 ± 1.5 93-108 5.98 ± 0.01 1.42 ± 0.04 0.92 ± 0.07 7.45 ± 1.97 0.69 ± 0.20 0.24 97-103 
F9 29.6 ± 1.0 95-105 5.98 ± 0.04 1.43 ± 0.04 0.90 ± 0.06 9.11± 2.62 0.83 ± 0.23 0.09 97-103 
F10 29.2 ± 1.9 92-109 5.98 ± 0.03 1.42 ± 0.06 0.90 ± 0.07 7.74 ± 1.87 0.72 ± 0.16 0.36 98-102 
F11 28.3± 1.1 88-108 5.99± 0.01 1.47 ± 0.04 0.97 ± 0.05 10.19 ± 1.86 0.88 ± 0.17 0.04 96-105 
F12 31.1 ± 1.1 93-107 5.98 ± 0.05 1.49 ± 0.04 0.92 ± 0.30 6.03 ± 1.92 0.80 ± 0.15 0.02 97-103 
F13 30.6 ± 1.2 93-106 5.99 ± 0.04 1.45 ± 0.05 1.02 ± 0.08 5.00 ± 2.61 0.73 ± 0.24 0.01 97-114 
F14 31.4 ± 1.5 94-111 5.96 ± 0.05 1.47 ± 0.04 1.02 ± 0.10 4.60 ± 3.47 0.83 ± 0.32 0.06 96-113 
F15 32.6 ± 1.1 94-106 5.95 ± 0.03 1.50 ± 0.04 1.10 ± 0.08 4.60 ± 2.62 0.96 ± 0.22 0.25 90-106 
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4.3.1.2 Ex vivo mucoadhesion  
Tablets of 30 mg weight were tested for Ex vivo mucoadhesion. All tablets 
successfully adhered to the chicken pouch while repeatedly immersed in the 
aqueous media for two hours using the disintegration tester, which represents the 
ideal residence time of a tablet in the buccal cavity.  
The modified balance method was performed for selected formulations (Figure 
4.5). As presented below, the force of detachment was not affected by the type 
of HPMC or the ratio of P407, results are ranging from ~11-18 gm/cm2. 
   
Figure 4.5 Average force of detachment of HPMC-S and HPMC formulations at 
37°C, Data are expressed as mean ± SD, n = 3. 
  
4.3.1.3 Swelling index (SI) 
The swelling index for both HPMC and HPMC-S formulations (Figure 4.6 and 
Figure 4.7) increased with time. Formulations with higher drug-to-polymer ratio 
showed higher SI when compared with lower ratios, possibly because of the 
higher surface area versus volume for increasing total tablet weights. However, 
statistical analysis (two-way ANOVA with replication) revealed no statistical 
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significance (p>0.05) of tablet SI between HPMC and HMPC-S (formulations F1 
and F11). There was a significant difference between the tested tablets 
(p<0.001), for HPMC-S (F1 and F5 – F10) and HPMC (F11 – F15) formulations.  
 
 
Figure 4.6 swelling index of tablets prepared using HPMC Sigma in ultrapure 
water and at 37 °C, Data are expressed as mean ± SD, n = 3. 
 
 
Figure 4.7 Swelling index of tablets prepared using HPMC Colorcon in ultrapure 
water and 37 °C, Data are expressed as mean ± SD, n = 3. 
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4.3.1.4 The morphology of the swollen tablets 
The internal morphology of swollen tablets was investigated using SEM. The 
SEM images (Figure 4.8) shows the swollen tablet formulations form a sponge-
like, porous network. The pores of F1 and F6 are smaller and more spherical 
compared to F11, F12 and F13. For instance, the average pores cross-sectional 
surface area of F1 and F11 were 0.46±0.86 and 1.86±2.95 mm2, respectively. 
Increasing P407 changes their morphology to small and irregular pores, and the 
tablets after freeze-drying was fragile, this may have affected the shape of the 
pores during sample cutting. 
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Figure 4.8 SEM images for swollen tablets of selected formulations. 
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4.3.1.5 In vitro dissolution of CHD 
The release of CHD from HPMC-S matrix tablets (Figure 4.9) increased with time 
for all formulations and was affected by the drug/polymer ratio: Increasing the 
polymer content from 5:1 (F1) to 17: 1 (F4) decreased drug release by 
approximately 40% after two hours.  
Cumulative CHD release from HPMC-S tablets, with the same drug/polymer ratio 
and weight, but varying P407 ratios indicated that increasing P407 content could 
elevate drug release by as much as 30%. For example, 60.53% CHD was 
released from F1 (25.00 mg HPMC-S and no P407) compared to 94.27% CHD 
release from F10 (6.25 mg HPMC-S and 18.75 mg P407). Moreover, cumulative 
CHD release from HPMC formulations F11 and F15 with the same composition 
of F1 and F10 were 57.77% and 94.58%, respectively (Figure 4.10). HPMC and 
HPMC-S formulations are similar in terms of cumulative drug release based on 
similarity factor (f2) and difference factor (f1) values of 79.62% and 7.05, 
respectively. F1 and F11 showed a cumulative release after two hours of 60.5% 
and 57.7%, respectively and F10 and F15 showed 94.3% and 94.6%, 
respectively. Both F10 and F15 considered similar with f2 of 72.67% and f1 of 7.87. 
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Figure 4.9 Cumulative percent release of chlorhexidine diacetate salt from tablets 
with different drug polymer ratios in ultrapure water at 37±0.1 °C and 50 rpm, 
results represent the average ± SD. 
 
 
 
Figure 4.10 Cumulative percent release of chlorhexidine diacetate salt from 
tablets with HPMC Colorcon and different P 407 content in ultrapure water at 
37±0.1 °C and 50 rpm, n = 3 ± SD. 
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4.3.1.6 Kinetics of drug release 
The kinetics of CHD release was investigated by fitting the release data to zero 
and first order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas models (Table 
4.5). For zero order, drug release is constant per unit time (drug concentration 
has no effect on the percentage of drug release). In the first order model, drug 
release rate decreases with time and it is concentration dependent. The Higuchi 
model predicts the mechanism of drug release from a matrix occurs by diffusion 
according to Fick’s law. In the Hixson-Crowell model, drug release is governed 
by dissolution in planes parallel to the surface of the dosage form but assumes 
that the geometric shape stays constant. Korsmeyer-Peppas equation (power 
low) is a semi-empirical equation in which the exponent n is used to characterise 
60% drug release. Using the correlation coefficient (R2) values, 30 and 50 mg 
CHD tablets fitted closest with the Korsmeyer-Peppas and for these formulations 
0.45<n<0.89. This indicating that drug release is anomalous from cylindrical 
tablets (0.45 representing diffusional control and 0.89 indicating case-II transport 
which corresponds to zero order kinetic); thus CHD release is anomalous 
(Siepmann and Peppas, 2012).  
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Table 4.5 CHD release kinetics using different models. 
 Zero Order (R2) First order(R2) Higuchi (R2) Hixon Crowel (R2) K-Peppas (R2) K-Peppas (n) 
F1 0.9540 ± 0.0533 0.9323 ± 0.1307 0.9695 ± 0.0140 0.9114 ± 0.1583 0.9942 ± 0.0085 0.672 ± 0.156 
F2 0.9879 ± 0.4940 0.9813 ± 0.0268 0.9563 ± 0.0042 0.9758 ± 0.0307 0.9946 ± 0.0079 0.772 ± 0.079 
F3 0.9125 ± 0.0585 0.7478 ± 0.1826 0.9731 ± 0.0191 0.7101 ± 0.2077 0.9856 ± 0.0054 0.510 ± 0.162 
F4 0.9127 ± 0.0612 0.7215 ± 0.1817 0.9612 ± 0.0183 0.6929 ± 0.2071 0.9706 ± 0.0181 0.503 ± 0.118 
F5 0.9542 ± 0.0376 0.9401 ± 0.0829 0.9755 ± 0.0124 0.9151 ± 0.1093 0.9936 ± 0.0061 0.651 ± 0.173 
F6 0.9672 ± 0.0202 0.9693 ± 0.0283 0.9762 ± 0.0174 0.9581 ± 0.0422 0.9958 ± 0.0035 0.676 ± 0.155 
F7 0.9587 ± 0.0358 0.9407 ± 0.0780 0.9727 ± 0.0084 0.9223 ± 0.1025 0.9886 ± 0.0151 0.650 ± 0.148 
F8 0.9487 ± 0.0462 0.9227 ± 0.1118 0.9731 ± 0.0116 0.8976 ± 0.1397 0.9907 ± 0.0137 0.623 ± 0.188 
F9 0.9809 ± 0.0052 0.9703 ± 0.0565 0.9732 ± 0.0064 0.9851 ± 0.0116 0.9981 ± 0.0012 0.718 ± 0.045 
F10 0.9819 ± 0.0047 0.9797 ± 0.0033 0.9697 ± 0.0064 0.9908 ± 0.0043 0.9968 ± 0.0039 0.739 ± 0.060 
F11 0.9712 ± 0.0054 0.9833 ± 0.0067 0.9736 ± 0.0063 0.9483 ± 0.0128 0.9965 ± 0.0007 0.698 ± 0.033 
F12 0.9663 ± 0.0025 0.9854 ± 0.0028 0.9796 ± 0.0019 0.9714 ± 0.0042 0.9959 ± 0.0005 0.671 ± 0.018 
F13 09791 ± 0.0107 0.9972 ± 0.0010 0.9606 ± 0.0071 0.9942 ± 0.0030 0.9983 ± 0.0015 0.796 ± 0.009 
F14 0.9727 ± 0.0117 0.9952 ± 0.0012 0.9703 ± 0.0105 0.9894 ± 0.0081 0.9981 ± 0.0015 0.740 ± 0.044 
F15 0.9907 ± 0.0079 0.9700 ± 0.0143 0.9475 ± 0.0190 0.9872 ± 0.0059 0.9987 ± 0.0005 0.870 ± 0.113 
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4.3.1.7 Drug polymer interaction (FTIR and DSC) 
FTIR analyses were performed (Figure 4.11) to evaluate possible interactions 
during the granulation and tabletting process, which might have resulted from the 
low melting point of P407. CHD displayed peaks at 3325  and 3119 cm-1 
(asymmetric and symmetric NH stretching vibrations), 2938 and 2886 cm-1 
(asymmetric and symmetric CH stretching), 1624 cm−1 (CN stretching vibration 
of imine group), 1522,1483 cm−1 (NH bending vibration of secondary amine and 
imine groups), 1406 cm−1 (C=C stretching vibrations of aromatic rings), 1290 and 
1245 cm-1CN stretching,   819 cm−1 out of plane vibration of the aromatic ring  
and the CCl group’s spectra at 718 cm-1 (Holešová et al., 2014 and Yang et al., 
2007). The characteristic peaks of HPMC are at 3445 cm-1 (OH stretching) and 
2897 cm-1 (CH stretching), 1375 cm-1 (asymmetric CH3 bending vibration), 1049 
cm-1 (C-O asymmetric stretching vibration) and 942 cm-1 (C-O symmetric 
stretching vibration (Ding et al., 2015). P407  is characterised by principal peaks 
at 2875 cm–1 (CH stretching), 1346 cm-1 (OH bending) and 1094 cm–1 (CO 
stretching) (Vyas et al., 2009). Analyses of tablet formulations F1, F6, F7, F9 and 
F10 and the (F11-F15) ( Figure 4.11 a and c) reveal that increasing the 
concentration of P407 leads to a decreased intensity of CHD and the 
disappearance of hydrogen bonding peaks at 3325 and 3119 cm-1, this is 
prominent for F10 and F15. In contrast, F1, F6, F11 and F12 show a combination 
of the peaks of all ingredients. The concentration-dependent interaction between 
CHD and P407 is attributed to the steric hindrance properties of P407 resulted in 
the shielding of CHD (Göppert and Müller, 2005). Whilst HPMC peaks overlap 
with P407, with the CO stretching of HPMC and P407 combined into one peak at 
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around 1097 cm-1 in F6, F8 and F10 and F13-F15; however, in F1 and F11, this 
peak shift to 1049 cm-1. Further investigation was performed to analyse  F10 and 
F15, physical mix, granules and tablets (Figure 4.11 b and d). All FTIR spectra 
have identical peaks, this means that during the mixing process of the excipient, 
hydrophobic interactions occur between  CHD and P407 ending in steric 
hindrance by the latter. Although this interaction is more common in liquid 
formulations, in the current formulation the interaction is aggravated by the small 
particle size of both CHD and P407.  
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Figure 4.11 FTIR spectra of a) HPMC-S formulations b) F10 physical mix (PM), granules (Gran) and tablet (Tab), c) 
HPMC formulations and d) F15 PM, Gran and Tab. 
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DSC analysis 
DSC thermograms for raw materials, physical mixture, granules and tablet of F15 
formulation which showed the highest drug release, are depicted in (Figure 4.12) 
CHD has two melting peaks at 158 and 176ºC which indicates its polymorphic 
nature, HPMC reflects its amorphous nature while P407 has a melting peak at 
57ºC. F15 physical mix, granules and tablet thermograms showed the 
endothermic peak of poloxamer around the same temperature. The first melting 
peak of CHD was shifted to 156ºC in the physical mix and to 153ºC for the 
granules and of the compressed tablet, this was accompanied by the 
disappearance of the small melting peak in the physical mix and granules and 
shifted to 173ºC in the tablet. Shifting and disappearance of the melting peaks in 
the physical mix and the granules indicates there is an interaction between the 
chlorhexidine and P407 However, the re-appearance of the second endothermic 
peak in the tablet is attributed to phase separation resulted from tablet 
compression (Singh et al., 2016).  
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Figure 4.12 DSC thermograms of F15 physical mix (PM), Granules (GRAN), 
tablet (TAB), CHD HPMC and P407. 
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4.4 Discussion                                                                                                                
Three groups of formulations with CHD were prepared based on different CHD 
to HPMC-S ratios, different HPMC-S to P407 ratios, and different HPMC to P407 
ratios (detailed in Table 4.1). 
Pre-formulation analyses were performed for particle size, distribution, 
morphology and flowability and all the tested powders were classified as fine 
powders according to BP criteria (BP, 2018 d). CHD and MgSt showed a bimodal 
particle size distribution, which is most likely due to the agglomeration of powders 
(Li et al., 2004) with adhesion of fine to coarse particles. Particle size analysis of 
HPMC showed a broadening of the distribution peak and a higher span value 
compared to HPMC-S (Figure 4.2) that can be attributed to the rod-like shape of 
the particles seen under SEM (Figure 4.3). Particle size distribution of HPMC-S 
approximates a nearly normal distribution with SEM revealing more spherical or 
irregular spheres for HPMC-S particles.  
The morphology of both HPMC samples (Figure 4.3) strongly influences their flow 
behaviour; HPMC-S displays “passable” powder flow (CI of 21.67 and HR of 
1.28), whereas HPMC has “poor” flow (CI of 33.33, HR of 1.50) (BP, 2018e). This 
finding was not unexpected as Hassan and Lau (2009)  reported the impeded 
flow of needle-shaped calcium carbonate particles (CI of 40), that resulted from 
inter-particulate interactions and aggregation. Moreover, the span value of HPMC 
is higher than HPMC-S which resulted in a decrease in the flowability. This is 
confirmed by a previous finding by Liu et al., (2008) who found that the flowability 
effected by both particle size and distribution. Particle size (Table 4.2) below 100 
µm resulted in increased cohesiveness and decreased flowability (Liu et al., 
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2008) with the narrower distribution showing better flowability. The flowability of 
the various powder formulation blends was found to be not flowable (Table 4.3) 
and may be due to the smaller mean particle size population of the formulations, 
which results in a relatively high surface area and the potential for increased inter-
particulate interactions that can decrease flowability. Dry granulation improved 
the flow properties of all formulation blends with most of improving from ‘very, 
very poor’ to ‘very poor’, or from ‘very poor’ to ‘poor’ based on the BP.  
The applied force used to prepare HPMC-S granules was 1 ton. In contrast, 
HPMC granules were initially prepared at 1 and 4 ton, but the 1 ton samples were 
rejected due to no improvement in flowability. This may be attributed to the rod-
like shape of HPMC-C particulates, which result in a weak granule compact, 
unable to maintain its shape. The flowability of granulated formulations prepared 
by both forces (1 or 4 tons) was similar. Increasing the ratio of polymer to drug 
from 5:1 to 17:1 had no effect on the flow properties of the various formulation 
blends. All these formulations had ‘very poor’ flowability with CI and HR values of 
35-37 and 1.54-1.58, but these improved after granulation to 25-29.41 and 1.27-
1.42, respectively. Similarly, increasing the P407 content has decreased the 
flowability of the powder blends most likely because of the irregular shape, small 
particle size and cohesive properties of P407, which increases inter-particulate 
interactions and decreases packing efficiency as evidenced by relatively high CI 
and HR values (40 and >1.7, respectively). Again, flow properties were improved 
after granulation, possibly as a result of the low melting point and the waxy nature 
of the P407, which has decreased inter-particulate interactions and improved the 
packing efficiency. Granulated formulations with a high P407 ratio, demonstrated 
C.I. and HR values of 27 and 1.4, respectively. Granules flowability did not show 
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a high improvement, this due to the generation of fine particles using dry 
granulation as confirmed using SEM images (Figure 4.4).  
To overcome the poor flowability, tablets were pressed at the lowest turret speed 
at 8.6 RPM. The resultant tablet gave acceptable friability, weight variation and 
content uniformity. Moreover, all tablets successfully adhered to the chicken 
pouch, as a model tissue, using the modified disintegration tester. Successful 
mucoadhesion of tablets containing both HPMCs and P407 may be due to chain 
entanglement and physical interlinking interaction with the chicken pouch mucous 
membrane; neither polymer is capable of interacting with the mucin component 
of mucous as they are both uncharged (Sosnik et al., 2014). In the modified 
balance method, the measured force of detachment was not affected by the ratio 
of the polymers. Using HPMC-S showing no significant difference (p <0.05) 
among the tested formulations (F1, F7, F9 and F10), however the increase in 
P407 in HPMC formulations (F11, F13, F14 and F15) showed a significant 
decrease in the force of detachment (p >0.05). Furthermore, there is no evidence 
that the source or the morphology of the particles influences the force of 
detachment. This variation might be attributed to the poor reproducibility using 
biological membrane (chicken pouch) due to the inter-individual variation of the 
tissue, as was previously highlighted by Khutoryanskiy (2011). Attempts have 
been made to replace the use of animal tissue in mucoadhesion tests. For 
instance, Hall et al., (2011) successfully developed a synthetic three-dimensional 
crosslinked hydrogel with hydroxyethyl methacrylate polymer and acryloyl 
glucosamine monomers, they found that mucoadhesion results of the synthetic 
membrane are in agreement with the porcine buccal mucosa results. 
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The swelling profiles of the tablet formulations (Figure 4.6 and Figure 4.7) in 
ultrapure water for two hours showed that tablets with a CHD to polymer ratios 
1:17 to 1:9 had a lower swelling index range from 3.0 to 3.6. This is possibly 
because of the higher surface area to volume ratio. Source of HPMC does not 
show any impact on the swelling index, however increasing P407 led to 
decreasing swelling index significantly ((p<0.001), for both sources.   
Upon hydration the mobility the macromolecules of HPMC and HPMC-S 
increases along with the rate of water movement (Siepmann and Peppas, 2012). 
Moreover, hydrated P407 arranges itself into micellar structures that 
subsequently adopt a cubic shape once the hydrogel is formed. Intriguingly, the 
presence of HPMC in some of these formulations might facilitate the formation of 
a network of interconnected P407 micelles (Koffi et al., 2006).  
Swollen SEM tablet morphology (Figure 4.9) has a strong relationship with 
particles morphology of HPMC and HPMC-S polymers (Figure 4.3) and their 
ratios in the formulations. F1 and F6 show clear spherical pores while F11, F12 
and F13 have elongated pores, the effect is prominent when the ratio is greater 
than 50% in the tablet. Increasing P407 lead to the formation of irregular pores 
which might be due to its surfactant properties which increase the solubility of 
other polymers and distorting their shapes. Another possibility is that it might be 
affected by thermosensitive properties of P407, which melts at low temperature, 
and so pore damage may occur during the freeze-drying process. 
The release of CHD from HPMC-S matrix tablets was affected by the 
CHD/polymer ratio, increasing the polymer content led to increased resistance to 
the release of CHD (Figure 4.9). The higher mass of F4 (90 mg) compared to F1 
(30 mg) would require more time to fully hydrate (data not presented), thus 
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resulting in decreased CHD release; furthermore, swelling index data (Figure 
4.6), for F1 and F4 were 4.98 and 3.00, respectively. Based on these results F1 
was selected for further investigation as it released more CHD and would be a 
more convenient size for patients to administer as a buccal dosage form. 
Cumulative CHD release from HPMC-S tablets, with the same drug/ polymer ratio 
and weight, but varying P407 ratios indicated that increasing P407 content could 
elevate drug release by as much as 30%. The increase in drug release was 
attributed to the solubilising activity of P407 (Figure 4.9). The copolymer P407 is 
a surfactant which is widely used to improve the aqueous solubility of poorly 
soluble drugs (Dumortier et al., 2006), and can also form a hydrogel at body 
temperature. Although different compression forces of 1 ton for HPMC-S 
formulations and 4 ton for HPMC formulations were used to prepare the granules, 
this should not affect drug release. Velasco et al., (1999) reported that 
compression force has a minimal effect on drug release or the kinetics of release 
but can influence initial matrix porosity (before hydration). 
Using the correlation coefficient (R2) values, tablets fitted closest with the 
Korsmeyer-Peppas kinetic model and the exponent n was found to be 
0.45<n<0.89, Indicating that drug release is anomalous from cylindrical tablets 
(0.45 representing diffusional control and 0.89 indicating case-II transport which 
corresponds to zero order kinetic); thus CHD release is anomalous (Siepmann 
and Peppas, 2012). This concludes that neither drug-polymer ratio nor P407 had 
an effect on the mechanism of drug release. 
The Interaction between excipients and CHD were tested using FTIR and DSC. 
FTIR spectra revealed increasing in P407 ratio led to decrease the intensity of 
CHD which was attributed to steric hindrance by P407. Comparing FTIR spectra 
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for F10 physical mix, granules and tablet showed identical spectra similarly for 
F15. This indicates that no interaction occurred during the process of tabletting 
and the source of the polymer showed no difference in behaviour. Moreover, DSC 
analysis was performed for F15 formulation only, showed no interactions 
between the drug and the polymers in the prepared table. 
4.5 Conclusions 
Formulation of buccal tablets using either HPMC-S or HPMC did not affect 
cumulative CHD release, in spite of their physical properties not being identical. 
The addition of the thermosensitive hydrogel-forming polymer; P407 to the 
formulations, improved CHD release from the tablets, whilst not negatively 
impacting on the time of mucoadhesion. Formulations prepared with HPMC-S 
and HPMC both showed comparable drug release and kinetics of drug release, 
although each one had different pore sizes and morphology. Furthermore, based 
on FTIR and DSC analysis, there was no interaction between CHD and any of 
the excipients. The results shown in this chapter are promising, although further 
adjustments are required in terms of a developing a safe and effective 
concentration under limited availability of salivary dissolution medium. 
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Chapter 5 : Tablet gelling, hydration and drug release 
The aim of this work is to investigate the effect of the flow rate of the dissolution 
media on the behaviour of the matrix tablet in terms of gelling, hydration and drug 
release. A novel method was used to compare the degree of hydration with 
different HPMC/P407 ratios using visible spectroscopy, to assess the hydrogel-
forming ability using image analysis and exploit polarized microscopy to examine 
the behaviour of the tablet after swelling. Based upon our knowledge, there is no 
standard method to assess the effect of different degree of hydration or salivation 
in the oral cavity upon drug release. In this chapter, the feasibility to design a new 
method to assess the release of CHD from the mucoadhesive buccal tablets was 
investigated and the release of CHD was assessed using water as a dissolution 
medium of different flow rates and compare it with Apparatus I (App1). 
Mathematical and statistical methods were used to analyze the drug release data. 
5.1 Materials and Methods 
5.2.1 Materials 
Based on the previous results in chapter four, which showed no significant 
difference in CHD release from mucoadhesive buccal tablets prepared using 
HPMC or HPMC-S. Formulations F11-F15 prepared with HPMC Dow-Colorcon 
were further investigated using the methods described below. 
5.2.2 Methods 
5.2.2.1  Rate of tablet hydration  
The rate of hydration or wetting was investigated by testing the rate of water 
uptake by the tablets, the measurement based on the change in the absorbance 
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(A) upon hydration, using wideband filters (405 to 600), in an automated 
Bioscreen C spectrophotometric plate reader (Thermo Labsystems, Finland). 
Tablets were placed in a honeycomb 100 well microtiter plate (one tablet per 0.4 
mL well size) 350 µL of distilled water was added to each well, water was used 
as a negative control. The change in optical density due to tablet swelling over 
time was recorded every 30 minutes for 24 hours.  
To plot the relationship of hydration with time: 
All absorbance data were blanked with water. A0 represents the absorbance of 
the tablet at time zero. The absorbance of the tablet (An) was decreased upon 
hydration, accordingly, a negative value was obtained by subtracting A0 from An. 
To calculate the change in the absorbance (∆At)  Equation 15 was applied. 
 
∆𝐴𝑡 = (𝐴𝑛 − 𝐴0) × −1 Equation 15 
∆At is the change in the absorbance at time t 
Water uptake or hydration (H) was calculated using Equation 16 
 
𝐻𝑡 =
(∆𝐴𝑡 × 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟)
∆𝐴𝑚𝑎𝑥
 
Equation 16 
Where (∆Amax is the maximum change in the absorbance at 24 hours), the volume of water is 350 
µL. 
Hydration curve is obtained by plotting H against time.  
Hydration kinetics 
Hydration data was fitted to piecewise linear regression 2 (PWL2) and to the 
exponential model. The AIC (Akaike information criterion) was calculated to find 
the best fitting model. The analysis was performed using OriginPro software.   
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5.2.2.2 Image analysis 
 Image analysis of gelling efficiency 
Each tablet was adhered to a glass slide, immersed in a beaker filled with water 
and placed in a prewarmed water bath at 37°C. Images were acquired for the 
swollen tablet at 15, 30, 60, 90 and 120 minutes using a digital camera. The area 
of the gel and the core base were calculated using ImageJ 1.51n software. 
Polarized optical microscopy imaging 
Tablets were treated similar to section 5.2.2.2 and investigated using polarized 
microscopy (Primotech-Zeiss, Germany), to monitor the change in tablet 
morphology upon swelling. Darkfield illumination and retardation plate using 50X 
magnification were used.  
5.2.2.3 In Vitro dissolution using controlled flow rate (CFR, Liebig 
condenser method) 
Drug dissolution from F11-F15 was tested at different flow rates of the dissolution 
medium. The dissolution was performed at 37.0 ± 0.1°C, in a Liebig condenser 
with circulating warm water (to maintain the temperature around the tablet). The 
dissolution media was pumped (Watson Marlow 502s peristaltic pump, UK) at 
0.48 ± 0.05 and 2 ± 0.05 mL/min over the tablet in the condenser. Then the media 
was collected in a measuring cylinder, samples were collected every 10 minutes 
for two hours. Similarly, the dissolution was performed using a fixed speed 
peristaltic pump (model PP1ML, UK) with a flow rate of 0.9mL/min (Figure 5.1).  
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Figure 5.1 Diagram of In-Vitro drug release using controlled rate of flow of 
dissolution medium over the tablet 
5.2.2.4 Analysis of dissolution profiles (statistical and mathematical 
modelling) 
5.2.2.4.1 Dissolution efficiency (D.E.) 
D.E. is determined from the percentile ratio of the area under the curve (AUC) of 
the dissolution data to the AUC of 100% release between time zero to the end of 
dissolution (Anderson et al., 1998). It is obtained using Equation 17 and OriginPro 
2017 software were used to calculate the area under the curve.  
𝐷. 𝐸. =
∫ 𝑦 × 𝑑𝑡
𝑡
0
𝑦100 × 𝑡
× 100% Equation 17 
 
Where t is the time, y is the percentage of drug dissolved at time t. 
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5.2.2.4.2 In vitro equivalence analysis (model independent) 
Statistical and mathematical methods were applied for each pair of the triplicates 
of the dissolution testing data to evaluate the degree of equivalence and the 
applicability of flow rate method compared to standard Apparatus I (Figure 4.10). 
i. One-way analysis of variance (ANOVA) 
 ANOVA was obtained using Microsoft Excel to examine the difference between 
each triplicate. This test compares the variability in drug release at each time 
point. However, it doesn’t correlate the whole dissolution profile (O'hara et al., 
1998). 
ii. Pairwise model independent methods 
Similarity factor (f2) and Difference factor (f1) were performed as explained in 
4.1.2.12. 
iii. Rescigno’s indices (ξj) 
Rescigno Index is used to measure the difference in drug concentration of a 
sample compared to a reference; it is obtained by applying Equation 18 (O'hara 
et al., 1998) 
𝜉𝑗 = (
∫ |𝑅𝑡 − 𝑇𝑡|
𝑗𝑑𝑡
𝑡𝑛
0
∫ |𝑅𝑡 + 𝑇𝑡|𝑗𝑑𝑡
𝑡𝑛
0
)
1/𝐽
 Equation 18 
Where ξj is rescigno index, j is the exponent and it is equal to 1 or 2, ξ1 is the absolute area 
difference and ξ2 is the square area difference, n is the number of sampling points, Rt and Tt 
represent the concentration at time t of the reference and the sample, respectively, the endpoint 
of the dissolution is denoted as tn. 
ξj value ranges between 0 and 1, when the test samples are identical it is equal 
to zero, however, 1 means there is no release from one of the samples. The 
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difference between similarity factor and the Rescigno ratio is the former take 
sampling time in consideration while the latter take spacing between sampling 
intervals as well (Vertzoni et al., 2003). In the current work, DDsolver (Zhang et 
al., 2010) software was used for the calculation of Rescigno’s Indices. 
iv. The ratio of the Area Under the Curve (AUC) 
The ratio of the AUC is used to measure the bioequivalence of drug release in 
vivo. It is used in vitro to compare between a reference and a sample. It is 
calculated by dividing the AUC of the sample over the AUC of the reference. The 
ratio should lie between 0.80- 1.25; this limit was selected based on 90% 
confidence intervals (Morais and Lobato, 2010).  
5.2.2.4.3 Model-dependent methods (Kinetics of drug release) 
Kinetics of drug release was applied to investigate the effect of the different flow 
rates of the dissolution medium on the mechanism of drug release and compare 
it to the standard App I. DDSolver software was used to calculate the Kinetic 
modelling of drug release, the advantage of this software is the use of non-linear 
fitting (Zhang et al., 2010) which is more reliable, the same models investigated 
in chapter four (4.1.2.13) were investigated (Zero order, First order, Higuchi 
model, Hixon-Crowell model and Korsmeyer-Peppas models). 
5.3 Results 
5.3.1 Rate of hydration 
The rate of water uptake by polymers is varied and it is based upon their 
properties. The mechanism of drug release from the matrix is mainly controlled 
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by diffusion and erosion, both of which are affected by the hydration state of the 
matrix (Colombo et al., 2000). In this work, the hydration rate was measured by 
the change in the light absorbance with time. Figure 5.2 displays the raw data 
obtained from the Bioscreen spectrophotometer, showing the decrease in light 
absorbance with time, which is obtained by the hydration of the tablets. 
 
Figure 5.2 original data of the change in the absorbance with time obtained from 
the Bioscreen spectrophotometer. 
 
Figure 5.3 shows the calculated values of tablets hydration over 24 hours and it 
was faster for both F14 and F15, they reached the plateau 4 hours faster than 
other formulations. 
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Figure 5.3 Hydration of F11-F15 formulations with time for 24 hours at 
37°C, n = 3. 
 
Based on the shape of the graphs, data were fitted to the piecewise linear 
regression 2 (PWL2) model (Figure A 1) and to the exponential model.  
All fitted data showed a high degree of fit (R2>0.99) to the PWL2 model. K1 and 
K2 represent the rate constant for tablet hydration in µL/tab (Table 5.1), the rate 
constant of the first line of the curve showed the rate of water uptake by the 
tablets, K1 increased from 19.52 µL/tab.hr to 72.64 µL/tab.hr from F11 to F15. 
 
Table 5.1 Rate constants and R2 for fitted hydration curves for F11-F15 using 
PWL2 
Formulations 
PWL2 Exponential 
K 1 K2 R2 R2 
F11 19.52 0.39 0.992 0.974 
F12 29.69 0.30 0.998 0.976 
F13 34.21 0.69 0.994 0.968 
F14 58.53 1.37 0.993 0.989 
F15 72.64 1.84 0.992 0.955 
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OriginPro software was used to compare the best fitting by obtaining AIC values, 
they were 215 and 299 for PWL2 and exponential fitting, respectively.  Which is 
further confirms the fitting to PWL2 model due to its lower value of AIC. 
To further investigate the effect of P407 on the rate of water absorption, the latter 
was plotted against the ratio of P 407 in the formulations (Figure 5.4). 
Interestingly the effect of P407 content in the tablets showed high linearity with 
the hydration rate constant, which indicates the increase P407 ratio from 0% in 
F11 to 62.5% in F15, lead to a consistent increase in the hydrophilicity of the 
formulations and consequently the rate of hydration, which is attributed to the 
surfactant properties of P407 (Beck-Broichsitter et al., 2017). 
 
Figure 5.4 relationship between the percentage of P407 and the rate of hydration 
(K1). 
 
5.3.2 Image analysis  
5.3.2.1 Tablet gelling 
To investigate tablets gelling, images were acquired using a digital camera at (15, 
30, 60, 90 and 120 min) during tablet hydration, and the surface area of the base 
of the tablet was calculated for both the core (solid glassy material) and the 
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hydrogel layer. Hence the tablet hydrates radially in all direction, thus the ratio of 
the hydrogel to the core will be constant in the swollen tablet (Figure 5.5). 
 
 
Figure 5.5 Swollen F11 tablet after 1.5 hours showing the two layers of the 
tablet. 
 
The results show that as the area of the whole tablet increases with time the core 
area decreases and the hydrogel area increases for all samples (Figure 5.6). The 
increase in the P407 in the tablets resulted in the increase of hydrogel to core 
area over time. Finally, the hydration profile in Figure 5.3 and Figure 5.6 is 
dissimilar, and this is attributed to the difference in the exposed surface area to 
water. For the former the surface area was constant which is represented by the 
surface area of the tablet (6mm in diameter and its equal to the surface area of 
the well). While in Figure 5.6, the surface area was increasing with time due to 
tablet swelling.  
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Figure 5.6 image analysis results for F11 - F15 tablet showing the planner area 
of both the core and the hydrogel layer at 37°C and 2 hours. 
5.3.2.2 Polarized microscopy imaging: 
Polarized microscopy images were obtained to investigate the behaviour of the 
tablet during the swelling process, it distinguishes between materials of a different 
refractive index. The hydrogel layer is transparent under a light microscope and 
it is difficult to monitor tablet swelling without staining which might affect the 
property of the tablet. However, the use of cross polarised illumination with the 
dark field (Figure 5.8) and the retardation plate (Figure 5.9)  gave more detailed 
information. 
Figure 5.7  shows the optical properties of the raw materials; CHD, HPMC and 
P407. They have anisotropic with birefringent properties, CHD and P407 for their 
crystalline structure and HPMC for its randomly oriented chains resultant from the 
stress of the manufacturing process (Arruda et al., 1993). 
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Figure 5.7 CHD, HPMC and P407, using cross polarised microscopy (darkfield) 
and a retardation plate, 50x and 400x, bars are 200 µm (a and c) and 50 µm (b 
and d).  
 
Images were obtained at the predetermined time intervals, by examining the core 
of the tablets within the hydrogel layer (F11, F13, F14 and F15) during their 
swelling (Figure 5.8). There is some fragments detached from the core of the 
tablets. The fragments are increased with time and also with P407 ratio.  
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Figure 5.8 F11, F13, F14 and F15 swollen tablets morphology under polarized microscopy (using cross polarised 
illumination, 50x 
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Using the retardation plate as shown in Figure 5.9, the fragments are more visible 
within the hydrogel layer due to their birefringent properties, which is more 
obvious with F14 and F15. Moreover, rod-shaped particles can be seen in Figure 
5.9 that are similar in size and shape to HPMC in Figure 5.7. Furthermore, the 
gel layer showed dichroic properties upon rotation to 90°. 
 
Figure 5.9 F11, F13, F14 and F15 swollen tablets morphology under polarized 
microscopy (using cross polarised illumination and a retardation plate, 50x).
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5.3.3 In Vitro dissolution studies and dissolution efficiency 
Drug release studies were investigated using App I (4.3.1.5) and using the novel 
method of controlling the flow rate over the tablet and the results are presented 
in (Figure 5.10). Generally, CHD release showed no substantial change in CHD 
release from F11, which is represented by 24.45%, 21.64% and 28.3% using flow 
rates of 0.48, 0.9 and 2mL/min, respectively, while the release using App I was 
57.78%. On the other hand, almost 40% of CHD released from F15 using flow 
rates of 0.48 and 0.9 mL/min, by increasing the flow rate to 2 mL/min the release 
increased to around 68% and using App l it was nearly 95% after 2 hours. 
This concludes the variability of the response of the formulations to the different 
flow rates, although for all formulation using App I showed the highest release. 
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Figure 5.10 Drug release studies of chlorhexidine buccal tablet in a) flow rate 0.48 mL/min, b) 0.9 mL/min flow rate c) 2 mL/min 
flow rate and d) 500 mL App I (basket method) 50 RPM. Release studies were performed at 37°C for 2 hours. Data are expressed 
as mean percentage ± SD, n = 3. 
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D.E. results are displayed in Figure 5.11, highest D.E. value was achieved by 
using App I, due to the abundant availability of water, however, flow rates of 0.48 
and 0.9 mL/min their D.E. values were minimum and comparable. However, at 2 
mL/min flow rate the results were higher compared to other flow rates. 
 
Figure 5.11 Dissolution Efficiency of CHD release using a) flow rate 0.48 mL/min, 
b) 0.9 mL/min flow rate c) 2 mL/min flow rate and d) 500mL App I (basket method) 
Data are expressed as mean ± SD, n = 3. 
Statistical analysis by ANOVA two factor with replication was conducted between 
each two consecutive methods; P-values are listed in Table 5.2. There was no 
significant difference for the same formulations between the flow rate of 0.49 and 
0.9 mL/min dissolution; P-Value >0.05. However, for the other two comparisons 
between (0.9 mL/min, 2 mL/min) and (2 mL/min, App I), there is a significant 
difference with a P-value < 0.05.  
Table 5.2 ANOVA; two-way with replication. Sample: within the same formulation, 
Columns: between different formulations and the interaction, effect of the volume 
of the dissolution medium on the different formulations. 
Comparison 
P-value 
Sample Columns Interaction 
0.48 mL/min and 0.9 mL/min 0.848427 0.001102 0.552698 
0.9 mL/min and 2 mL/min 7.74E-08 1.51E-08 1.86E-05 
2 mL/min and App I 1.51E-15 3.66E-11 0.07217 
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Comparing formulations (F11-F15) intra and inter dissolution methods (Table 
5.2), D.E appears to increase with increasing P407. The statistical analysis shows 
P-value <0.5 which means different P407 ratio influences the release of the drug 
for the same method. Finally, the interaction reflects the effect of the flow rate or 
the volume of the dissolution medium on different content of P407. The only 
significant difference was between 0.9 mL/mL and 2 mL/min, which means 
increase the flow rate from 0.9 to 2 mL/min effect differently on CHD release with 
the increase of P407. 
Based on these results, it is concluded that the dissolution efficiency was grouped 
into 2 groups; group one; 0.48 and 0.9 mL/min and group two; 2 mL/min and App 
I. each group has the same behaviour regardless the concentration of drug 
released. 
5.3.4 Kinetics of drug release (Model dependent methods) 
The kinetics of drug release was calculated using DDsolver software (Zhang et 
al., 2010). The coefficients of determination (R2) are listed in Table 5.3. The best 
linearity was achieved with Korsmeyer-Peppas model, with n value in the range 
of 0.45 - 0.89. This indicates the release is anomalous which is governed by 
swelling and diffusion. The only formulation with n value of 0.934 > 0.89 was for 
F15 and 2 mL/min method, based on this result the release was zero order, and 
this is confirmed by R2 of zero order and Korsmeyer-Peppas of 0.9976 and 
0.9982, respectively. 
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Table 5.3 Coefficients of determination, using DDsolver software.  
 
Zero Order (R2) First order (R2) Higuchi (R2) 
Hixon Crowel 
(R2) 
K-Peppas (R2) K-Peppas (n) 
500 ML 
F11 0.9712 ± 0.0054 0.9833 ± 0.0067 0.9736 ± 0.0063 0.9483 ± 0.0128 0.9955 ± 0.0009 0.698 ± 0.033 
F12 0.9663 ± 0.0025 0.9854 ± 0.0028 0.9796 ± 0.0019 0.9714 ± 0.0042 0.9966 ± 0.0004 0.671 ± 0.013 
F13 09791 ± 0.0107 0.9972 ± 0.0010 0.9606 ± 0.0071 0.9942 ± 0.0030 0.9961 ± 0.0040 0.764 ± 0.029 
F14 0.9727 ± 0.0117 0.9952 ±0.0012 0.9703± 0.0105 0.9894 ± 0.0081 0.9973 ± 0.0002 0.718 ± 0.050 
F15 0.9896 ± 0.0086 0.9700 ± 0.0143 0.9475 ± 0.0190 0.9872 ± 0.0059 0.9988 ± 0.0004 0.824 ± 0.087 
0.48- ML 
F11 0.9809 ± 0.0183 0.9694± 0.0405 0.9678 ± 0.0205 0.9635 ± 0.0448 0.9997 ± 0.0002 0.746 ± 0.115 
F12 0.9653 ± 0.0099 0.9388 ± 0.0189 0.9863 ± 0.0059 0.9288 ± 0.0216 0.9995 ± 0.0002 0.645 ± 0.038 
F13 0.9853 ± 0.0040 0.9871 ±0.0028 0.9639 ± 0.0047 0.9821± 0.0033 0.9984 ± 0.0014 0.774 ± 0.023 
F14 0.9796 ± 0.0099 0.9771 ± 0.0131 0.9736 ± 0.0090 0.9691 ± 0.0164 0.9996 ± 0.0004 0.721 ± 0.050 
F15 0.9816 ± 0.0154 0.9819 ± 0.0185 0.9670 ± 0.0239 0.9737 ± 0.0250 0.9993 ± 0.0006 0.742 ± 0.113 
0.9 ML 
F11 0.9703 ± 0.0038 0.9556 ± 0.0091 0.9792± 0.0053 0.9477 ± 0.0089 0.9975 ± 0.0037 0.684 ± 0.019 
F12 0.9757 ± 0.0258 0.9559 ± 0.0622 0.9710 ± 0.0218 0.9487 ± 0.0674 0.9994 ± 0.0004 0.718 ± 0.129 
F13 0.9760 ± 0.0300 0.9120 ±0.0744 0.9803 ± 0.0201 0.8977 ± 0.0840 0.9987 ± 0.0006 0.722 ± 0.128 
F14 0.9792 ± 0.0021 0.9698± 0.0050 0.9749 ± 0.0053 0.9624 ± 0.0064 0.9989 ± 0.0017 0.708 ± 0.023 
F15 0.9801 ± 0.0054 0.9765 ± 0.0090 0.9748 ± 0.0058 0.9681 ± 0.0106 0.9992 ± 0.0008 0.710 ± 0.029 
2 ML 
F11 0.9806 ± 0.0150 0.9713 ± 0.0245 0.9685± 0.0216 0.9650 ± 0.0292 0.9992 ± 0.0008 0.740 ± 0.111 
F12 0.9798 ± 0.0084 0.9765 ± 0.0055 0.9745 ± 0.0078 0.9683 ± 0.0088 0.9997 ± 0.0001 0.715 ± 0.038 
F13 0.9798 ± 0.0111 0.9764 ± 0.0170 0.9716 ± 0.0125 0.9681 ± 0.0202 0.9981 ± 0.0015 0.719 ± 0.069 
F14 0.9883 ± 0.0063 0.9917 ± 0.0102 0.9590 ± 0.0163 0.9882 ± 0.0153 0.9986 ± 0.0013 0.788 ± 0.084 
F15 0.9976 ± 0.0010 0.9779 ± 0.0112 0.9254 ± 0.0176 0.9889 ± 0.0071 0.9982 ± 0.0001 0.934 ± 0.078 
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5.4 In vitro equivalence comparison 
5.4.1 One-way ANOVA 
One-way ANOVA results were displayed in Table 5.4, for each dissolution 
triplicate performed for all formulations and all methods, there was no significant 
difference between the triplicate according to the P-value.  
Table 5.4 P-values of One-way ANOVA statistics. 
Formulations 
P-values 
0.48 mL/min 0.9 mL/min 2 mL/min App I 
F11 0.97 0.45 0.41 0.99 
F12 0.53 0.55 0.06 0.96 
F13 0.20 0.91 0.36 0.99 
F14 0.17 0.76 0.61 0.97 
F15 0.05 0.76 0.45 0.97 
 
5.4.2 Pairwise methods 
i. Similarity factor(f2) 
As approved, f2 ≥ 50 concludes the two replicates are similar, f2=50 represents 
the average of 90% equivalence between different time points of two replicates 
(Langenbucher, 1999). Figure 5.12 displays the values of f2, they are equal or 
greater than 50 except three values, 43.99 for (F15, R2-R3 and 0.49mL/min) and 
49,45 and 45,21 for (F12; R1-R3 and F15; R2-R3), respectively using 2 mL/min 
flow rate. The lowest value achieved between two replicates of 43.99 means the 
difference was less than 15%. 
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Figure 5.12 Similarity factor between two replicates of each triplicate of the 
dissolution data. 
 
ii. Difference factor (f1): 
Difference factor values are displayed in Figure 5.13, the minimum difference 
among the four dissolutions was achieved with the standard App I, all f1 values 
lies below 15 except one value of R1-R2; F15 which is equal to 15.73. The highest 
dissolution data f1 values were shown for 2 mL/min flow rate, 11 values were 
above 15, they are ranging from 15.87 to 48.45. This followed by 0.49 mL/min; 8 
values above the accepted value ranging from 21.9 to 55.28. While for the flow 
rate of 0.9 mL/min only 4 values were out of the acceptable range with a highest 
f1 value of 23.64.  
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Figure 5.13 Difference factor (f1) between the replicates of each triplicate of the 
dissolution data. 
iii. Rescigno indices (ξj) 
Rescigno indices for the studied formulations are displayed in Figure 5.14. There 
is no cut off value to decide if the two profiles are dissimilar, but the dissimilarity 
increases while the value approaches 1. All the results were below 0.3 and the 
lowest error value was shown with the standard dissolution method. Similar to f2 
and f1 the least difference between the replicates of each formulation was for 
App1, followed by the 0.9 mL/min. 
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Figure 5.14 Rescigno’s indices for the dissolution of the tablet with different 
volume of Water, R1, R2, and R3 represent the replicates of the triplicate 
iv. Ratio of the area under the curve(AUC) 
AUC ratios are listed in Table 5.5. The values obtained from the standard 
dissolution App I lies between 0.8 -1.25, one value (0.79) of 0.9 mL/min flow rate 
lies out of the acceptable ratio. However, for the other two flow rates, 5 and 7 
ratios are out of the acceptable range. 
Table 5.5 AUC Ratio for formulations replicates using App I and different flow 
rates method. 
Formulations 
0.45 ML/MIN  0.9 ML/MIN 2 ML/MIN USPI 
R1-R2 R1-R3 R2-R3 R1-R2 R1-R3 R2-R3 R1-R2 R1-R3 R2-R3 R1-R2 R1-R3 R2-R3 
F11 0.95 1.23 1.30 1.02 0.81 0.79 0.96 1.27 1.33 1.02 1.04 1.03 
F12 0.80 0.92 1.15 0.80 0.86 1.08 1.40 1.64 1.17 1.10 1.04 0.95 
F13 1.55 1.26 0.81 1.04 1.05 1.02 1.25 1.33 1.07 1.05 0.99 0.95 
F14 1.48 1.07 0.72 1.14 1.15 1.01 0.85 0.80 0.94 0.97 1.04 1.08 
F15 0.91 1.61 1.77 0.98 1.13 1.16 0.82 1.12 1.36 1.07 0.99 0.93 
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5.5 Discussion 
HPMC and P407 are hydrophilic polymers that form transparent hydrogels upon 
hydration. HPMC is commonly used in swellable hydrophilic matrices (Colombo 
et al., 2000), while P407 is widely exploited in oral localised drug delivery for its 
thermo-reversible hydrogel-forming ability due to self-aggregation (Bonacucina 
et al., 2011). Water uptake was calculated in terms of change in the absorbance 
of visible light with time at 37°C and hydration data showed an excellent fitting to 
PWL2 model. All formulations absorbed the same amount of water but at different 
rates Table 5.1. The fitting to the PWL2 model can be explained by zero order 
rate of hydration for the first linear part of the graph. The rate of hydration was 
also observed when measuring the area of hydrogels to the core of the tablet 
which was also higher for F15 than F11 (Figure 5.6). Currently, swelling index is 
the only method to measure the water uptake capacity. For water-soluble 
matrices, this process is accompanied by dissolution or fragmentation of the 
tablet, accordingly, the rate of water uptake cannot be identified precisely 
(Kavanagh and Corrigan, 2004). Light transmission was previously applied by 
Sarkar and Walker (1995) to measure the hydration and dehydration of solutions 
of HPMC and Methyl cellulose. This infrared light transmission was measured 
with the change of temperature and this method cannot be applied to tablets. 
Based on the analysis of gel to core ratio, the opacity of the tablets decreased 
with the increase in P407, and this might be attributed to a lower water holding 
capacity of P407 compared to HPMC. This lower holding capacity might be due 
firstly, to its low molecular weight of 12,600 compared to 86,000 for HPMC and 
secondly, to its surfactant properties. The thickness of the gel layer was 
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previously investigated by Yang et al., (1998) using texture analyser profiling. 
They found the thickness of the gel layers is affected by the type of the polymer 
and its molecular weight, for both polyethylene oxide and HPMC when 
investigated individually. Polarized microscopy images were obtained for the 
boundary of the core material and within the gel layer. The results showed the 
fragmentation of the core under cross-polarized illumination (Figure 5.8), which 
was increased with the increasing of P407 ratio. Retardation plate was applied, 
to enhance the birefringent properties of the fragments, Figure 5.9 shows the 
birefringent fragments and presumed HPMC particles embedded in the gel layer. 
Moreover, the latter had a dichroic property by rotating to 90° the colour and the 
intensity of the gel layer change from pink to violet which may be attributed to the 
weak birefringent properties of the gel layer. From polarized microscopy images 
(Figure 5.8 and Figure 5.9) it is assumed that upon hydration, P407 hydrated first, 
expanded and formed a gel layer which apparently decreased in the homogeneity 
with the increase in the P407 ratio. This might also be accompanied by the 
hydration and swelling of small particles of HPMC. The big particles of the latter 
take more time to hydrate, due to its lower surface area to particle size ratio and 
it can be seen clearly in the gel layer. Earlier investigations were used to monitor 
HPMC matrices swelling using confocal microscopy in the presence of 
fluorescence markers either embedded in the matrix or added externally to the 
swelling media. Adler et al., (1999) used non-diffusive latex microspheres loaded 
with Nile red. They found that the external gel layer continues in expanding even 
after the core of the tablet is hydrated. Bajwa et al., (2006) used Congo red an 
external fluorescence stain and monitored HPMC matrix under different NaCl 
concentration. They found the increase in the salt concentration resulted in the 
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decrease in the swelling and increase in the erosion. The advantages of polarised 
microscopy over the confocal microscopy in monitoring the matrices is that no 
marker is added and the morphology of swollen polymers can be tracked (Figure 
5.8Figure 5.9).   
The main objective of the in vitro dissolution testing is to analyse the release of 
the drug from the tablets, and this is performed by using conventional dissolution 
testing (Apparatuses I and II), using 500 -1000 mL of the dissolution media. 
However, in vivo dissolution of buccal tablets is affected by the limited volume of 
saliva (Azarmi and Löbenberg, 2007). For this reason, three different flow rates 
were investigated in this work and to the best of our knowledge, the effect of the 
flow rate on drug release has not been investigated previously. 
Dissolution data showed that CHD release from formulations F11 to F15 was 
sensitive to the flow rate or the volume of the dissolution medium and to the P407 
ratio in the tablets. There was approximately  33% and 56% increase in the 
release from F11 and F15,  respectively, using 0.48 mL/min flow rate and App I. 
Moreover, formulations with high percentages of P407 (F14 and F15) showed 
greater CHD dissolution in response to the change in flow rate. This is attributed 
to their higher rate of hydration observed in (Table 5.1 and Figure 5.3). In addition, 
higher P407 ratio resulted in a looser fragmented core as noticed in polarized 
microscopy images (Figure 5.9 and Figure 5.9) and facilitating CHD release, this 
may be due to the high hydrophilic properties of P407 (Dumortier et al., 2006).  
Attempts have been made to develop new methods to analyse localised drug 
release to the oral cavity by using small volumes of dissolution medium. For 
instance, Mohammed and Khedr (2003) performed the dissolution of 
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mucoadhesive sustained release buccal tablet in a shaking water bath using 10 
mL dissolution medium. A similar study was performed using 22 mL of dissolution 
medium in a modified Franz diffusion cell (Ìkinci et al., 2004). Another (Mumtaz 
and Ch'ng, 1995), design involved a small cell chamber contains tablet and water 
recirculated from the dissolution apparatus to the cell at a speed of 4 mL/min. In 
these methods, tablets were immersed in the dissolution media, unlike the 
developed flow rate method which simulates drug release in the oral cavity.   
Although all formulation showed a similar swelling index after two hours (5.2 to 
4.7 for F11 and F15, respectively), there was a greater CHD release with a higher 
P407 ratio over time, can be explained by increasing tablet erosion or dissolution 
with continuous swelling associated with higher the P407 ratio (Dürig, and 
Fassihi, (2002) 
To validate drug release based upon different flow rates, statistical equivalence 
analysis was performed for the drug release using the three different methods 
and compared with the release using the standard App I (BP, 2018 b).  The three 
different rates were chosen to simulate the release of the drug under different 
salivary flow rates (Cho et al., 2010). The effect of the different flow rates and 
App I (500 ml) on drug release was investigated using D.E.. By applying ANOVA 
(2-way with replication), there was no significant difference in D.E.  between the 
flow rates of (0.48 and 0.9 mL/min). However, this is not applicable to other 
comparisons (9 mL/min with 2 mL/min) and for (2 mL/min with App I) (Table 5.2). 
This indicates that CHD release was increased by increasing the flow rate >0.9 
ml/min. This indicates that patients with xerostomia or of low salivary flow rate will 
have less drug release compared to the patients with normal salivary flow rate 
(Cho et al., 2010). 
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Statistical analyses were performed for each triplicate to explore how consistent 
the drug release was for each formulation using the three different flow rate 
methods compared to App I. The statistical analysis using two-way ANOVA 
confirmed that there was no significant difference between each triplicate for the 
tested formulations and the four methods (Table 5.4). There are dissimilarities 
when comparing between each two replicates of the tablets using one way 
ANOVA, the consistency in the dissolution data was ranked as follows App 1> 
0.9 mL/min> 0.2 and 0.48 mL/min. 
The high consistency of the standard dissolution App I, might be attributed to the 
full immersion of the tablet in the dissolution medium, accompanied by basket 
rotation (BP, 2018 b), facilitating tablet swelling, erosion and then dissolution. 
There was only one value of f1 out of the acceptable range, and this confirms the 
uniformity of the tablets.  
The results of 0.9 mL/min flow rate; showed a higher equivalence over the other 
two flow rates, this is explained by the constant flow rate of 9 mL/min with no 
variation. Out of 15 comparisons per test, there is one value of AUC ratio and four 
values out of the acceptable values. 
While for the 0.48 mL/min and 2 mL/min, the exact flow rates were 0.48 ± 0.5 and 
2 ± 0.5 mL/min. Although this has been considered in the calculation of the 
concentration, it may contribute to the inequivalences between the replicates. 
The number of values out of range for the AUC ratio, f1 and f2 were (5,8,1) and 
(6,11,2) for 0.48 and 2 mL/min, respectively. Nafee et al., (2003) found variability 
of in vivo drug release data resulting in a high standard deviation, which resulted 
from different salivary flow rate and cheek movement. 
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Based on the above analyses both the volume and variation of flow rate affect 
the release of CHD from the matrix tablets. Moreover, the kinetics of drug release 
was anomalous with a best fitting to a Korsmeyer-Peppas model. 
5.6 Conclusion 
The study of the rate of water uptake provide a further understanding of the CHD 
release from the hydrophilic matrix tablets, and it has a strong relationship with 
the gelling of the tablet which converts the tablet to a porous structure and 
facilitates CHD release.  
Moreover, the use of different methods of dissolution with different flow rates or 
volume of the dissolution medium affected drug release. The higher flow rate or 
higher volume increases drug release. Although some of the equivalent analytical 
methods showed some variation among some formulations, it showed good 
compliance with other tests. This proves that the rate of CHD release from the 
hydrogel tablet is likely affected by salivary flow with greater CHD being delivered 
at a higher flow rate. Furthermore, P407 accelerate hydrogel formation by 
increasing the rate of water uptake by the tablets, via its faster hydration rate. 
Moreover, drug release under a limited volume of dissolution medium as in 
patients with xerostomia has not been taken into consideration in the standard 
dissolution method. To our knowledge, there is no method which simulates the 
release of CHD locally in the oral cavity based on different flow rates. The above 
attempts showed promising results to investigate drug release for localised oral 
drug delivery, however, formulations need to be further adjusted to improve CHD 
release and the dissolution method needs to be further optimised to exclude 
unfavourable variation.  
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Chapter 6 : Formulation development and dissolution 
adjustment 
In the current chapter, sorbitol mannitol and xylitol were added to improve the 
taste perception of the tablets, especially they have a non-cariogenic properties, 
and due to their ability to relief oral dehydration. Their effect was investigated on 
the physical properties and drug release of CHD mucoadhesive buccal tablet. 
Three groups of formulations were prepared each contains one of the sugars with 
HPMC and poloxamer.  
6.1 Materials and methods 
Tablet formulations were prepared using CHD, P407, HPMC, sorbitol, mannitol 
and xylitol.  
6.2.1 The morphology of sorbitol, mannitol and xylitol. 
SEM images were performed as explained in 4.2.1.3. for the three polyols. 
6.2.2 Formulations and charectarisation of the tablets  
Three groups of formulations were prepared, each group had sorbitol or mannitol 
or xylitol with HPMC and P407. Two different ratios of P407: HPMC and two ratios 
of the polyols were considered, resulting in four tablets per formulation. The 
dosage of CHD was 2.5 mg and was based on the microbiology and cytotoxicity 
studies. 
6.2.2.1 Tablet formulations  
CHD mucoadhesive tablets were prepared as shown in Table 6.1. The powders 
were blended for 15 minutes in V-shaped powder blender (CapsulCN). Mg St 
0.5% was added and mixed for three minutes before pressing. 
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Table 6.1 formulation of CHD mucoadhesive tablets with Sorbitol or mannitol or 
xylitol. 
Formulations 
Ratio 
P407: HPMC: Sugar 
alcohol 
CHD 
P407 
 
HPM
C 
Sorbitol 
or 
Mannitol 
or Xylitol 
Tablet 
weight 
mg 
S1, M1, X1 2:2:1 
2.5 
14 14 7 37.5 
S2, M2, X2 2:2:2 14 14 14 44.5 
S3, M3, X3 3:1:1 21 7 7 37.5 
S4, M4, X4 3:1:2 21 7 14 44.5 
 
6.2.2.2 Melt granulation  
The tablet blend was placed in 100 mL beaker and placed in a prewarmed water 
bath at 57°C and mix with a spatula for 1-3 minutes. Then removed and placed 
in a high shear mixer for 10 seconds to dismantle the big clumps. The granules 
were left to cool and then passed through a 1 mm sieve (mesh no. 18). Then 
collected and characterised for flowability and morphology. Magnesium stearate 
was added to the granules and mixed for 3 min in the V blender prior pressing 
into tablets.  
6.2.2.3 Powder Flow properties and compressibility 
Performed as explained in 4.1.2.3. 
Flow through an orifice 
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The flow rate of the powders and granules was measured by passing 12 g 
through 10, 15 and 25 mm diameter orifices using ERWEKA Granulate & Powder 
Flow Tester, Type GTL, Germany, the results were displayed in g/sec. 
 
6.2.2.4 Preparation and characterisation of CHD buccal tablets 
Tablets were pressed as explained in 4.1.2.4 
Tablets Characterisation has been performed a described earlier; for Friability 
4.1.2.5, Tensile strength 4.1.2.6, content uniformity and mass variation 4.1.2.7, 
Ex-vivo mucoadhesion  4.1.2.8, Swelling Index 4.1.2.9, tablet morphology 
4.1.2.10, Dissolution test (type I apparatus) 4.1.2.11, FTIR and DSC 4.1.2.14, 
Rate of hydration 5.2.2.1, Image analysis 5.2.2.2 and Analysis of dissolution 
profiles 5.2.2.4. 
6.2.2.5 XRD analysis 
X-ray diffractometry (PANalytical empyrean X-ray diffractometer, Netherland) 
was used to analyse the crystallinity of the various tablet ingredients, physical 
mixture, granules for selected formulations. The samples were analysed from 5-
80°, at a 2θ range, and diffraction patterns recorded using Cu-Kα x-ray radiation 
source. 
6.2.2.6 SEM/EDX mapping 
Electron dispersive X-ray analysis was conducted to investigate the spatial 
distribution of the elements on the sample. Images were acquired by SEM 
equipped with electron dispersive detector which detects the x-ray of the 
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elements. In the current work, it was performed to show the spatial distribution of 
nitrogen atoms which is only available in CHD in the investigated formulations. 
This shows the distribution of the drug on the surface of the tablets.  
6.2.2.7 In Vitro dissolution under controlled flow rate (CFR)  
CFR method was developed from the previous method described in 5.2.2.3, due 
to the variation of the achieved results in the latter, the method was further 
developed aiming to get more reproducible results. In the current work, the 
dissolution was performed under a constant flow rate (1mL/min) for two hours. 
The aim of this investigation was to mimic the salivary flow rate in the oral cavity. 
Figure 6.1 illustrates the set-up of the CFR method, ultrapure water was used as 
a dissolution media and placed in a Schott bottle inside a water bath set at 37°C. 
The flow rate of water was controlled using a peristaltic pump at 1mL/min. The 
tablet was adhered with one drop of water on a pre-weighed sample holder (the 
head of a plastic Pasteur pipette cut into two pieces) and placed in a beaker in 
the water bath, this followed by starting the dissolution experiment for two hours. 
Samples of 10 mL were collected every 10 minutes and measured using UV-VIS 
spectrophotometer at 254.  
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Figure 6.1 Diagram illustrating drug release using CFR method. 
6.2.2.8 Tablet erosion  
Tablet erosion was investigated to measure the weight of the tablet after swelling 
and dissolution studies using CFR method, tablets were dried in the oven at 37°C 
for 24-48 hours and the erosion percentage (E%) was calculated based on the 
following equation 
𝐸% =
𝑊0 − 𝑊𝑒
𝑊0
× 100 
Equation 19 
Where W0 is the initial weight of the tablet and We is the dried weight of the tablet after swelling 
or dissolution. 
6.2.2.9 Kinetics of drug release 
Kinetics of drug release was performed as explained in 4.1.2.13 for zero order, 
first order, second order, Higuchi, Hixon Crowell, Korsmeyer-Peppas models and 
Hopfenberg model. The latter is an empirical model used to describes drug 
release from erodible matrices (Costa and Lobo, 2000), it was used to investigate 
Peristaltic Pump  
Beaker 
Tablet 
Sample 
holder 
Dissolution 
media 
Water bath Rack 
Pasteur 
pipette 
head, 
cut in 
halves 
Tablet 
silicone 
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CHD release from formulation prepared with sorbitol, mannitol and xylitol. Non-
linear fitting was performed based on Equation 20 using DDsolver software.   
𝐹 = 100 × [1 − (1 − 𝐾𝐵𝑡 × 𝑡)
𝑛] Equation 20 
Where F is the fraction per cent of drug released at time t. 
KBt is the combined constant, and it can be obtained from Equation 21 
𝐾𝐵𝑡 = 𝐾0/(𝐶0 × 𝑎0) Equation 21 
C0 is the initial concentration of drug in the matrix, and a0 is the initial radius for a sphere or a 
cylinder or the half thickness for a slab; n is 1, 2, and 3 for a slab, cylinder, and sphere, 
respectively. 
To examine the best fitting model, the Akaike Information Criterion (AIC) was 
obtained using DDsolver software, it is used to measure the goodness of fitting, 
the lowest value of AIC shows the best fitting (Govender et al., 2005).  
6.2.2.10 Hydration kinetics 
Tablet hydration was performed as explained in hydration 5.2.2.1. 
Based on the shape of the figures obtained from the Bioscreen C 
spectrophotometric plate reader, the data were fitted to piecewise linear 
regression 2 (PWL2) model, exponential and two-phase exponential model. AIC 
was calculated to find the best fit model. The analysis was performed using 
Originpro software. 
6.3 Result and discussion 
6.3.1 Characterization of raw materials 
The morphology of CHD, HPMC and P407 was displayed in 4.3.1.2. Figure 6.2 
shows the morphology of sorbitol mannitol and xylitol granules. Sorbitol granules 
were more spherical followed by mannitol then xylitol. 
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Figure 6.2 SEM images of a- Sorbitol b- mannitol and c-xylitol, x500. 
 
6.3.2 Characterization of tablet blends and granules 
The flowability of powder formulation blends varied from ‘poor’ to ‘very very poor’ 
(Table 4.3). Melt granulation improved the flow properties of all formulations to 
passable, except X3 showed ‘poor’ flowability and S2 and S4 showed ‘good’ 
flowability. 
a 
a 
 
b 
a 
  
c 
  
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
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Table 6.2 Compressibility index (CI%) and Hausner ratio for tablet bend before and after granulation for sorbitol (S), mannitol 
(M) and Xylitol (X) formulations, 
Formulations Powder Blends Granules 
 CI% Flow Character HR CI% Flow Character HR 
S1 30.81 ± 0.87 Poor 1.45 ± 0.02 20.72 ± 0.61 Fair, passable 1.26 ± 0.10 
S2 37.20 ± 0.073 Very poor 1.59 ± 0.02 20.57 ± 2.05 Fair, passable 1.26± 0.03 
S3 40.07 ± 0.66 Very very poor 1.67 ± 0.02 12.50 ± 0.00 Good 1.14 ± 0.00 
S4 29.60 ± 0.37 poor 1.42 ± 0.01 11.81 ± 0.16 Good 1.13 ± 0.00 
M1 39.11 ± 1.32 Very very poor 1.64 ± 0.04 20.86 ± 1.04 Fair, passable 1.26 ± 0.02 
M2 34.97 ± 4.23 Very poor 1.54 ± 0.10 22.72 ± 1.09 Passable 1.29 ± 0.02 
M3 35.43 ± 3.81 Very poor 1.55 ± 0.09 21.79 ± 1.43 Passable 1.28 ± 0.02 
M4 39.47 ± 2.70 Very very poor 1.65 ± 0.08 21.81 ± 1.42 Passable 1.28 ± 0.02 
X1 39.50 ± 2.09 Very very poor 1.65 ± 0.06 22.76 ± 1.05 Passable 1.29 ± 0.02 
X2 39.87 ± 1.66 Very very poor 1.66 ± 0.02 22.32 ± 1.74 Passable 1.29 ± 0.03 
X3 39.32 ± 1.65 Very very poor 1.65 ± 0.04 27.46 ± 1.37 Poor 1.38 ±0.03 
X4 41.55 ± 3.57 Very very poor 1.72 ± 0.10 22.88 ± 1.26 Passable 1.30 ± 0.02 
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
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The flow of the powders and granules was further investigated using flow through 
the orifice of different diameter 15, 20 and 25 mm. Powder blends failed to pass 
through all orifice sizes, however, Figure 6.3 and Error! Reference source not 
found. shows the successful passability of the granules through the three orifice 
sizes. 
 
Figure 6.3 Flow rate (g/sec) of sorbitol(S), mannitol (M) and xylitol (X) granules 
through 10, 15 and 25   mm orifice sizes. Data are expressed as mean ± SD, n 
= 3. 
 
The morphology and the surface morphology of the granules were depicted using 
SEM images, and all granules were semi-spherical with HPMC component 
particles being distinguished by their distinctive rod shape (Figure 6.4). This is 
also observed in Figure 6.5, which additionally shows the surface of the granules 
was more smooth at low P407 ratio and the granules with the higher P407 ratio 
were more grainy in morphology. 
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Figure 6.4 SEM images of CHD formulations using sorbitol, mannitol and xylitol, 200x.
HPMC 
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 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
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Figure 6.5 SEM images of CHD formulations using sorbitol, mannitol and xylitol, 1000x.
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M1 M2 M3 M4 
X1 X2 X3 X4 
HPMC 
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
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6.3.3 Physical properties of the tablets 
The physical properties of the prepared tablets are presented in Table 4.4. The 
tablets showed an acceptable level of friability; less than 1%, acceptable weight 
variation (none of the 20 tablets deviate from 90-110% of the average weight) 
and content uniformity (none of the 10 tablets deviate from 85-115% of the 
average content). Tensile strength was ≤1, both sorbitol and mannitol showed 
higher tensile strength than xylitol formulations. Two way-ANOVA with 
replications showed a significant difference of the tensile strength between each 
two group of formulations (sorbitol and mannitol, sorbitol and Xylitol, and mannitol 
and Xylitol) with a p-value <0.5, which means that at the investigated ratios, the 
type of polyol affect tablet hardness. 
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
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Table 6.3 Physical characteristics of CHD mucoadhesive buccal tablets (n = 10 ± SD).  
Average 
Weight* 
(mg) 
Diameter 
(mm) 
Height 
(mm) 
Thickness 
(mm) 
Hardness 
(N) 
Tensile 
Strength 
(MPa) 
Friability** 
)%( 
Average 
Content 
(mg) 
S1 36.77 ± 0.05 5.96 ± 0.03 1.58 ± 0.05 0.99 ± 0.21 12.21 ± 3.54 1.03 ±0.29 0.00 2.38 ± 0.12 
S2 44.14 ± 1.44 5.98 ± 0.02 1.77 ± 0.05 1.31 ± 0.07 12.54 ± 3.66 0.80 ± 0.23 0.07 2.49 ± 0.09 
S3 36.16 ± 1.45 5.94 ± 0.03 1.57 ± 0.04 0.97 ± 0.12 10.68 ± 3.35 0.90 ± 0.28 0.17 2.23 ± 0.07 
S4 43.58 ± 1.16 5.96 ± 0.01 1.77 ± 0.04 1.29 ± 0.09 12.94 ± 2.06 0.85 ± 0.14 0.01 2.50 ± 0.07 
M1 38.06 ± 1.16 5.97 ± 0.04 1.72 ± 0.10 1.25 ± 0.24 8.82 ± 4.13 0.63 ± 0.35 0.19 2.58 ± 0.13 
M2 43.28 ± 2.14 5.97 ± 0.02 1.82 ± 0.03 1.23 ± 0.11 14.01 ± 2.57 0.94 ± 0.16 0.08 2.46 ± 0.16 
M3 36.06 ± 1.47 5.97 ± 0.03 1.60 ± 0.05 1.03 ± 0.60 12.05 ± 2.7 0.96 ± 0.22 0.33 2.46 ± 0.06 
M4 43.43 ± 2.24 5.99 ± 0.02 1.84 ± 0.05 1.36 ± 0.08 14.21 ± 3.21 0.88 ± 0.18 0.26 2.64 ± 0.15 
X1 38.06 ± 1.16 5.97 ± 0.03 1.73 ± 0.09 1.20 ± 0.08 4.80 ± 1.93 0.37 ± 0.06 0.26 2.64 ± 0.12 
X2 42.34 ± 1.57 5.98 ± 0.03 1.76 ± 0.04 1.32 ± 0.07 10.29 ± 1.55 0.67 ± 0.11 0.10 2.47 ± 0.09 
X3 37.81 ± 1.25 5.96 ± 0.02 1.68 ± 0.03 1.29 ± 0.15 8.23 ± 2.50 0.56 ± 0.17 0.23 2.38 ± 0.08 
X4 42.82 ± 1.31 5.97 ± 0.02 1.77 ± 0.03 1.31 ± 0.07 11.37 ± 3.24 0.74 ± 0.21 0.08 2.44 ± 0.07 
*n=20 tablets 
** Friability was performed with 1g of tablets 
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
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6.3.4 SEM/EDX mapping 
Elemental mapping was performed to explore the homogeneity or the distribution 
of the drug on the surface of the tablet. Since atomic nitrogen is only available in 
the chemical structure of CHD within the formulation, its availability is linked to 
CHD molecules. The results (Figure 6.6) show that CHD is distributed over the 
surface of all tablets and often available as small clusters. 
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
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Figure 6.6 SEM/EDX images of CHD mucoadhesive buccal tablets showing the presence of nitrogen (in CHD) in red on the tablets 
surfaces (x 500), scale bar is 300 µm. 
S2 S1 S4 S3 
M4 M3 M2 
X4 X3 X2 X1 
M1 
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
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6.3.5 Ex vivo mucoadhesion  
Initially, the residence time of the tablet on the chicken pouch was tested using 
the disintegration apparatus. The tested tablets have successfully adhered to the 
chicken pouch as it was repeatedly immersed in the aqueous media for two hours 
using the disintegration tester, which represents the ideal residence time of the 
designed tablets in the buccal cavity. Figure 6.7 shows S4, M4 and X4 tablets 
after two hours. 
 
Figure 6.7 S4, M4 and X4 after two-hour Ex-Vivo mucoadhesion using 
disintegration apparatus, arrows showing the hydrogel tablet after two hours. 
 
Furthermore, the force of detachment of the mucoadhesive tablet was performed 
to investigate the effect of HPMC, P407 and the polyols ratios on the force of 
detachment. Generally, mannitol formulations showed a higher force of 
detachment, whereas increasing xylitol in the formulations showed a negative 
effect on the mucoadhesion, sorbitol showed a similar effect of xylitol but to a less 
extent (Figure 6.8). Statistical analysis for each formulation group was performed 
S4     M4            X4 
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
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using one-way ANOVA. No significant difference was found between mannitol 
formulations p>0.05, however, both sorbitol and xylitol showed a significant 
difference p<0.05. 
   
Figure 6.8 Force of detachment of CHD formulations containing sorbitol, mannitol 
and xylitol from the chicken pouch at 37°C. Data are expressed as mean ± SD, n 
= 3.   
  
6.3.6 Swelling index (SI) 
The swelling of CHD tablets using different polyols is displayed in Figure 6.9, all 
formulations showed an initial rapid swelling during the first 30 minutes followed 
by a slower rate of swelling for the followed 90 minutes. S4, M4 and X4 showed 
SI of 3 after 2 hours, however, S1, M1 and X1 showed swelling of 3.8, 4.2 and 
4.4, respectively, which is statistically not significant based on two-way ANOVA 
analysis. All other formulations showed swelling of 3.4 to 3.6. 
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Figure 6.9 Swelling index of CHD containing a-sorbitol, b-mannitol and c-xylitol in 
ultrapure water and at 37 °C. Data are expressed as mean ± SD, n = 3.   
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Tablet erosion after swelling 
Tablet erosion percentages (E%) (Table 6.4) generally increased with the 
increase of both P407 and sugar alcohol. This can be explained by increasing 
the solubility attributed to the increase in the hydrophilicity of the tablets. 
Table 6.4 Erosion percentage from tablets after two hours swelling, Data are 
expressed as mean percentage ± SD, n = 3. 
  Formulations E% 
S1 26.50 ± 0.39 
S2 38.43 ± 0.69 
S3 50.94± 5. 14 
S4 50.36 ± 3.95 
M1 28.90 ± 2.55 
M2 30.06 ± 2.46 
M3 40.81 ± 1.61 
M4 43.54 ± 4.71 
X1 28.99 ± 4.05   
X2 37.42 ± 2.32 
X3 39.65 ± 1.56 
X4 48.63 ± 1.23 
 
6.3.7 The Internal morphology of the tablets after swelling 
All formulations successfully formed a porous structure (Figure 6.10), although 
formulations with high P407 ratio were very fragile after freeze-drying, and pores 
were damaged during tablets cutting. 
 
  
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
215 
 
    
    
    
Figure 6.10 SEM images showing the porous structure of the freeze dried swollen tablets containing sorbitol, mannitol and xylitol, 
2000x. 
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6.3.8 Rate of hydration 
Tablets hydration was performed using Bioscreen C plate reader, the change in 
the hydration was recorded as a change in the absorbance, Figure 6.11 shows 
both the raw data obtained from Bioscreen spectrophotometer and after 
calculating the water absorbed by the tablets as explained in 5.2.2.1. It is obvious. 
The results show that tablet hydration was affected mainly by the P407: HPMC 
ratio rather than the polyols, probably because the polymers turn into hydrogels 
with different degrees of transparency whereas polyols dissolve to form a 
colourless solution upon hydration.  
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Figure 6.11 Bioscreen C data of optical density change with time, for a- sorbitol, b-mannitol and c-xylitol formulations. Hydration curves of 
d-sorbitol, e-mannitol and f-xylitol formulations with time for 24 hours at 37°C. Data are expressed as mean ± SD, n = 3.   
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Three models were used for the fitting of the hydration curve, PWL2, exponential 
and two-phase exponential, Both PWL2 and two-phase exponential has two rates 
(Table B 2), however, the exponential model has one rate. The best fitting based 
on the regression coefficient (R2) was for the two-phase exponential (Table 6.5), 
fitted curves are displayed in Figure A 2. 
Table 6.5 Hydration data fitting, R2 using PWL2, exponential, two-phase 
exponential and biphasic exponential association models. 
Formulations 
R2 
PWL2 Exponential 
Two-phase 
exponential 
S1 0.963 0.991 0.999 
S2 0.962 0.991 0.999 
S3 0.952 0.992 0.998 
S4 0.959 0.984 1.000 
M1 0.980 0.996 1.000 
M2 0.989 0.991 0.992 
M3 0.968 0.997 1.000 
M4 0.988 0.983 0.996 
X1 0.950 0.975 1.000 
X2 0.958 0.980 0.999 
X3 0.958 0.989 0.999 
X4 0.955 0.994 1.000 
 
AIC was calculated using Originpro software were used to find the best fitting for 
the exponential and the two-phase exponential model, AIC values were 172 and 
-18, respectively. This means the best fitting to two-phase exponential due to 
lower AIC value.  
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6.3.9 Evaluation of tablet gelation by Image analysis 
Gelling efficiency 
Photographic images were obtained by a digital camera, they were analysed to 
monitor the conversion of the glassy tablet to a hydrogel (rubbery) and from 
these, the core and hydrogel areas were measured/determined (Figure 6.12). 
Both Sorbitol and xylitol formulations showed a comparable behaviour, 3:1:1 and 
3:1:2 formulations, showed complete loss of the integrity of the glassy core and 
formed hydrogel tablets after 30 minutes. Mannitol formulations took more than 
90 minutes for the same ratios. For the lower P407 ratio, all tablets required a 
longer time ≥90 minutes for the former and ≥120 for the latter to completely, form 
hydrogels which were influenced by the type of sugar alcohol, although the time 
decreased with the increase in the sugar ratio.  
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; 
 
 
Figure 6.12 Image analysis results for a-Sorbitol (S), b-mannitol(M) and c-
xylitol(X) formulations, showing the planner area of both the core and the 
hydrogel layer at 37°C after 2 hours gelation. 
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Polarized microscopy imaging 
Polarized microscopy was explored for visualising tablet hydration, gelling and 
fragmentation, in order to potentially interpret gel imagery (and particularly 
fragments) the components of the tablets were first analysed. Images were 
obtained for CHD and the excipients, they all have anisotropic birefringent 
properties (Figure 6.13) under cross polarized light (darkfield), which improved 
by using a retardation plate or  (red) quarter waveplate. 
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cross polarised light (darkfield)  retardation plate (wave plate) 
 
 
 
 
 
 
Figure 6.13 CHD, HPMC, P407, sorbitol, mannitol and xylitol using cross 
polarised light (darkfield) and red plate (purple), 50x and 400x. 
 
Polarized microscopy images were then obtained to investigate the behaviour of 
the tablet during the swelling process with time. Initially, dark field illumination 
was used (Figure 6.14 and Figure 6.16). Sorbitol formulations did not show any 
erosion for the first 15 minutes. Fragments from S4 formulation appeared at 30 
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minutes, S1, S2 and S3 showed fragmentation at 60 minutes, which increased 
towards the end of the analysis (Figure 6.14).  
Figure 6.15 shows mannitol formulations with more pronounced fragmentation 
started from the first 15 minutes for M3 and M4. However, xylitol formulations had 
a similar appearance to sorbitol formulations with more pronounced 
fragmentation started from the first 15 minutes for X3 and X4 (Figure 6.16), this 
can be explained by the higher solubility of sorbitol and xylitol compared to 
mannitol. 
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Figure 6.14 Sorbitol formulations morphology changes with time under polarized microscopy (using cross polarised 
illumination at 50x magnification. Bar marker represents 200 µm). 
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Figure 6.15 Mannitol formulations morphology changes with time under polarized microscopy (using cross polarised 
illumination at 50xmagnification. Bar marker represents 200 µm). 
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Figure 6.16 Xylitol formulations morphology changes with time under polarized microscopy (using cross polarised 
illumination at 50xmagnification. Bar marker represents 200 µm). 
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Additionally, images were obtained for tablets after 2 hours using quarter-
waveplate (Figure 6.17) to check the availability of the optical path difference or 
the birefringent properties of the gel layer. Formulations with ratios of 2:2:1 and 
2:2:2 had a clear boundary gel layer preceding the coloured fragments detached 
from the core indicating the non-homogenous feature of the fragments. Whereas, 
the gel layer is less distinctive with higher P407 ratio and eroded particles are 
mixed within the gel layer (Figure 6.17). 
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Figure 6.17 CHD formulations morphology under polarized microscopy (using 
cross polarised illumination and a retardation plate at 0 and 90 degree, (arrows 
showing the gel layer) 50x and 200 µm scale bar). 
6.3.10 Drug release studies: 
6.3.10.1 Apparatus I dissolution method 
Tablets dissolution was performed using 500 mL of ultrapure water, using App I 
at 50 rpm, CHD release is displayed in Figure 6.18 a, b and c. For all three set of 
formulations, CHD release rate was increased with the increase in the ratio of 
S1 ,0° S2 ,0° S3 ,0° S4 ,0° 
S1 ,90° S2 ,90° S3 ,90° S4 ,90° 
M1 ,0° M2 ,0° M3 ,0° M4 ,0° 
M1 ,90° M2 ,90° M3 ,90° M4 ,90° 
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P407. The highest release was 93% for M4 and X4 of and 87% for S4 after two 
hours and the lowest was 65% for M1 and X1 and 72% for S1 and S2. 
6.3.10.2 Controlled flow rate (CFR) method 
The dissolution was performed using the constant flow rate method at 1 mL/min. 
CHD release from 2:2:1 and 2:2:2 ratios were comparable. Both S1 and S2 
showed a release of 34 and 35%, respectively, M1 and M2 of 31% and X1 and 
X2 of 32%, moreover, this means that the increase in sorbitol, mannitol and xylitol 
ratios do not have an impact on drug release for these formulations. On the other 
hand, there was an 11-20% increase in CHD release with the increase of the 
polyols from S3, M3 and X3 to S4, M4 and X4, respectively, with approximately 
90% release after two hours (Figure 6.18 d, e and f). 
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Figure 6.18 CHD release from a-sorbitol, b-mannitol and c-xylitol formulations using App1 and d-sorbitol, e-mannitol and f-xylitol using 
CFR method. Data are expressed as mean percentage ± SD, n = 3.   
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Erosion after CFR release 
Tablet erosion (%E) was determined for the tablets after two-hour dissolution 
using the CFR method (Table 6.6). The %E increased with the increase of the 
hydrophilicity of the formulation (attained by increasing the ratio of P407 and 
sorbitol, mannitol or xylitol). Furthermore, there are comparable results between 
%E and CHD dissolution, which might indicate that erosion played a significant 
role in CHD release. 
Table 6.6 Erosion percentage (±SD, n=3) of the tablets after two hours release 
using CFR method, compared to the release of CHD from the same 
formulations. 
Formulations % E (2 hours) 
% CHD release 
 (2 hours) 
S1 36.87 ± 5.88 35.57 ± 0.76 
S2 39.70 ± 9.04 33.87 ± 4.16 
S3 70.84 ± 10.17 76.14 ± 2.52 
S4 88.15 ± 2.62 87.18 ± 2.99 
M1 28.43 ± 3.12 30.97 ± 4.58 
M2 28.86 ± 1.69 30.92 ± 2.92 
M3 69.50 ± 5.65 68.41 ± 3.40 
M4 84.63 ± 4.07 89.81 ± 1.22 
X1 30.41 ± 5.25 32.14 ± 2.35 
X2 36.44 ± 2.54 32.31 ± 1.00 
X3 70.41 ± 1.67 69.35 ± 2.03 
X4 87.21 ± 5.67 88.05 ± 3.26 
 
6.3.11 Kinetics of drug release 
CHD release Data was fitted to zero order, first order, Higuchi, Hixon Crowell, 
Korsmeyer-Peppas (the power law) and Hopfenberg models. The coefficients of 
determination R2 are displayed in Table 6.7 and Table 6.8 for fitted drug release 
profiles obtained from App I and CFR methods, respectively. Although R2 for K-
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Peppas showed the best fitting for most of the formulations, some of them had a 
similar or a higher R2 obtained from other models. For this reason, AIC was 
calculated to explore the best-fitted models. 
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Table 6.7 Drug release kinetics using different fitting models for CHD formulation (App1 dissolution) 
 Zero Order (R2) First order (R2) Higuchi (R2) Hixon Crowell (R2) K-Peppas (R2) K-Peppas n Hopffenberg (R2) Hopffenberg n 
S1 0.9779 ± 0.0122 0.9907 ± 0.0094 0.9651 ± 0.0029 0.9883 ± 0.0142 0.9918 ± 0.0112 0.771 ± 0.053 0.9918 ± 0.0103 181.82 ± 292.67 
S2 0.9917 ± 0.0050 0.9840 ± 0.0032 0.9434 ± 0.0083 0.9907 ± 0.0060 0.9921 ± 0.0064 0.859 ± 0.084 0.9968 ± 0.0029 2.15 ±0.90 
S3 0.9790 ± 0.0104 0.9909 ± 0.0031 0.9818 ± 0.0089 0.9864 ± 0.0062 0.9955 ± 0.0031 0.741 ± 0.031 0.9914 ± 0.0036 248.60 ± 368.73 
S4 0.9849 ± 0.0022 0.9801 ± 0.0090 0.9531 ± 0.0147 0.9924 ± 0.0045 0.9952 ± 0.0050 0.928 ± 0.162 0.9957 ± 0.0009 1.95 ±0.047 
M1 0.9877 ± 0.0078 0.9882 ± 0.0133 0.9504 ± 0.0252 0.9917 ± 0.0056 0.9970 ± 0.0006 0.865 ± 0.136 0.9964 ± 0.0011 6.79 ± 5.92 
M2 0.9751 ± 0.0065 0.9908 ± 0.0012 0.9559 ± 0.0084 0.9886 ± 0.0038 0.9893 ±0.0021 0.819 ± 0.078 0.9912 ± 0.0012 291.13 ± 492.32 
M3 0.9963 ± 0.0011 0.9600 ± 0.0094 0.9234 ± 0.0053 0.9795 ± 0.0071 0.9968 ± 0.0010 1.047 ± 0.041 0.9975 ± 0.0013 1.12 ± 0.12 
M4 0.9932 ± 0.0032 0.9647 ± 0.0093 0.9422 ± 0.0106 0.9823 ± 0.0074 0.9961± 0.0013 0.825 ± 0.064 0.9926 ± 0.0028 1.39 ± 0.25 
X1 0.9701 ± 0.0080 0.9832 ± 0.0202 0.9791 ± 0.0113 0.9711 ± 0.0308 0.9971 ± 0.0013 0.694 ± 0.114 0.9833 ±0.0204 1344.84± 1232.74 
X2 0.9800 ± 0.0050 0.9942 ± 0.0008 0.9571 ± 0.0076 0.9925 ± 0.0036 0.9909 ± 0.0030 0.826 ± 0.044 0.9948 ± 0.0014 99.49 ± 161.84 
X3 0.9880 ± 0.0044 0.9797 ± 0.0128 0.9394 ± 0.0140 0.9907 ± 0.0078 0.9909 ± 0.0050 1.058 ± 0.117 0.9957 ± 0.0027 1.73 ±0.62 
X4 0.9920 ± 0.0025 0.9723 ± 0.0073 0.9531 ± 0.0078 0.9887 ± 0.0042 0.9954 ±0.0032 0.815 ± 0.037 0.9952 ± 0.0017 1.62 ± 0.23 
Table 6.8  Drug release kinetic using different fitting models for CHD formulation (CFR Method). 
 Zero Order (R2) First order (R2) Higuchi (R2) Hixon crowell (R2) K-Peppas (R2) K-Peppas n Hopffenberg (R2) Hopffenberg n 
S1 0.9844 ± 0.0171 0.9804 ± 0.0238 0.9661 ± 0.0195 0.9737 ± 0.0306 0.9985 ± 0.0003 0.756 ± 0.103 0.9803 ± 425.72 425.72 ± 211.64 
S2 0.9747 ± 0.0133 0.9515 ± 0.0254 0.9731 ± 0.0179 0.9416 ± 0.0314 0.9932 ± 0.0039 0.677 ± 0.092 0.9515 ± 0.0255 605.60 ± 458.47 
S3 0.9980 ± 0.0017 0.9702 ± 0.0128 0.9314 ± 0.0167 0.9852 ± 0.0087 0.9990 ± 0.0006 0.941 ± 0.077 0.9984 ± 0.0007 1.21 ± 0.37 
S4 0.9982 ± 0.0007 0.9439 ± 0.0045 0.9207 ± 0.0047 0.9698 ± 0.0027 0.9982 ± 0.0007 0.992 ± 0.023 0.9982 ± 0.0006 1.02 ± 0.03 
M1 0.9911 ± 0.0032 0.9896 ± 0.0057 0.9635 ± 0.0075 0.9852 ± 0.0074 0.9995 ± 0.0004 0.783 ± 0.043 0.9896 ± 0.0057  671.80 ± 259 .46 
M2 0.9920 ± 0.0079 0.9886 ± 0.0126 0.9553 ± 0.0177 0.9853 ± 0.0162 0.9983 ± 0.0003 0.813 ± 0.089 0.9886 ± 0.0127 177.29 ± 147.62 
M3 0.9982 ± 0.0014 0.9844 ± 0.0023 0.9390 ± 0.0073 0.9940 ± 0.0019 0.9998 ± 0.0001 0.895 ± 0.022 0.9989 ± 0.0001 1.39 ± 0.21 
M4 0.9990 ± 0.0003 0.9430 ± 0.0054 0.9253 ± 0.0039 0.9704 ± 0.0038 0.9988 ± 0.0004 0.962 ± 0.025 0.9991 ± 0.0002 1.06 ± 0.04 
X1 0.9882 ± 0.0039 0.9884 ± 0.0022 0.9669 ± 0.0042 0.9830 ± 0.0026 0.9990 ± 0.0009 0.766 ± 0.014 0.9884 ± 0.0222 495.60 ± 393.71 
X2 0.9917 ± 0.0028 0.9858 ± 0.0053 0.9553 ± 0.0081 0.9824 ± 0.0066 0.9956 ± 0.0023 0.792 ± 0.037 0.9857 ± 0.0053 438.59 ± 224.10 
X3 0.9982 ± 0.0016 0.9793 ± 0.0083 0.9351 ± 0.0113 0.9903 ± 0.0049 0.9989 ± 0.0010 0.901 ± 0.058 0.9978 ± 0.0022 1.33 ± 0.36 
X4 0.9991 ± 0.0005 0.9472 ± 0.0020 0.9242 ± 0.0056 0.9722 ± 0.0013 0.9993 ± 0.0003 0.956 ±0.060 0.9990 ± 0.0005 1.03 ± 0.06 
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Table 6.9 and Table 6.10 display the AIC for both dissolution methods. The lowest 
values were obtained with the K-Peppas model, indicating its best fitting accept 
for S4 formulation analysed by App I, which showed AIC value of 38.8 using 
Hopfenberg model, compared to 40.7 with K-Peppas model. Thus, the release 
kinetics from S4 and App I was erosion controlled. This can be explained by the 
higher solubility of sorbitol compared to xylitol and mannitol. 
  
Table 6.9 AIC values for App I Dissolution data fitted with different kinetics 
models. 
Formulation
s 
Zero 
Order  
First 
order 
Higuch
i  
Hixon 
Crowell 
K-
Peppas  
Hoffenber
g 
S1 49.9 36.4 55.4 37.2 28.1 35.3 
S2 40.2 45.7 60.4 39.1 31.8 37.2 
S3 49.5 39.7 48.0 43.0 20.7 40.8 
S4 51.5 51.6 62.6 41.5 40.7 38.8 
M1 42.6 38.1 58.0 37.4 29.6 32.4 
M2 50.4 38.7 56.3 40.5 38.5 40.2 
M3 36.5 58.6 67.2 51.6 22.9 32.3 
M4 43.2 58.1 65.2 50.7 25.1 44.1 
X1 53.1 37.4 48.7 44.4 24.4 37.4 
X2 48.2 34.1 56.0 35.7 33.8 34.6 
X3 46.7 48.8 63.1 39.0 27.5 35.2 
X4 45.6 56.1 63.5 46.8 23.4 40.3 
 
 
Table 6.10 AIC values for CFR Dissolution data fitted with different kinetics 
models. 
Formulation
s 
Zero 
Order  
First 
order 
Higuch
i  
Hixon 
Crowell 
K-
Peppas  
Hoffenber
g 
S1 39.4 38.9 52.4 43.4 16.0 40.9 
S2 46.3 52.7 46.5 55.0 30.9 54.7 
S3 35.4 70.3 83.9 60.0 8.2 33.9 
S4 40.4 84.0 90.5 75.9 21.4 40.9 
M1 32.8 31.7 51.7 36.7 -3.3 33.8 
M2 27.8 29.5 53.8 32.7 14.0 31.6 
M3 31.4 60.0 79.7 47.0 1.7 27.9 
M4 34.7 85.0 90.5 76.5 14.4 32.9 
X1 38.0 36.1 51.8 41.1 0.4 38.1 
X2 32.6 37.5 55.0 40.2 26.0 39.5 
X3 30.9 63.4 80.9 53.3 14.2 31.5 
X4 30.9 83.0 89.7 74.6 12.1 32.2 
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Accordingly, using App I, and based on the n value the release was anomalous 
except for M3 and X3 which shows super case II release. Furthermore, the 
release kinetics using CFR method were anomalous for formulations with an 
equal amount of P407 and HPMC (S1, S2, M1, M2, X1 and X2), and formulations 
with higher P407 the release was super case II. 
Based on the drug release studies S4, M4 and X4 showed the best release and 
the least effect by the volume and the dissolution media and they were further 
investigated for possible interaction between CHD and the excipients. 
6.3.12 Drug polymer interaction (FTIR, DSC and XRD) 
FTIR Analysis 
FTIR analysis was conducted to explore possible interactions between tablet 
contents during the granulation process.  
FTIR spectra for all tablet contents and physical mix (PM), granules (Gran) for 
S4, M4 and X4 are displayed in Figure 6.19. FTIR spectra for CHD, HPMC and 
P407 are explained in 4.3.2.7. The absorption bands of the functional groups of 
sorbitol, mannitol and xylitol are summarised in Table 6.11, which show 
agreement with previous work (Wang et al., 2012, Bruni et al., 2009 and Arafa et 
al., 2016), respectively. 
Table 6.11 FTIR spectroscopy absorption bands of the functional groups for 
sorbitol, mannitol and xylitol. 
Functional groups Sorbitol  Mannitol  Xylitol  
O-H stretching 3224 3279  3148, 3289,3355 
C-H stretching 2922  2939  2911  
C-O stretching 1050, 1093  1077, 1016 1011, 1064,1089, 1117  
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As discussed in chapter 4 (4.3.1.7), P407 is characterised by principal peaks at 
2875 cm-1 (CH stretching) and 1094 cm–1 (CO stretching). By comparing the 
spectra of the physical mixes and the granules of each formulation, no difference 
is observed between each spectrum. Consequently, it is concluded that there is 
no interaction due to the granulation process. Moreover, all formulations spectra 
showed the dominant of P407 peaks and this attributed to the steric hindrance or 
stabiliser effect of P407 which is potentiated by its content in the tablets which 
constituted approximately 50% of the tablet weight (Beck-Broichsitter et al., 
2017). 
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DSC Analysis 
DSC analysis was applied for the raw materials CHD, HPMC, P407, Sorbitol, 
Mannitol and Xylitol, S4, M4 and X4 formulations physical mix, granules and 
tablets, to investigate possible interactions between CHD and the excipients 
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Figure 6.19 FTIR spectra of tablet excipients, CHD, S4, M4 and X4 physical mix 
(PM) and granules (Gran). 
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during tablets preparation. As shown in Figure 6.20, HPMC is amorphous, 
whereas the rest of the ingredients are crystalline with distinctive melting peaks. 
The thermograms indicate no interaction during granulation and tablets pressing. 
Moreover, the disappearance of the melting peak of CHD in the physical mixes, 
granules and tablets suggests the dissolution of CHD in P407, the latter has a 
low melting point ~70. A summary of the melting peaks is presented in Table 
6.12.  
Table 6.12 Melting peaks obtained from the DSC thermograms of CHD, the 
excipients, S4, M4 and X4 PM, Gran and Tablets. 
Material 
Melting 
Peak (°C) 
S1 
PM 
S1 
G 
S1 
T 
M1 
PM 
M1 
G 
M1 
T 
X1 
PM 
X1 
G 
X1 
T 
CHD 156.79 - - - - - - - - - 
P407 56.79 56.97 57.23 57.38 56.83 57.24 57.43 56.65 57.08 57.07 
Sorbitol 99.80 99.54 99.62 99.19 - - - - - - 
Mannitol 166.31 - - - 165.62 165.24 165.10 - - - 
Xylitol 94.06 - - - - - - 93.95 93.32 93.54 
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Figure 6.20 DSC thermograms of tablets excipients, CHD, S4, M4 and X4 physical mix (PM) and granules (Gran) and tablets 
(Tab). 
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XRD analysis 
XRD was used to investigate further a possible interaction resulted from the 
granulation process. Apart from HPMC, all tablet ingredients showed a crystalline 
nature (Figure 6.21). The spectra of the physical mixtures and the granules of 
each formulation show the same XRD pattern which confirms no interaction 
produced by the granulation process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.21 XRD patterns of tablets excipients, CHD, S4, M4 and X4 physical mix 
(PM) and granules (Gran). 
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6.3.13 Statistical analysis 
Dissolution data were analysed statistically for both methods App I and CFR, 
using Dissolution efficiency (D.E.), Invitro equivalent comparison (model 
independent) and kinetics of Drug release (model dependent). The analyses 
were performed to investigate the variation between the replicates of the CFR 
method and compare it to the standard App 1 method. 
Dissolution efficiency (D.E.%) 
D.E. is used to compare between different batches, in the current work it was 
used to compare the different methods of dissolution to investigate the effect of 
the volume of the dissolution media. D.E. for CHD release using App 1 was higher 
for all formulation. Moreover, it is double for S1, S2, M1, M2, X1 and X2 than that 
of the CFR method, and this is attributed to the effect of higher volume of 
dissolution media. In contrast, the difference was much less for S4, M4 and X4 
with a value of 5%, 3% and 7%, respectively (Figure 6.22). 
 
Figure 6.22 Dissolution Efficiency of CHD release using App I and CFR 
methods. Data are expressed as mean percentage ± SD, n = 3 
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In Vitro equivalence comparison  
Single Way ANOVA 
Single way ANOVA was performed to investigate the equivalence of each 
triplicate, the results revealed no significant difference for all formulations and for 
both methods (Table 6.13). 
Table 6.13 P-values of One-way ANOVA statistics. 
Formulations 
 
P-value 
App I CFR 
S1 0.95 0.81 
S2 0.90 0.24 
S3 0.93 0.92 
S4 0.97 0.96 
M1 0.89 0.38 
M2 0.97 0.58 
M3 1.00 0.86 
M4 0.96 1.00 
X1 0.97 0.74 
X2 0.98 0.96 
X3 0.95 0.99 
X4 1.00 0.92 
 
Pairwise method 
Pairwise statistical analysis was used to analyse the equivalence between each 
two replicates within the triplicates. 
i. Similarity factor (f2) 
Based on f2 values, all replicates considered similar with a value greater than 50 
(Figure 6.23). 
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Figure 6.23 Similarity factor (f2) for the replicates of each triplicate of the 
dissolution data. 
ii. Difference Factor (f1) 
Figure 6.24 illustrates the difference factor (f1) for the tested formulations. The 
difference among App I dissolution data are much less than of CFR data. One 
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replicate of S2 and two replicates of M1 with f1 value less than 20. CFR 
comparison data showed two values out of three for S1, S2, M1, M2 formulations 
with 15< f1<30. 
 
 
 
Figure 6.24 Difference factor (f2) between the replicates of each triplicate of 
the dissolution data. 
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iii. Resigno’s indices 
As mentioned earlier (chapter five), there is no cut off value for Resigno’s indices, 
the values are ranging from 0 to 1. The closest to 0 showed the less difference. 
By comparing both methods most of the formulations have comparable values 
except S2, M1 and M2, the highest value is 0.15 (Figure 6.25). 
 
 
 
Figure 6.25 Resigno's indices for the replicates of each triplicate of the dissolution 
data. 
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iv. AUC ratio 
AUC ratio results are listed in Table 6.14, formulations analysed using App I are 
within the acceptable range (0.8-1.25), CFR methods show 4 ratios out of the 
acceptable range. S1 showed two ratios, and one ratio for each M1, M2 out of 
the acceptable range, although all data using App I are acceptable. 
Table 6.14 AUC ratio for formulations replicates using App I and CFR methods  
Formulations  
App 1 CFR 
R1-R2 R1-R3 R2-R3 R1-R2 R1-R3 R2-R3 
S1 1.05 0.93 0.89 1.11 1.15 1.03 
S2 0.90 1.03 1.14 1.33 1.36 1.02 
S3 1.03 1.02 0.99 1.05 0.95 0.90 
S4 1.03 1.04 1.01 1.09 1.00 0.97 
M1 0.90 0.88 0.98 0.80 1.07 1.34 
M2 1.02 1.07 1.05 1.26 1.05 0.83 
M3 0.97 0.98 1.01 0.98 0.88 0.90 
M4 0.93 0.89 0.96 0.98 0.99 1.02 
X1 1.01 1.02 1.02 1.15 1.17 1.02 
X2 0.93 0.92 0.99 1.01 0.96 0.96 
X3 1.13 1.02 0.90 1.01 1.04 1.03 
X4 0.99 0.98 0.99 0.93 0.90 0.96 
 
6.4 Discussion  
Three groups of CHD hydrogel mucoadhesive buccal tablets were prepared based 
on the type of the polyol; sorbitol mannitol and xylitol (Table 6.1).  Each group had 
two different ratios of polymers (P407 to HPMC) and two different ratios of polyols. 
Pre-formulation analysis showed the low flowability of the blends (Table 4.3) 
ranging from ‘poor’ to ‘very very poor’, and failed to pass through 10, 15 and 25 mm 
orifices. This is attributed to particle size variation of the drug and the excipients 
(Figure 6.2 and Figure 6.13) and (as explained in 4.3.3), the percentage of fine 
particles and the cohesive nature of some of the excipients exerted a negative 
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effect on the flowability. To improve the flowability of the blends, melt granulation 
was performed by exploiting the low melting point of P407 which is equal to 57°C 
as confirmed by DSC analysis (4.3.2.8). Granules flowability displayed remarkable 
improvement ranging from ‘passable’ to ‘good’, and they were successfully passed 
through 10,15 and 25 mm orifices diameter. Chaturvedi et al., (2018) have 
compared the flowability of ibuprofen-HPC granules prepared by melt granulation 
using co-rotating screw extruder and wet granulation using a high shear mixer. Melt 
granulation gave a superior improvement of flowability from “passable” to “good”, 
whilst for wet granulation, it was only improved from “passable” to “fair”.  
SEM micrographs (Figure 6.5) show an irregular morphology of the granules, this 
finding is similar to a previous work performed by Passerini et al., (2002) who 
prepared Ibuprofen-Poloxamer 188 melt granules using a high shear mixer. The 
surface topography of the granules (Figure 6) depicted that formulations with equal 
amounts of HPMC and P407 have smoother surfaces compared to the formulations 
with a higher P407 ratio. Conceivably, in the former P407 melted and formed a 
layer on the surfaces of other tablet ingredients, however in the latter there was 
more poloxamer associated into clumps on the surface of the granules. Elemental 
mapping was performed to check the homogeneity of the CHD on the surface of 
the tablet. Figure 6.6 shows the distribution of CHD on the surfaces of the tablets, 
there are some visible clusters which may be attributed to the hand mixing being 
not optimised during the granulation process. Elemental mapping, of sulphur in 
spironolactone, was previously applied by Nagy et al (2012) to investigate the 
distribution of spironolactone in melt extruded solid dispersion samples prepared 
with Soluplus® polymer. Thus SEM-EDX provides a useful tool for evaluating drug 
distribution issues within particles.  
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Tablet characterisation was acceptable based on weight variation, content 
uniformity and friability. Both sorbitol and mannitol showed higher tensile strength 
than xylitol. The low tensile strength of xylitol is explained by its elastic recovery 
(Bolhuis et al., 2005). On the other hand, sorbitol displays plastic deformation and 
produced good binding properties (Stoltenberg & Breitkreutz, 2011). Additionally, 
tablets prepared with granular mannitol produce a porous structure resulting in a 
higher surface area and increasing bonding and consequently the tensile strength 
(Westermarck et al., 1998) 
All formulations successfully adhered to the chicken pouch for two hours using 
the disintegration tester (Figure 6.7). However, by measuring the force of 
detachment, it was found that with increasing sorbitol and xylitol ratio the force of 
detachment decreased, which might be explained by their solubility and 
hygroscopic property. Sorbitol is highly hygroscopic, whereas xylitol is 
moderately hygroscopic, and mannitol is considered as non-hygroscopic (Bolhuis 
et al., 2009). Sorbitol, mannitol and xylitol form hydrogen bonding with water 
(Yamaguchi et al., 2017), which might be competing with the binding to the 
chicken mucosa, the lower solubility of mannitol resulted in the higher force of 
mucoadhesion compared to sorbitol and xylitol (Figure 6.8). On the other hand, 
the type of sugar does not show a significant effect on the swelling indices, but it 
does have a clear effect on the erosion percentages. The more the sugar alcohol 
in the tablet the more is the E% (Table 6.4). The effect was more prominent with 
xylitol then sorbitol, however, mannitol did not show a similar effect which might 
be explained by their solubility. 
Regarding the hydration data, which was obtained under a constant surface area 
(the diameter of both the tablet and the well is 6 mm), three models were used. 
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Firstly; PWL2 which is represented by two regression lines; secondly; one phase 
exponential change which is a first order process, the rate being proportional to 
the concentration of the reactant at a specific time; thirdly a two-phase 
exponential model is used when there are two first order rates, both fast and slow. 
Data showed the best fitting to the two-phase exponential model based on both 
R2 (Table 6.5) and AIC. This can be explained by the different solubility of the 
excipients in the matrix which resulted in a slow and fast hydration (Tosun, 2012). 
Upon tablet hydration, it is assumed that highly water-soluble ingredients 
hydrated faster followed by the less soluble ingredients resulting in a two-phase 
exponential pattern.   
Polyols solubility increased the rate of hydrogel formation within the tablets as 
detected by the image analysis using a digital camera, in this method tablets were 
expanded in three-dimensional directions. Both sorbitol and xylitol possess high 
solubility and humectant properties (Bolhuis et al., 2009), the latter reflects the 
water holding capacity of both sugars, which clearly has been noticed by the 
larger gel area compared to that of mannitol formulations (Figure 6.12). Dürig and 
Fassihi, (2002) found that sugars such as sorbitol and sucrose enhanced water 
diffusion into the matrix, and the leaching of soluble sugar acts as a changeling 
agent resulting in improving the release of the drug.  
Generally, both sorbitol and xylitol formulations turned to a hydrogel rubbery 
tablet after 90 minutes for the equal ratio of HPMC and P407, increasing the ratio 
of P407 decreased the time to after 60 minutes, which is attributed to the increase 
in the hydrophilicity of the tablets.  
Cross polarized microscopy has been used for gel characterization (Hikmet, 
1991, Hikmet and Howard, 1993). To our knowledge, this work is the first attempt 
 
 S1, M1, X1 S2, M2, X2 S3, M3, X3 S4, M4, X4 
P407: HPMC: polyols 2:2:1 2:2:2 3:1:1 3:1:2 
Sorbitol (S), Mannitol (M), Xylitol (X) 
  250 
 
to use cross polarized microscopy monitor as part of tablet characterisation 
during the different swelling stages of the tablet. Using cross polarized 
microscopy and quarter wave plate, there was no noticeable difference between 
the formulations based on the type of the sugar (Figure 6.14  to Figure 6.17). The 
noticed difference is within the same group depending on the polymers ratio, for 
instance, there were more fragments detaching from the core in S3 and S4 than 
S1 and S2 which is attributed to the higher ratio of P407. Moreover, both S1 and 
S2 have a dark boundary of the gel layers which may have resulted from their 
thickness and/or strength, accompanied by a lower water content due to lower 
P407 content.  P407 plays a significant role in enhancing the hydration of the 
tablet and the dissolution of CHD. The gel layer in mannitol and xylitol 
formulations have similar behaviour to sorbitol formulations under polarised 
microscopy.  
Drug release studies were performed using both App I and CFR methods (Figure 
6.18). Based on App I, cumulative drug release after two hours was increased 
with the increase in both sugar and P407 ratio, the increase was limited due to 
the high volume of the dissolution medium (500 mL), with the greatest difference 
of 27% from X1 to X4 and M1 to M4. On the other hand, using CFR the release 
was greatly affected by P407: HPMC ratio, as shown in Figure 6.18 the change 
of the ratio of P407 to HPMC from 2:2 to 3:1 lead to an increase in the release to 
around 50%. Moreover, the release for S4, M4 and X4 using 1mL/min CFR 
method is comparable to the release using App I, this indicates that CHD release 
from these formulations is not affected by the volume of the dissolution medium. 
This is attributed to the hydrogel-forming ability with the higher P407 ratio, as 
indicated by image analysis, and resulted from the fast hydration or water uptake 
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by the tablets (Figure 6.12). Sorbitol and xylitol formulations formed hydrogel 
tablets after 30 minutes, while mannitol still had some glassy core up to 90 
minutes (Figure 6.12), which is attributed to their higher solubility (Rowe et al., 
2005). Dissolution efficiency (D.E.) results confirmed the results of CHD release 
using both methods. CFR method results showed a difference in the release rate 
based on polymer ratios, whereas App I did not show the same pattern (Figure 
6.22), for instance, there was >20% difference in D.E. for S1, M1 and X1 by 
comparing the two methods, which decreased to around 5% for S4, M4 and X4. 
Furthermore, CHD release using the CFR method is more representative for 
buccal drug delivery by mimicking salivary flow rate with the advantage of an 
infinite sink condition. 
E% for tablets investigated with the CFR method (Table 6.6) has a good 
agreement with the dissolution data for all formulations which indicates that there 
is a strong correlation between tablet erosion and CHD release. Kinetics of drug 
release was studied using six models, the best fitting was with Korsmeyer Peppas 
and the second best fitting is with Hopfenberg model (Table 6.9 and Table 6.10. 
Fitting to Hopefenberg model indicates the involvement of erosion mostly for high 
P407 and polyols content, which is attributed to their high solubility (Dürig and 
Fassihi, (2002) 
In vitro equivalence analysis was performed to investigate the difference within 
the triplicate of each formulation using CFR method and compare it with the 
triplicate obtained by App I. Single way ANOVA showed no significant difference 
within the triplicates for both methods (p>0.5), and they were similar based on 
similarity factor with f2>50% data. However, difference factor f1 and AUC ratio did 
not show the same agreement; interestingly the variation was noticed with few 
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replicates of 2:2 P407: HPMC ratios. Resigno indices do not have a cut-off value, 
but it showed a similar comparison. Finally, based on the equivalence analysis, 
S3, S4, M3, M4, X3 and X4 have similar acceptance to App I data.  
The interaction between CHD and the excipients during the granulation and tablet 
pressing were investigated using FTIR, DSC and XRD (Figure 6.19, Figure 
6.20and Figure 6.21). The data showed that there was no interaction between 
the physical mixtures and the granules for the investigated formulations S4, M4 
and X4. This means that the matrix tablet can be applied to control the release of 
various types of active ingredients to the buccal cavity without being affected by 
salivary flow rate. 
6.5 Conclusions 
CHD Mucoadhesive buccal tablets were successfully formulated with the aid of 
polyols. To overcome poor powder flowability of the excipients, melt granulation 
showed remarkable improvement in powder flow and no interaction was 
observed between CHD and the excipients using FTIR, DSC and XRD. Moreover, 
CFR method preferred over the App I by miming salivary flow rate, although 
further adjustment needs to be performed to be considered for all buccal 
formulation drug delivery.  
Moreover, S4, M4 and X4 formulations were not affected by the volume of the 
dissolution media, so they can be considered as a suitable candidate for local 
buccal drug delivery especially for xerostomia patients and will not be affected by 
drinking during tablet application. Moreover, due to the successful drug release 
from these formulations, further investigations on different drugs with different 
physical properties and for trans buccal applications is required 
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Chapter 7: Summary, Discussion and Conclusion 
Oropharyngeal candidiasis is a fungal infection caused by Candida spp especially 
C. albicans. The targeted population is mostly the immunocompromised patients. 
CHD, farnesol and thymol were investigated for their anticandidal activity followed 
by a series of investigations for drug selection, effective and safe concentration. 
The final goal was to design and prepare mucoadhesive hydrogel buccal tablets 
and to evaluate the tablets under a condition simulating salivary flow rate in the 
oral cavity.   
7.2 CHD and Farnesol or Thymol 
Studies to increase the efficacy of CHD against Candida, using thymol and 
farnesol were investigated. Farnesol showed a negative effect on CHD activity, 
so it was excluded from the investigation. Thymol showed a minimum 
enhancement, but the effect was not considered synergistic. Although both CHD 
and thymol showed concentration and time-dependent biocidal effect on Candida 
(Bobichon and Bouchet, 1987, Braga et al., 2008), they showed a concentration-
dependent effect on HEK293 cell line as well (Bobichon and Bouchet, 1987, 
Llana-Ruiz-Cabello et al., 2014). However, because the combination of CHD and 
thymol increased the cytotoxic effect of CHD, accordingly thymol was excluded 
from future formulations.  
Consequently, further studies on combining CHD with farnesol or thymol was 
discontinued and mucoadhesive buccal tablet formulations only with CHD were 
developed. 
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7.3 CHD Dose Selection 
Based on the BNF, CHD dosage form for oral application is available in the form 
of a mouthwash, dental gel and oral spray, none of the formulations has a 
controlled release effect. In this work, the effect of CHD was investigated for two 
hours to prolong its activity, which is less than that of the marketed miconazole 
mucoadhesive buccal tablet (Loramyc®), which is designed to be applied for 6 
hours. Although, mucoadhesive buccal tablets are not interfering with eating and 
drinking (Rahamatullah et al., 2011).  , the two hours duration for CHD release 
was chosen to minimise possible poor patient compliance obtained from the 
repeated and prolonged application of the tablet especially for patients who fears 
to eat or drink while applying the tablet or due to the lack of its physical flexibility 
as stated by Salamat-Miller et al., (2005).  
The effect of CHD was investigated on C. albicans planktonic cells, biofilm and 
on HEK 293 cells. MIC and MBC against C. albicans (ATCC 10231) planktonic 
cells are 2.5 and 5 µg/ml respectively after 24-48 hours.  By comparing the effect 
of CHD on 24-h Candida biofilm and HEK 293 cell line, it was found that a 
concentration of 20 µg/ml and 2 hours treatment effected an 85% and 40% 
decrease in the oxidative stress, respectively. Furthermore, there was a 78% loss 
of vacuolar activity and 60% of the protein content of Candida biofilm. On the 
other hand, neither the lysosomal activity nor protein content of HEK 293 cells 
was affected by the treatment. This concentration (20 µg/ml) was considered as 
that required to be maintained in the oral cavity for two hours to be effective 
against Candida cells. Consequently, this concentration needs to be considered 
when designing the buccal mucoadhesive tablet for CHD release. However, this 
concentration is considered only as a starting point and it might be increased or 
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decreased depending on the in vivo activity. Thus Lilly et al., (2006) showed that 
epithelial cells appear to prevent the growth of Candida in the oral cavity by 
stimulating the release of cytokines. Moreover, salivary antimicrobial proteins 
prevent overgrowth of Candida (Akpan and Morgan, 2002), which might 
potentiate the anticandidal activity of CHD.  
7.4 Tablet Preparation 
Formulation development design of mucoadhesive buccal tablets was 
implemented in three different stages. Firstly, drug: polymer ratio was examined. 
Secondly: after selecting the proper ratio (1:5) with a tablet weight of 30mg, P407 
was introduced to the formulation to improve CHD release, different HPMC: P407 
ratios were tested. Finally, to improve drug release and taste perception, sugar 
alcohol namely sorbitol, xylitol and mannitol (water soluble and non-cariogenic)  
(Carocho et al., 2017) were investigated. 
Tablet blends showed poor flowability, making it unsuitable for direct 
compression, and this urged the need for blend granulation. Dry granulation and 
melt granulation was applied, the former showed a limited improvement of the 
flowability, due to the generation of fine particle fraction, the results showed an 
agreement with Herting and Kleinebudde, (2007) findings. This was confirmed by 
dry granules SEM micrographs (Figure 4.4). As a consequence, the low melting 
point of P407 and the thermal stability of CHD were exploited to prepare melt 
granules, which showed improvement in the flowability (Table 6.2). 
7.6 Tablet physical properties 
The subsequently prepared tablet formulations had acceptable physical 
properties, although they did not show high hardness, they were not friable, which 
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according to Dugar et al. (2016) is due to the waxy nature of P407. Moreover, 
they all successfully adhered to the chicken mucosa for two hours in the 
disintegration apparatus, promising an in vivo mucoadhesion to the oral mucosa 
of the patients.   
Referring to the kinetics of tablets hydration and by comparing the first group of 
formulations (Table 5.1 which contain HPMC, P407 and CHD with the second 
group of formulations with the addition of polyols (Table 6.5), it is noticeable that 
sorbitol, mannitol and xylitol have increased the rate of hydration. Khan et al., 
(2007)  also found that increasing the amount of polyols in the tablets resulted in 
increasing their wetting. Consequently, this facilitated the conversion of the 
tablets to form hydrogels. Although the homogeneity of the hydrogel layer is 
questionable, since by examining the tablets under polarized microscopy, the 
hydrated tablet showed an anisotropic birefringent appearance which increased 
with P407 ratio, and to more extent with the added sugar alcohols (sorbitol, 
mannitol and xylitol). This agrees with the hydration results, which showed faster 
hydration with the added polyols. The fast hydration of polyols is attributed to their 
water solubility (Rowe et al., 2006) and considering the humectant property of 
both sorbitol and xylitol (Ergun et al., 2010). This facilitated the formation of the 
hydrogel tablet, this would add an advantage of soft texture to improve patients’ 
compliance especially for xerostomia patients. 
Drug Excipient interaction was analysed for the selected formulations for a 
possibility of chemical interaction between the excipients and the drug. It was 
noticed that P407 produced a steric hindrance (Göppert and Müller, 2005) which 
might have been obtained from the mixing of the blends and resulted in 
enveloping of other excipients and CHD. The difference in the DSC thermograms 
     
     
258 
 
of CHD between the 5 mg formulation; F15 (Figure 4.12) and the 2.5 mg dosage 
S4, M4 and X4 (Figure 6.20) is the disappearance of the CHD melting peak, 
which might be attributed to the low dosage and the higher amount of P407 and 
HPMC (the former was 18.25 mg and 6.25 mg while the latter was 21 mg and 7 
mg, respectively). Another scenario is the availability of polyols in the formulation. 
Since both sorbitol and xylitol have a lower melting point than CHD, they might 
affect the disappearance of the CHD peak. However, the mannitol melting point 
is higher than that of CHD of around 157 and 165°C, respectively, therefore the 
CHD melting point peak might be masked by the mannitol melting peak.  
The formulated tablets were designed to be applied directly to the oral mucosa 
and the homogeneity of the drug on the surface of the tablet is important to 
overcome the irritation produced by the drug. The homogeneity of the CHD in the 
formulations is evidenced in the SEM Nitrogen mapping studies using SEM/EDX 
imaging, showing CHD is spread evenly over the tablets surfaces 
7.7 Drug release conventional versus CFR  
The lack of a proper method to analyse drug release from mucoadhesive tablets 
might result in a non-effective dose or drug activity measurement. Moreover, 
using conventional dissolution methods, showed a higher percentage of drug 
released than the CFR method, most likely due to the higher volume of the 
dissolution media. This highlights the importance to develop an alternative 
suitable method to analyse drug release in the oral cavity. Three different flow 
rates were investigated using the CFR method and Liebig condenser, it was 
found that the higher the flow rate resulted in a higher drug release. This means 
that in patients with xerostomia or hyposalivation drug release will be less than 
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that for patients with normal salivary flow rate, and this is confirmed by Bouckaert 
et al., (1996) finding that buccal drug release is substantially decreased by the 
low volume of saliva. 
Furthermore, due to the statistical inequivalence in some replicates using the 
Liebig condenser method and to decrease the complexity of the experimental 
setting, the method was further developed (Figure 6.1), The results obtained were 
more reliable and showed only minor inequivalence compared to Apparatus I 
analysis.   
Considering the final developed formulations by the addition of polyols with a 
proper ratio of P407: HPMC the resultant formulations S4, M4 and X4, were not 
affected by the volume of the dissolution media, and this is of immense 
importance for the treatment of OPC especially for xerostomic patients. The 
release kinetics for these formulations was super-case II resultant from the higher 
rate of water penetration into the tablets faster than polymer relaxation (Bruschi, 
2015).  CHD Mucoadhesive buccal tablets have been previously investigated by 
other researchers. Irwin et al., (2003), prepared the mucoadhesive tablet using 
75 mg hydroxyethyl cellulose, 25 mg polyacrylic acid and 10 mg CHD. The 
formulation was tested both in vitro using 900 mL of PBS and in vivo (n=5). In 
vitro study showed around 2 mg CHD release from the tablet (20% of the original 
formulation) which is equivalent to 2.2 µg/ml and this concentration is considered 
as not effective against Candida biofilm, based upon our findings. In vivo studies 
of Irwin et al (2003) showed only 0.5-0.8 mg CHD after 4 hours but they did not 
specify the salivary volume. It did indicate that drug release was affected by the 
volume of the dissolution media and so there will be individual variations based 
on salivary flow rates. Finally, neither antimicrobial nor cytotoxicity investigation 
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was performed in this study to evaluate whether the concentration range used 
was effective. The size of the prepared tablet was greater than two times bigger 
than S4, X4 and M4 which might produce patient distress, with more drug loading 
and less drug release (drug release for S4, X4 and M4 was nearly 90% which is 
equivalent to 2.25 mg of CHD).  
Giunchedi et al., (2001) prepared 100 mg buccal tablet using spray dried CHD 
with chitosan, the drug content was 13 mg and drug release after 12 hours using 
App I and 300 mL of PBS was (40%). The in vivo release was performed in 
replicate for 4 hours in one volunteer, and the release profile was not comparable 
to the in vitro release as it increased with time reaching a maximum concentration 
of 20 µg/ml at one hour and then decreases to the end of the analysis at 4 hours. 
Compared to release studies of our formulations the release was nearly constant 
over time and volume of the dissolution media did not affect drug release or its 
profile. In Giunchedi et al., (2001), the MIC and the MBC of the prepared CHD: 
chitosan microspheres against  C. albicans were 15.6 µg/ml after 24 hours, and 
no antibiofilm testing was performed. Based upon the antibiofilm activity 
conducted in our work the successful application of these formulations for the 
treatment of OPC is doubtful. Moreover, chitosan is practically insoluble in saliva 
(Savica et al., 2009) compared to our formulation which is completely soluble in 
saliva. Moreover, there is a lack of information regarding how the tablet was 
removed from the oral cavity and analysed to see if all of the drug has been 
released or not. 
Another investigation was performed by Ceschel et al., (2006). They prepared 60 
mg tablets of 2.5 mg CHD and Lactose monohydrate with different ratios of 
Carbomer 974p to HPMC. They investigated drug release using three dissolution 
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methods; App II and 900 mL PBS and two ex vivo methods. One of the latter was 
conducted at 1 mL/min flow rate and the second one using 4.8 mL of media in a 
Franz diffusion cell. The release profile of CHD was erratic and was greatly 
affected by the volume of the dissolution media. The selected formulation showed 
a 60% (2.7 µg/ml) burst release from the first few minutes using the puddle 
method and 900 ml followed by gradual release reaching 90% (1.6 µg/ml) after 6 
hours. These concentrations are considered as not effective based upon our 
anticandidal activity results. The same formulation showed a maximum release 
of 80% (average of 20 µg/ml) after ~1 hour using an ex vivo method and 1 ml/min 
flow rate. Again, based upon our findings this would not be sufficient to be 
effective against C. albicans biofilm. Moreover, the authors did not investigate the 
mucoadhesion of their formulations, nor the antimicrobial activity. 
Finally, our selected formulations S4, X4 and M4 release studies using CFR at 
1mL/min flow rate showed an average release around 19 µg/mL, showed 
promising results against Candida biofilm. Although, the effect on more mature 
biofilm is not predictable taking into consideration the different factors in the oral 
cavity which might increase or decrease CHD activity. 
7.8 Conclusion and future work 
Based on the current findings, CHD hydrogel-forming mucoadhesive buccal 
tablets were successfully prepared. They showed acceptable properties, good 
mucoadhesion and drug release which was not affected by the volume of the 
dissolution media, and consequently by salivary flow rates. Consequently, the 
tablets are a suitable candidate for the treatment of OPC patients with or without 
xerostomia and salivary glands hypofunction. Clinical investigation is needed to 
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be performed to check drug release in the oral cavity, patient perception and 
acceptance, and the effect on Candida biofilm in the oral cavity. Moreover, one 
of CHD side effects is teeth staining, and this should be tested both in vitro and 
in vivo, although the used dosage in this formulation is much less than the dose 
available in the marketed products. Moreover, regarding the CFR method, a 
further adjustment needs to be performed to consider different sizes and shapes 
for local buccal drug delivery. The availability of marketed mucoadhesive buccal 
tablets, gels and films urged the need for an appropriate method of drug release 
analysis to mimic the release in the oral cavity. The developed method showed a 
good start to further adopt other dosage forms.    
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Appendices 
Appendix A: Hydration fitted curves  
 
Figure A 1 Hydration curves fitted with PWL2 for F11-F15 (obtained from origin 
pro software). 
 
 
Figure A 2 Hydration curves fitted with two-phase exponential model 
(ExponAssoc1). 
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Appendix B: Rate constant of the hydration curves  
Table B 1 Rate constant of the hydration curves for Exponential fitted model 
Formulations Exponential (K) 
F11 0.06 
F12 0.14 
F13 0.18 
F14 0.36 
F15 0.37 
 
 
Table B 2 Rate constant of the hydration curves for PWL2, EXP and AxpAss2 
fitted models. 
Formulations PWL2 Exponential ExpAss2 
K1 
(µL/tab.hr) 
K2 
(µL/tab.hr) 
K 
 (hr-) 
K1 
(hr-) 
K2 
(hr-) 
S1 72.64 2.29 0.44 0.99 0.26 
S2 84.80 2.15 0.51 1.12 0.29 
S3 74.16 1.52 0.51 1.10 0.32 
S4 102.58 2.28 0.58 0.23 1.18 
M1 54.19 3.85 0.28 0.13 0.46 
M2 61.55 3.14 0.30 0.00 0.35 
M3 79.94 1.85 0.48 1.00 0.34 
M4 68.30 2.30 0.34 0.95 0.44 
X1 79.12 2.92 0.44 0.23 1.48 
X2 126.34 2.15 0.69 1.35 0.25 
X3 83.86 2.07 0.53 1.21 0.30 
X4 87.61 1.57 0.56 0.42 1.90 
 
